RNA-containing LNP compositions and methods for preparing, storing, and using same
Patent Information
- Application Number
- JP2023528666
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-12
- Filing Date
- 2021-11-15
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current lipid nanoparticle (LNP) compositions containing ionizable lipids for RNA delivery face challenges in achieving sufficient shelf life and stability at temperatures relevant to pharmaceutical use, with RNA fragmentation and stable folding issues limiting their effectiveness.
The use of specific buffer substances like Tris and its protonated forms, along with inorganic phosphate and citrate anions, at controlled concentrations, to stabilize LNPs and RNA, allowing storage at temperatures between -25°C and 20°C, and enabling freeze-thaw cycles without significant RNA integrity loss.
The described compositions and methods provide stable, ready-to-use LNPs with improved RNA integrity and morphology inhibition, suitable for pharmaceutical storage and use, even after freeze-thaw cycles.
Smart Images

Figure 2022101470000001 
Figure 2022101470000002 
Figure 2022101470000003
Abstract
Description
Technical field
[0001] Technical field The present invention relates generally to the field of lipid nanoparticle (LNP) compositions containing RNA, methods of preparing and storing such compositions, and the use of such compositions in therapy. [Background technology]
[0002] background The use of recombinant nucleic acids (eg, DNA or RNA) to deliver foreign genetic information to target cells is well known. Advantages of using RNA include transient expression and non-transforming characteristics. RNA does not need to enter the nucleus to be expressed, and furthermore cannot be integrated into the host genome, thus eliminating multiple risks such as carcinogenesis.
[0003] Recombinant nucleic acids can be administered to a subject in need thereof in naked form; however, usually recombinant nucleic acids are administered using compositions. For example, RNA can be prepared by so-called nanoparticle formulations comprising RNA and a nanoparticle-forming medium, such as a cationic lipid (e.g. a permanently charged cationic lipid), a mixture of a cationic lipid and one or more additional lipids, or a cationic polymer. can be delivered. The fate of such nanoparticle formulations is controlled by a variety of key factors, such as nanoparticle size and size distribution. These factors are, for example, referred to as special attributes to be analyzed and identified in the FDA "Liposomal Drug Guidance" from 2018. A limitation to the clinical application of current nanoparticle formulations may be due to the lack of homogeneous, pure and well-characterized nanoparticle formulations.
[0004] LNPs containing ionizable lipids may show advantages in terms of targeting and efficacy compared to other RNA nanoparticle products. However, it is difficult to obtain sufficient shelf life required for normal pharmaceutical use. For stabilization, LNPs containing ionizable lipids need to be frozen at much lower temperatures, such as -80 °C, which imposes a considerable burden on the cold chain or freezes that provide only limited stability. It can only be stored at temperatures above temperature, e.g. 5°C.
[0005] RNA in solution or LNPs is known to undergo slow fragmentation. Furthermore, in the presence of phosphate-buffered saline (PBS), RNA tends to adopt a very stable folded form that is hardly available for translation. Both mechanisms, i.e., fragmentation and the formation of this stable RNA fold, are temperature dependent and result in loss of intact and available RNA, thereby limiting the stability of liquid products; however, they are So essentially it doesn't exist. [Summary of the invention] [Problem to be solved by the invention]
[0006] Therefore, (i) the LNPs containing ionizable lipids and RNA are stable and suitable for use in a temperature range consistent with normal technology in pharmaceutical practice, in particular at temperatures of approximately -25°C or in liquid form from +2 to +20°C; (ii) compositions that are ready to use; (iii) compositions that can preferably be repeatedly frozen and thawed; and (iv) preparation and storage of such compositions. There remains a need in the art for methods to do so. The present invention addresses these and other needs. [Means to solve the problem]
[0007] The inventors have surprisingly discovered that the compositions and methods described herein meet the above requirements. In particular, certain buffer substances, particularly tris(hydroxymethyl)aminomethane (Tris) and its protonated forms, are used at low concentrations (e.g., up to about 25 mM), and inorganic phosphate anions as well as citrate and EDTA anions are used. It has been shown that by exclusion it is possible to prepare compositions that are stable and can be stored at about -25°C or in liquid form.
[0008] overview In a first aspect, the invention provides a composition comprising lipid nanoparticles (LNPs) dispersed in an aqueous phase, wherein the LNPs include a cationically ionizable lipid and RNA; From the group consisting of Tris and its protonated form, bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (bis-Tris-methane) and its protonated form and triethanolamine (TEA) and its protonated form Buffer systems containing selected buffer substances and anions of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS) and 2-[4 -(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES); the concentration of the buffering substance in the composition is up to about 25mM; and water The phase provides a composition that is substantially free of inorganic phosphate anions, substantially free of citrate anions, and substantially free of ethylenediaminetetraacetic acid (EDTA) anions.
[0009] As shown in this application, by using a buffer system based on the specific buffer substances identified above, in particular Tris and its protonated form, instead of PBS in compositions containing LNPs, extremely stable folding of RNA can be achieved. Morphological formation is inhibited. Furthermore, the present application surprisingly shows that by simply lowering the concentration of the buffer substance in a composition comprising LNPs and a buffer system, where the LNPs are those containing cationically ionizable lipids and RNA, the same buffer substance can be reduced to 50mM. It is possible to obtain RNA LNP compositions with improved RNA integrity after freeze-thaw cycles compared to compositions containing at concentrations of . The compositions claimed herein thus provide ready-to-use compositions that have improved stability and can be stored at a temperature range consistent with common technology in pharmaceutical practice.
[0010] In a preferred embodiment of the first aspect, the buffer substance is Tris and its protonated form, ie a mixture of Tris and its protonated form.
[0011] In certain embodiments, the monovalent anion is the group consisting of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid and 3-(N-morpholino)propanesulfonic acid or chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid. The group consisting of ethanesulfonic acid and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, preferably the chloride, the group consisting of acetic acid, lactic acid and morpholinoethanesulfonic acid, more preferably the chloride , acetic acid and morpholinoethanesulfonic acid or chloride, acetic acid and lactic acid, for example chloride or acetic acid.
[0012] In certain embodiments, the buffer substance is Tris and its protonated form, and the monovalent anion is a member of the group consisting of chloride, acetate, glycolic acid, lactic acid, morpholinoethanesulfonic acid, and 3-(N-morpholino)propanesulfonic acid. or the group consisting of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, preferably chloride, acetic acid, lactic acid and morpholinoethanesulfonic acid. selected from the group consisting of ethanesulfonic acid, more preferably from the group consisting of chloride, acetic acid and morpholinoethanesulfonic acid or from the group consisting of chloride, acetic acid and lactic acid, for example chloride or acetic acid.
[0013] In certain embodiments of the first aspect, the concentration of buffering substances in the composition, in particular the total concentration of Tris and its protonated form, is up to about 20mM, such as up to about 19mM, up to about 18mM, up to about 17mM, up to about 16mM, up to about 15mM, up to about 14mM, up to about 13mM, up to about 12mM, up to about 11mM or up to about 10mM. In certain embodiments, the lower limit of the buffer substance, particularly Tris and its protonated form, in the composition is at least about 1 mM, preferably at least about 2 mM, such as at least about 3 mM, at least about 4 mM, at least about 5 mM, at least about 6 mM, At least about 7mM, at least about 8mM or at least about 9mM. For example, the concentration of buffering substances in the composition, particularly the total concentration of Tris and its protonated form, can range from about 1 mM to about 20 mM, such as from about 2 mM to about 15 mM, from about 5 mM to about 14 mM, from about 7 mM to about 13 mM, about 8 mM. ~about 12mM, about 9mM to about 11mM, such as about 10mM.
[0014] In certain embodiments of the first aspect, the aqueous phase is substantially free of inorganic sulfate and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions. In the first subgroup at least one of these criteria applies. For example, in certain embodiments of this first subgroup, the aqueous phase is substantially free of inorganic sulfate anions. In further embodiments of this first subgroup, the aqueous phase is substantially free of carbonate anions. In further embodiments of this first subgroup, the aqueous phase is substantially free of dibasic organic acid anions. In further embodiments of this first subgroup, the aqueous phase is substantially free of polybasic organic acid anions.
[0015] In the second subgroup of the first embodiment, at least two of the above apply. For example, in certain embodiments of this second subgroup, the aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions. In further embodiments of this second subgroup, the aqueous phase is substantially free of inorganic sulfate anions and substantially free of dibasic organic acid anions. In further embodiments of this second subgroup, the aqueous phase is substantially free of inorganic sulfate anions and substantially free of polybasic organic acid anions. In further embodiments of this second subgroup, the aqueous phase is substantially free of carbonate anions and substantially free of dibasic organic acid anions. In further embodiments of this second subgroup, the aqueous phase is substantially free of carbonate anions and substantially free of polybasic organic acid anions. In further embodiments of this second subgroup, the aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions.
[0016] In a third subgroup of the first embodiment, at least three of the above apply. For example, in certain embodiments of this third subgroup, the aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions. In further embodiments of this third subgroup, the aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of polybasic organic acid anions. In further embodiments of this third subgroup, the aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. . In further embodiments of this third subgroup, the aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions.
[0017] In a fourth subgroup of the first embodiment, at least four of the above apply. That is, in this fourth subgroup, the aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. Substantially free of anions.
[0018] In certain embodiments of the first aspect (particularly in certain embodiments of the above first, second, third or fourth subgroups of the first aspect), the composition comprises a cryoprotectant. In another embodiment of the first aspect (particularly in certain embodiments of the first, second, third or fourth subgroups of the first aspect), the composition substantially comprises a cryoprotectant. do not have. Specific examples of these embodiments are thus: (1) the aqueous phase is substantially free of inorganic sulfate anions and the composition includes a cryoprotectant; (2) the aqueous phase is substantially free of carbonate anions and the composition includes a cryoprotectant; (3) the aqueous phase is substantially free of dibasic organic acid anions and the composition includes a cryoprotectant; (4) the aqueous phase is substantially free of polybasic organic acid anions and the composition includes a cryoprotectant; (5) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions and the composition includes a cryoprotectant; (6) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of dibasic organic acid anions and the composition includes a cryoprotectant; (7) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of polybasic organic acid anions and the composition includes a cryoprotectant; (8) the aqueous phase is substantially free of carbonate anions and substantially free of dibasic organic acid anions and the composition includes a cryoprotectant; (9) the aqueous phase is substantially free of carbonate anions and substantially free of polybasic organic acid anions and the composition includes a cryoprotectant; (10) the aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions, and the composition includes a cryoprotectant; (11) the aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions, and the composition includes a cryoprotectant; (12) the aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of polybasic organic acid anions, and the composition includes a cryoprotectant; (13) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions, and the composition contains a cryoprotectant. ; (14) the aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions, and the composition includes a cryoprotectant; (15) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. and the composition includes a cryoprotectant; (16) the aqueous phase is substantially free of inorganic sulfate anions and the composition is substantially free of cryoprotectants; (17) the aqueous phase is substantially free of carbonate anions and the composition is substantially free of cryoprotectants; (18) the aqueous phase is substantially free of dibasic organic acid anions and the composition is substantially free of cryoprotectants; (19) the aqueous phase is substantially free of polybasic organic acid anions and the composition is substantially free of cryoprotectants; (20) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions and the composition is substantially free of cryoprotectants; (21) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of dibasic organic acid anions and the composition is substantially free of cryoprotectants; (22) the aqueous phase is substantially free of inorganic sulfate anions and substantially free of polybasic organic acid anions and the composition is substantially free of cryoprotectants; (23) the aqueous phase is substantially free of carbonate anions and substantially free of dibasic organic acid anions and the composition is substantially free of cryoprotectants; (24) the aqueous phase is substantially free of carbonate anions and substantially free of polybasic organic acid anions and the composition is substantially free of cryoprotectants; (25) the aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions and the composition is substantially free of cryoprotectants; (26) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions, and the composition is substantially free of cryoprotectants. ; (27) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of polybasic organic acid anions, and the composition is substantially free of cryoprotectants. ; (28) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions, and the composition is substantially free of cryoprotectants. does not include; (29) The aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions, and the composition is substantially free of cryoprotectants. Not included; (30) The aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. and the composition is substantially free of cryoprotectant.
[0019] In certain embodiments of the first aspect, the composition comprises a cryoprotectant (in particular the first, second, or In certain embodiments of the third or fourth subgroup), the cryoprotectant comprises one or more compounds selected from the group consisting of carbohydrates and sugar alcohols. For example, the cryoprotectant may be selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof. In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (30)) said first, second, third or fourth subgroup of the first aspect In some embodiments), the composition includes sucrose and / or glycerol as cryoprotectants.
[0020] In certain embodiments of the first aspect, the composition comprises a cryoprotectant (in particular the first, second, or In some embodiments of the third or fourth subgroup), the concentration of cryoprotectant in the composition is at least 1% w / v, such as at least 2% w / v, at least 3% w / v, at least 4 %w / v, at least 5%w / v, at least 6%w / v, at least 7%w / v, at least 8%w / v or at least 9%w / v. In certain embodiments, the concentration of cryoprotectant in the composition is up to 25%w / v, such as up to 20%w / v, up to 19%w / v, up to 18%w / v, up to 17%w / v. v, up to 16%w / v, up to 15%w / v, up to 14%w / v, up to 13%w / v, up to 12%w / v or up to 11%w / v. In certain embodiments, the concentration of cryoprotectant in the composition is between 1%w / v and 20%w / v, such as between 2%w / v and 19%w / v, 3%w / v and 18%w. / v, 4%w / v~17%w / v, 5%w / v~16%w / v, 5%w / v~15%w / v, 6%w / v~14%w / v , 7%w / v~13%w / v, 8%w / v~12%w / v, 9%w / v~11%w / v or about 10%w / v. In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the composition comprises 5%w / v to 15%w / v, such as 6%w / v to 14%w / v, 7%w / v to 13%w / v, 8% Contains a cryoprotectant (particularly sucrose and / or glycerol) at a concentration of from w / v to 12% w / v or from 9% w / v to 11% w / v or at a concentration of about 10% w / v.
[0021] In certain embodiments of the first aspect, the composition comprises a cryoprotectant (in particular the first, second, or In some embodiments of the third or fourth subgroup), the cryoprotectant is added to the composition in an amount of about 50 x 10 based on the total weight of the composition. -3 osmol / kg ~ approx. 400×10 -3 osmol / kg (e.g. approximately 50×10 -3 osmol / kg ~ approx. 390×10 -3 osmol / kg, approximately 60×10 -3 osmol / kg ~ approx. 380×10 -3 osmol / kg, approximately 70×10 -3 osmol / kg ~ approx. 370×10 -3 osmol / kg, approximately 80×10 -3 osmol / kg ~ approx. 360×10 -3 osmol / kg, approximately 90×10 -3 osmol / kg ~ approx. 350×10 -3 osmol / kg, approximately 100×10 -3 osmol / kg ~ approx. 340×10 -3 osmol / kg, approximately 120×10 -3 osmol / kg ~ approx. 330×10 -3 osmol / kg, approximately 140×10 -3 osmol / kg ~ approx. 320×10 -3 osmol / kg, approximately 160×10 -3 osmol / kg ~ approx. 310×10 -3 osmol / kg, approximately 180×10 -3 osmol / kg ~ approx. 300×10 -3 osmol / kg or about 200×10 -3 osmol / kg ~ approx. 300×10 -3 osmol / kg).
[0022] In certain embodiments of the first aspect, wherein the buffer substance is Tris and its protonated form (in particular the first above of the first aspect, as in any of embodiments (1) to (30) listed above), In some embodiments of the second, third or fourth subgroup), particularly in embodiments of the first aspect, the monovalent anion is selected from the group consisting of chloride, acetic acid, glycolic acid and lactic acid, and the composition The concentration of monovalent anions therein (especially the total concentration of all monovalent anions) is equal to the concentration of the buffer substance at maximum composition. For example, the concentration of monovalent anions (particularly the total concentration of all monovalent anions) in the composition may be lower than the concentration of buffer substances in the composition. Thus, in embodiments of the first aspect, where the concentration of the buffer substance, particularly Tris and its protonated form, in the composition is up to about 20 mM, the monovalent anions (especially the total concentration of all monovalent anions) in the composition The concentration of is up to about 20mM, eg, less than 20mM. Generally, the concentration of monovalent anions such as chloride and / or acetate (particularly the total concentration of all monovalent anions) in the composition will be less than about 15 mM, such as less than about 14 mM, less than about 13 mM, less than about 12 mM, less than about 11 mM. less than about 10mM, less than about 9mM, less than about 8mM, less than about 7mM, less than about 6mM or less than about 5mM. In certain embodiments, the chloride concentration in the composition is as defined above (eg, less than about 15 mM, etc.) and the composition does not include acetic acid. In another embodiment, the acetic acid concentration in the composition is as defined above (eg, less than about 15 mM, etc.) and the composition is chloride-free.
[0023] In certain embodiments of the first aspect, wherein the buffer substance is Tris and its protonated form (in particular the first above of the first aspect, as in any of embodiments (1) to (30) listed above), In some embodiments of the second, third or fourth subgroup), particularly in embodiments of the first aspect, the sodium concentration in the aqueous phase and / or composition is less than 20mM, such as less than about 15mM, such as , less than about 14mM, less than about 13mM, less than about 12mM, less than about 11mM, less than about 10mM, less than about 9mM, less than about 8mM, less than about 7mM, less than about 6mM or less than about 5mM.
[0024] In certain embodiments of the first aspect, wherein the buffer substance is Tris and its protonated form (in particular the first above of the first aspect, as in any of embodiments (1) to (30) listed above), In some embodiments of the second, third or fourth subgroup), particularly in embodiments of the first aspect, the monovalent anion is selected from the group consisting of the anions of MES, MOPS and HEPES, and in the composition The concentration of monovalent anions (particularly the total concentration of all monovalent anions) is at least equal to the concentration of buffer substance in the composition. For example, the concentration of monovalent anions (particularly the total concentration of all monovalent anions) in the composition may be higher than the concentration of buffer substances in the composition. Thus, in embodiments of the first aspect, where the concentration of the buffer substance, particularly Tris and its protonated form, in the composition is up to about 20 mM, the monovalent anions (especially the total concentration of all monovalent anions) in the composition The concentration of is at least equal to about 20mM, eg, greater than 20mM. Generally, the concentration of monovalent anions (particularly the total concentration of all monovalent anions) in the composition will be greater than about 20 mM, such as greater than about 21 mM, greater than about 22 mM, greater than about 23 mM, greater than about 24 mM, greater than about 25 mM, greater than about 26 mM. , more than about 27mM, more than about 28mM, more than about 29mM or more than about 30mM and preferably up to 50mM, such as up to 45mM, up to 40mM or up to 35mM.
[0025] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the pH of the composition is from about 6.5 to about 8.0. For example, the pH of the composition can be about 6.9 to about 7.9, such as about 7.0 to about 7.9, about 7.1 to about 7.8, about 7.2 to about 7.7, about 7.3 to about 7.6, about 7.4 to about 7.6, or about 7.5. .
[0026] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the composition comprises water as a major component and / or the total amount of solvent other than water included in the composition is less than about 1.0% (v / v). For example, the amount of water included in the composition is at least 50% (w / w), such as at least at least 55% (w / w), at least 60% (w / w), at least 65% (w / w), at least 70% (w / w), at least 75% (w / w), at least 80% (w / w), at least 85% (w / w), at least 90% (w / w) or at least 95% (w) / w). In particular, if the composition comprises a cryoprotectant, the amount of water included in the composition should be at least 50% (w / w), such as at least at least 55% (w / w), at least 60% (w / w). ), at least 65% (w / w), at least 70% (w / w), at least 75% (w / w), at least 80% (w / w), at least 85% (w / w) or at least 90% It can be (w / w). If the composition is substantially free of cryoprotectant, the amount of water included in the composition can be at least 95% (w / w). Additionally or alternatively, the total amount of solvent other than water in the composition is less than about 1.0% (v / v), such as less than about 0.9% (v / v), less than about 0.8% (v / v). / v), less than about 0.7% (v / v), less than about 0.6% (v / v), less than about 0.5% (v / v), less than about 0.4% (v / v), less than about 0.3% (v / v), less than about 0.2% (v / v), less than about 0.1% (v / v), less than about 0.05% (v / v), or less than about 0.01% (v / v). In this regard, cryoprotectants that are liquid under normal conditions, and not solvents other than water, are considered cryoprotectants. In other words, the above optional limitation that the total amount of solvent other than water in the composition may be less than about 1.0% (v / v) applies to cryoprotectants that are liquid under normal conditions. Not done.
[0027] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the osmolarity of the composition is up to about 400 x 10 -3 osmol / kg, e.g. up to about 390×10 -3 osmol / kg, maximum approximately 380×10 -3 osmol / kg, maximum approximately 370×10 -3 osmol / kg, maximum approximately 360×10 -3 osmol / kg, maximum approximately 350×10 -3 osmol / kg, maximum approximately 340×10 -3 osmol / kg, maximum approximately 330×10 -3 osmol / kg, maximum approximately 320×10 -3 osmol / kg, maximum approximately 310×10 -3 osmol / kg or up to about 300×10 -3 osmol / kg. If the composition does not contain a cryoprotectant, the osmolarity of the composition is 300 x 10 -3 Less than osmol / kg, e.g. up to about 250×10 -3 osmol / kg, maximum approximately 200×10 -3 osmol / kg, maximum approximately 150×10 -3 osmol / kg, maximum approximately 100×10 -3 osmol / kg, maximum approximately 50×10 -3 osmol / kg, maximum approximately 40×10 -3 osmol / kg or up to about 30×10 -3 It can be osmol / kg. If the composition includes a cryoprotectant, it is preferred that a major portion of the osmolality of the composition is provided by the cryoprotectant. For example, the cryoprotectant may contain at least 50%, such as at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% or at least 90% of the osmolality of the composition. can be provided.
[0028] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the concentration of RNA in the composition is from about 5 mg / l to about 150 mg / l. For example, the concentration of RNA in the composition is about 10 mg / l to about 140 mg / l, such as about 20 mg / l to about 130 mg / l, about 25 mg / l to about 125 mg / l, about 30 mg / l to about 120 mg / l. l, about 35 mg / l to about 115 mg / l, about 40 mg / l to about 110 mg / l, about 45 mg / l to about 105 mg / l or about 50 mg / l to about 100 mg / l.
[0029] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the buffering substance is Tris and its protonated form, the pH of the composition is from about 6.5 to about 8.0, and the concentration of RNA in the composition is from about 5 mg / l to about 150 mg / l. be. In this embodiment, the pH of the composition is from about 6.9 to about 7.9, and the concentration of RNA in the composition is from about 25 mg / l to about 125 mg / l, such as from about 30 mg / l to about 120 mg / l. preferable. In particularly preferred embodiments of the compositions claimed herein, the buffer substance is Tris and its protonated form; the pH of the composition is from about 6.9 to about 7.9; the concentration of RNA in the composition is about 30 mg / l ~120 mg / l; the aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acids, substantially free of polybasic organic acids; and the composition is frozen Contains protectant. In another particularly preferred embodiment of the compositions claimed herein, the buffering substance is Tris and its protonated form; the pH of the composition is from about 6.9 to about 7.9; and the concentration of RNA in the composition is about 30 mg / l ~ about 120 mg / l; the aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acids, substantially free of polybasic organic acids; and the composition is substantially free of cryoprotectants.
[0030] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the cationically ionizable lipid comprises a head group that includes at least one nitrogen atom that can be protonated under physiological conditions. For example, a cationically ionizable lipid has the formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where L 1 ,L 2 ,G 1 ,G 2 ,G 3 ,R 1 ,R 2 and R 3 is as defined herein. Preferably, the cationically ionizable lipid is selected from: structures I-1 to I-36 (as shown here); and / or structures A to F (as shown here); and / or N ,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraene-19- yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadec-9,12-dien-1-yl)amino)oxy)-N,N- Dimethyl-4-oxobutan-1-amine (DPL-14). In a particularly preferred embodiment, the cationically ionizable lipid is a lipid having structure I-3.
[0031] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the LNP further comprises one or more additional lipids. Preferably, the one or more additional lipids are selected from the group consisting of polymer conjugated lipids, neutral lipids, steroids and combinations thereof. In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (30)) said first, second, third or fourth subgroup of the first aspect In some embodiments), the LNPs are cationically ionizable lipids, polymer-conjugated lipids (e.g., pegylated lipids or polysarcosine-lipid conjugates or conjugates of polysarcosine and lipid-like substances) as described herein. , neutral lipids (eg, DSPC) and steroids (eg, cholesterol).
[0032] In certain embodiments of the first aspect, the LNPs further comprise a polymer-conjugated lipid as one of the one or more additional lipids, particularly as in any of the embodiments (1) to (30) listed above. In certain embodiments of the above first, second, third or fourth subgroup of one embodiment), the polymer conjugate lipid is a pegylated lipid. For example, a pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where R 12 ,R 13 and w are as defined herein.
[0033] In certain embodiments of the first aspect, the LNP further comprises a polymer-conjugated lipid as one of the one or more additional lipids, particularly as in any of the embodiments (1) to (30) listed above. In certain embodiments of the first, second, third or fourth subgroup of one embodiment), the polymer-conjugated lipid is a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-mimetic substance. For example, polysarcosine-lipid conjugates or polysarcosine and lipid-like substance conjugates include polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates. and mixtures thereof.
[0034] In some embodiments of the first aspect, the LNP further comprises a neutral lipid as one of the one or more additional lipids (in particular the first embodiment as in any of embodiments (1) to (30) above). In certain embodiments of the first, second, third or fourth subgroup of embodiments), the neutral lipid is a phospholipid. Such phospholipids are preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin. Specific examples of phospholipids are distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialachidoyl Phosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl -sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine amine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE). In particularly preferred embodiments, the neutral lipid is DSPC.
[0035] In certain embodiments of the first embodiment, the LNP further comprises a steroid as one or more additional lipids (particularly in any of the embodiments (1) to (30) listed above). In certain embodiments of the first, second, third or fourth subgroup), the steroid is a sterol, such as cholesterol.
[0036] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the aqueous phase is free of chelating agent.
[0037] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the LNP comprises at least about 75% of the RNA included in the composition. For example, the LNP comprises at least about 76%, such as at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95%.
[0038] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) is encapsulated or bound to the LNP.
[0039] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) includes a modified nucleoside in place of uridine. For example, the modified nucleoside may be selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0040] In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (e.g., mRNA) has the following: (a) a 5' cap, such as a cap 1 or cap 2 structure; (b) a 5' UTR; (c) a 3' UTR; and (d) A poly-A sequence, such as a poly-A sequence comprising at least 100 nucleotides, preferably one or more poly-A sequences that are interrupted sequences of A nucleotides.
[0041] In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (30)) said first, second, third or fourth subgroup of the first aspect In certain embodiments), the RNA (eg, mRNA) encodes one or more polypeptides. For example, one or more polypeptides can include an epitope for inducing an immune response against an antigen in a subject. In a preferred embodiment, the RNA (e.g., mRNA) encodes an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof. Contains an open reading frame (ORF). In certain embodiments of the first aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1. For example, a SARS-CoV2 S protein variant can have at least 80% identity to SEQ ID NO:7.
[0042] In a preferred embodiment of the first aspect (in particular in any of the above-mentioned embodiments (1) to (30)) said first, second, third or fourth subgroup of the first aspect In some embodiments), the composition is in frozen form. Preferably, the RNA integrity of the frozen composition after thawing is at least 50%, such as at least 52%, at least 54%, at least 55%, at least 56% after thawing a frozen composition stored at -20°C. , at least 58% or at least 60%. Additionally or separately, the size of the LNPs after thawing the frozen composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)) is the size (Z 平均 )(and / or size distribution and / or PDI). In certain embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm. In certain embodiments, the PDI of the LNPs after thawing the frozen composition is less than 0.3, preferably less than 0.2, more preferably less than 0.1. In certain embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, and the size of LNP after thawing the frozen composition (Z 平均 ) (and / or size distribution and / or PDI) is the size (Z 平均 )(and / or size distribution and / or PDI). In certain embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, and the PDI of LNPs after thawing the frozen composition is less than 0.3 (preferably less than 0.2, more preferably 0.1 less than).
[0043] In another preferred embodiment of the first aspect (in particular any of the above first, second, third or fourth embodiments of the first aspect, as in any of the embodiments (1) to (30) listed above). In certain embodiments of the subgroup), the composition is in liquid form. Preferably, the RNA integrity of the liquid composition is sufficient to produce the desired effect, eg, induce an immune response, when stored for at least one week, eg, at or above 0°C. For example, when stored for at least one week at or above 0°C, the RNA integrity of the liquid composition is at least 50%, such as at least 52%, at least 54%, at least 55%, at least 56%, at least 58%, or It can be at least 60%. In addition or separately, the size of the liquid composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)), e.g., when stored above 0°C for at least one week, is sufficient to produce the desired effect, e.g., induce an immune response. be. For example, when stored at 0°C or higher for at least one week, the size of the liquid composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, for example, the size of the LNPs (Z 平均) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm. In certain embodiments, for example, the PDI of the LNPs of the liquid composition after storage for at least one week at or above 0° C. is less than 0.3, preferably less than 0.2, more preferably less than 0.1. In some embodiments, for example, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, for example, the size (Z 平均 ) (and / or size distribution and / or PDI) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, for example, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, for example, the PDI of the LNP of the liquid composition after storage at 0° C. or higher for at least 1 week is less than 0.3. (preferably less than 0.2, more preferably less than 0.1).
[0044] In a second aspect, the invention provides a method of preparing a composition comprising LNPs dispersed in a final aqueous phase, wherein the LNPs include a cationically ionizable lipid and RNA; comprises a buffer system comprising a final buffer substance and a final monovalent anion, the final buffer substance selected from the group consisting of Tris and its protonated form, bis-Tris-methane and its protonated form, and TEA and its protonated form. , the final monovalent anion is selected from the group consisting of chloride, acetate, glycolic acid, lactic acid, an anion of MES, an anion of MOPS, and an anion of HEPES; the concentration of the final buffer substance in the composition is up to about 25 mM; and the final aqueous phase is substantially free of inorganic phosphate anions, substantially free of citrate anions, and substantially free of EDTA anions; (I) preparing a formulation comprising LNPs dispersed in a final aqueous phase, wherein the LNPs comprise cationically ionizable lipids and RNA; and (II) If desired, freeze the preparation to approximately -10°C or lower, thereby obtaining a composition; Here, step (I) is: (a) preparing an RNA solution containing water and a first buffer system; (b) preparing an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; (c) mixing the RNA solution prepared under (a) and the ethanolic solution prepared under (b), thereby producing an intermediate formulation containing LNPs dispersed in an intermediate aqueous layer containing the first buffer system; prepare; and (d) filtering the first intermediate formulation prepared under (c) using the final aqueous buffer solution containing the final buffer system; Thereby, a method is provided comprising preparing a formulation comprising LNPs dispersed in a final aqueous phase.
[0045] As shown in this application, the use of the above-mentioned specific buffer substances instead of PBS in compositions containing LNPs, in particular a specific buffer system based on Tris and its protonated form, leads to extremely stable folding of RNA. Inhibits morphology formation. Additionally, the present application surprisingly provides that the same buffer at 50 mM concentration can be obtained by simply lowering the concentration of buffer substances in the composition comprising LNPs and buffer systems, where the LNPs are those containing cationically ionizable lipids and RNA. We show that it is possible to obtain LNP RNA compositions with improved RNA integrity after freeze / thaw cycles compared to compositions containing substances. Thus, the compositions prepared by the present method offer improved stability and can be stored in a temperature range consistent with common technology in pharmaceutical practice, providing a ready-to-use formulation.
[0046] In a particularly preferred embodiment of the second aspect, the final buffer substance is Tris and its protonated form, ie a mixture of Tris and its protonated form.
[0047] In certain embodiments of the second aspect, the final monovalent anion is the group consisting of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid and 3-(N-morpholino)propanesulfonic acid or chloride, acetic acid, the group consisting of glycolic acid, lactic acid, morpholinoethanesulfonic acid and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, preferably the group consisting of chloride, acetic acid, lactic acid and morpholinoethanesulfonic acid , more preferably selected from the group consisting of chloride, acetic acid and morpholinoethanesulfonic acid or the group consisting of chloride, acetic acid and lactic acid, for example chloride or acetic acid.
[0048] In certain embodiments of the second aspect, the final buffer substance is Tris and its protonated form, and the final monovalent anions are chloride, acetate, glycolic acid, lactic acid, morpholinoethanesulfonic acid, and 3-(N-morpholinosulfonic acid). ) propanesulfonic acid or the group consisting of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, preferably chloride the group consisting of acetic acid, lactic acid and morpholinoethanesulfonic acid, more preferably the group consisting of chloride, acetic acid, lactic acid and morpholinoethanesulfonic acid, more preferably the group consisting of chloride, acetic acid and morpholinoethanesulfonic acid, e.g. selected from chloride or acetic acid.
[0049] In certain embodiments, particularly if preparation of the composition in frozen form is desired, the method of the second aspect comprises (II) freezing the formulation to about -10°C or less. Thus, in this embodiment, performance of the method of the second aspect results in a composition in frozen form.
[0050] In another embodiment, the method of the second embodiment does not include step (II), particularly if preparation of the composition in liquid form is desired. Thus, in this embodiment, performance of the method of the second aspect results in a composition in liquid form.
[0051] In certain embodiments of the second aspect, step (I) further comprises, after step (c), one or more steps selected from dilution and filtration, such as tangential flow filtration and diafiltration. For example, the dilution step can include adding a diluent solution to the intermediate formulation. Such dilute solutions may include one or more additional compounds and optionally a final buffer system, where the one or more additional compounds may include a cryoprotectant. One or more filtration steps (including steps (d), (f'), (g') and (h')) are performed to remove unwanted compounds from the intermediate formulation (e.g. ethanol and / or one or more di- and / or or polybasic organic acids) and / or to increase the RNA concentration of the intermediate formulation and / or to change the pH and / or buffer system of the intermediate formulation. For this purpose, the aqueous buffer solution is free of undesired compounds (so that the undesired compounds are washed out of the intermediate formulation into the aqueous buffer solution) and / or is hypertonic compared to the aqueous buffer solution (so that water is washed out of the intermediate formulation into the aqueous buffer solution). Aqueous buffer solutions can be used that have a pH and / or buffer system other than the intermediate formulation (such as a flowing buffer solution) and / or a pH and / or buffer system other than the intermediate formulation.
[0052] In a preferred embodiment of the second aspect, step (I): (a’) prepare an aqueous RNA solution; (b') preparing a first aqueous buffer solution comprising a first buffer system; (c') Mix the aqueous RNA solution prepared under (a') and the first aqueous buffer solution prepared under (b'), thereby preparing an RNA solution containing water and the first buffer system. death; (d') preparing an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; (e') Mix the RNA solution prepared under (c') and the ethanolic solution prepared under (d'), thereby dispersing the LNPs dispersed in the first aqueous phase containing the first buffer system. preparing a first intermediate formulation comprising; (f') optionally filtering the first intermediate formulation prepared under (e') using a further aqueous buffer solution containing a further buffer system, thereby dispersing it in a further aqueous phase containing a further buffer system; preparing a further intermediate formulation comprising the LNPs, wherein the further aqueous buffer solution may be the same or different from the first aqueous buffer solution; (g') optionally repeating step (f') one or more times, wherein a further step (f') comprising LNPs dispersed in a further aqueous phase comprising a further buffer system obtained after one cycle of step (f'); using the intermediate formulation as the first intermediate formulation in the next cycle, where in each cycle the further aqueous buffer solution may be the same or different from the first aqueous buffer solution; (h') If there is no filtration step (f'), then the first intermediate preparation obtained in step (e') or step (f') exists, and if step (g') does not exist, then step (f') ) or, if steps (f') and (g') are present, the further intermediate formulation obtained after step (g'), including the final buffer system and having a pH of at least 6.0. filtered using an aqueous buffer solution; and (i') optionally diluting the formulation obtained in step (h') with a diluent solution; Thereby, it involves preparing a formulation comprising LNPs dispersed in a final aqueous phase.
[0053] In certain embodiments of the second aspect, the final concentration of buffer substances in the composition, particularly the total concentration of Tris and its protonated form, is up to about 20mM, such as up to about 19mM, up to about 18mM, up to about 17mM, up to About 16mM, up to about 15mM, up to about 14mM, up to about 13mM, up to about 12mM, up to about 11mM or up to about 10mM. In certain embodiments, the lower limit of the final buffer substance in the composition, particularly Tris and its protonated form, is at least about 1 mM, preferably at least about 2 mM, such as at least about 3 mM, at least about 4 mM, at least about 5 mM, at least about 6 mM. , at least about 7mM, at least about 8mM or at least about 9mM. For example, the final concentration of buffer substances in the composition, particularly the total concentration of Tris and its protonated form, can range from about 1 mM to about 20 mM, such as from about 2 mM to about 15 mM, from about 5 mM to about 14 mM, from about 7 mM to about 13 mM, from about It can be from 8mM to about 12mM, from about 9mM to about 11mM, for example about 10mM.
[0054] In certain embodiments of the second aspect, the final aqueous phase is substantially free of inorganic sulfate and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions. In the first subgroup of the second embodiment, at least one of these criteria applies. For example, in certain embodiments of this first subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions. In a further embodiment of this first subgroup of the second aspect, the final aqueous phase is substantially free of carbonate anions. In a further embodiment of this first subgroup of the second aspect, the final aqueous phase is substantially free of dibasic organic acid anions. In a further embodiment of this first subgroup of the second aspect, the final aqueous phase is substantially free of polybasic organic acid anions.
[0055] In a second subgroup of the second embodiment, at least two of the above apply. For example, in certain embodiments of this second subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions. In a further embodiment of this second subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of dibasic organic acid anions. In a further embodiment of this second subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of polybasic organic acid anions. In a further embodiment of this second subgroup of the second aspect, the final aqueous phase is substantially free of carbonate anions and substantially free of dibasic organic acid anions. In a further embodiment of this second subgroup of the second aspect, the final aqueous phase is substantially free of carbonate anions and substantially free of polybasic organic acid anions. In a further embodiment of this second subgroup of the second aspect, the final aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions.
[0056] In a third subgroup of the second embodiment, at least three of the above apply. For example, in some embodiments of the third subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions. Not included in In a further embodiment of this third subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions and substantially free of polybasic organic acid anions. Not included. In a further embodiment of this third subgroup of the second aspect, the final aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. Contains virtually no. In a further embodiment of this third subgroup of the second aspect, the final aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions. Substantially not included.
[0057] In a fourth subgroup of the second embodiment, at least four of the above apply. That is, in this fourth subgroup of the second embodiment, the final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions. and substantially free of polybasic organic acid anions.
[0058] In certain embodiments of the second aspect (particularly in certain embodiments of the above first, second, third or fourth subgroup of the second aspect), the formulation and / or composition obtained in step (I) The product contains a cryoprotectant. In another embodiment of the second aspect (particularly in certain embodiments of the above first, second, third or fourth subgroup of the second aspect), the preparation obtained in step (I) and / or The composition is substantially free of cryoprotectants. Specific examples of these embodiments are thus: (1) the final aqueous phase is substantially free of inorganic sulfate anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (2) the final aqueous phase is substantially free of carbonate anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (3) the final aqueous phase is substantially free of dibasic organic acid anions and contains the formulation and / or composition obtained in step (I) and a cryoprotectant; (4) the final aqueous phase is substantially free of polybasic organic acid anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (5) the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (6) the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of dibasic organic acid anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (7) the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of polybasic organic acid anions, and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (8) the final aqueous phase is substantially free of carbonate anions and substantially free of dibasic organic acid anions and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (9) the final aqueous phase is substantially free of carbonate anions and substantially free of polybasic organic acid anions, and the formulation and / or composition obtained in step (I) contains a cryoprotectant; (10) The final aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions, and the preparation and / or composition obtained in step (I) is a cryoprotectant. including; (11) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions, and the preparation obtained in step (I) and / or The composition includes a cryoprotectant; (12) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of polybasic organic acid anions, and the preparation obtained in step (I) and / or The composition includes a cryoprotectant; (13) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, substantially free of polybasic organic acid anions, and is obtained in step (I). The formulation and / or composition includes a cryoprotectant; (14) The final aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions, and the preparation obtained in step (I) and / or the composition includes a cryoprotectant; (15) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. The formulation and / or composition obtained in step (I) comprises a cryoprotectant; (16) the final aqueous phase is substantially free of inorganic sulfate anions and the formulation and / or composition obtained in step (I) is substantially free of cryoprotectants; (17) the final aqueous phase is substantially free of carbonate anions and the formulation and / or composition obtained in step (I) is substantially free of cryoprotectants; (18) the final aqueous phase is substantially free of dibasic organic acid anions and the formulation and / or composition obtained in step (I) is substantially free of cryoprotectants; (19) the final aqueous phase is substantially free of polybasic organic acid anions and the formulation and / or composition obtained in step (I) is substantially free of cryoprotectants; (20) the final aqueous phase is substantially free of inorganic sulfate anions and substantially free of carbonate anions and the formulation and / or composition obtained in step (I) is substantially free of cryoprotectants; (21) The final aqueous phase is substantially free of inorganic sulfate anions and dibasic organic acid anions, and the preparation and / or composition obtained in step (I) contains substantially no cryoprotectant. Not included; (22) The final aqueous phase is substantially free of inorganic sulfate anions and polybasic organic acid anions, and the preparation and / or composition obtained in step (I) contains substantially no cryoprotectant. Not included; (23) The final aqueous phase is substantially free of carbonate anions and dibasic organic acid anions, and the preparation and / or composition obtained in step (I) contains substantially no cryoprotectant. Not included; (24) The final aqueous phase is substantially free of carbonate anions and polybasic organic acid anions, and the preparation and / or composition obtained in step (I) contains substantially no cryoprotectant. Not included; (25) The final aqueous phase is substantially free of dibasic organic acid anions and substantially free of polybasic organic acid anions, and the preparation and / or composition obtained in step (I) is a cryoprotectant. substantially free of; (26) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of dibasic organic acid anions, and the preparation obtained in step (I) and / or the composition is substantially free of cryoprotectants; (27) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, and substantially free of polybasic organic acid anions, and the preparation obtained in step (I) and / or the composition is substantially free of cryoprotectants; (28) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of dibasic organic acid anions, substantially free of polybasic organic acid anions, and is obtained in step (I). the formulation and / or composition is substantially free of cryoprotectants; (29) The final aqueous phase is substantially free of carbonate anions, substantially free of dibasic organic acid anions, substantially free of polybasic organic acid anions, and is the preparation obtained in step (I). and / or the composition is substantially free of cryoprotectants; (30) The final aqueous phase is substantially free of inorganic sulfate anions, substantially free of carbonate anions, substantially free of dibasic organic acid anions, and substantially free of polybasic organic acid anions. The formulation and / or composition obtained in step (I) is substantially free of cryoprotectants.
[0059] In certain embodiments of the second aspect, wherein the formulation and / or composition obtained in step (I) comprises a cryoprotectant, in particular as in any of the embodiments (1) to (30) listed above. In certain embodiments of the first, second, third or fourth subgroup of the second aspect), the cryoprotectant comprises one or more compounds selected from the group consisting of carbohydrates and sugar alcohols. For example, the cryoprotectant may be selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof. In a preferred embodiment of the second aspect (in particular the first, second, third or fourth subgroup of the second aspect as in any of the embodiments (1) to (30) listed above) In certain embodiments), the formulation and / or composition obtained in step (I) comprises sucrose and / or glycerol as cryoprotectants.
[0060] In certain embodiments of the second aspect, wherein the formulation and / or composition obtained in step (I) comprises a cryoprotectant, in particular as in any of the embodiments (1) to (30) listed above. In certain embodiments of the above first, second, third or fourth subgroup of the second aspect), the concentration of cryoprotectant in the formulation and / or composition is at least 1% w / v, e.g. at least 2%w / v, at least 3%w / v, at least 4%w / v, at least 5%w / v, at least 6%w / v, at least 7%w / v, at least 8%w / v or at least It is 9%w / v. In certain embodiments, the concentration of cryoprotectant in the formulation and / or composition is up to 25%w / v, such as up to 20%w / v, up to 19%w / v, up to 18%w / v, up to 17%w / v, maximum 16%w / v, maximum 15%w / v, maximum 14%w / v, maximum 13%w / v, maximum 12%w / v or maximum 11%w / v. In certain embodiments, the concentration of cryoprotectant in the formulation and / or composition is between 1%w / v and 20%w / v, such as between 2%w / v and 19%w / v, 3%w / v ~18%w / v, 4%w / v~17%w / v, 5%w / v~16%w / v, 5%w / v~15%w / v, 6%w / v~14 %w / v, 7%w / v~13%w / v, 8%w / v~12%w / v, 9%w / v~11%w / v or about 10%w / v. In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the formulations and / or compositions contain 5%w / v to 15%w / v, such as 6%w / v to 14%w / v, 7%w / v to 13%w / v. v, cryoprotectants (especially sucrose and / or glycerol) at a concentration of 8%w / v to 12%w / v or 9%w / v to 11%w / v or a concentration of about 10%w / v. include. For example, the method of the second aspect may further comprise a dilution step using a diluted solution, wherein the diluted solution is a diluent of the cryoprotectant in the formulation and / or composition obtained in step (I). Contains sufficient cryoprotectant to achieve concentration.
[0061] In certain embodiments of the second aspect, wherein the formulation and / or composition obtained in step (I) comprises a cryoprotectant, in particular as in any of the embodiments (1) to (30) listed above. In certain embodiments of the first, second, third or fourth subgroup of the second aspect), the cryoprotectant is about 50 x 10 -3 osmol / kg ~ approx. 400×10 -3 osmol / kg (e.g. approximately 50×10 -3 osmol / kg ~ approx. 390×10 -3 osmol / kg, approximately 60×10 -3 osmol / kg ~ approx. 380×10 -3 osmol / kg, approximately 70×10 -3 osmol / kg ~ approx. 370×10 -3 osmol / kg, approximately 80×10 -3 osmol / kg ~ approx. 360×10 -3 osmol / kg, approximately 90×10 -3 osmol / kg ~ approx. 350×10 -3 osmol / kg, approximately 100×10 -3 osmol / kg ~ approx. 340×10 -3 osmol / kg, approximately 120×10 -3 osmol / kg ~ approx. 330×10 -3 osmol / kg, approximately 140×10 -3 osmol / kg ~ approx. 320×10 -3 osmol / kg, approximately 160×10 -3 osmol / kg ~ approx. 310×10 -3 osmol / kg, approximately 180×10 -3 osmol / kg ~ approx. 300×10 -3 osmol / kg or about 200×10 -3 osmol / kg ~ approx. 300×10 -3 osmol / kg). For example, the method of the second aspect may include a dilution step using a dilute solution, wherein the dilute solution achieves the above osmolarity value of the formulation and / or composition obtained in step (I). Contains a sufficient amount of cryoprotectant.
[0062] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), particularly in embodiments of the second aspect, where the final buffer substance is Tris and its protonated form, the final monovalent anion is selected from the group consisting of chloride, acetate, glycolic acid and lactic acid; The final concentration of monovalent anions in the composition (particularly the total concentration of all final monovalent anions) is at most equal to the concentration of the final buffer substance in the composition. For example, the concentration of final monovalent anions in the composition (particularly the total concentration of all final monovalent anions) may be less than the concentration of final buffer material in the composition. Thus, in embodiments of the second aspect where the concentration of the final buffer substance in the composition, particularly Tris and its protonated form, is up to about 20 mM, the concentration of final monovalent anions in the composition (especially the total final monovalent (total concentration of anions) up to about 20mM, e.g., less than 20mM. Generally, the concentration of monovalent anions such as chloride and / or acetate (particularly the total concentration of all monovalent anions) in the composition will be less than about 15 mM, such as less than about 14 mM, less than about 13 mM, less than about 12 mM, less than about 11 mM. less than about 10mM, less than about 9mM, less than about 8mM, less than about 7mM, less than about 6mM or less than about 5mM. In certain embodiments, the chloride concentration in the composition is as defined above (eg, less than about 15 mM, etc.) and the composition does not include acetic acid. In another embodiment, the acetic acid concentration in the composition is as defined above (eg, less than about 15 mM, etc.) and the composition is chloride-free.
[0063] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), particularly in embodiments of the second aspect, where the final buffer substance is Tris and its protonated form, the sodium concentration in the aqueous phase and / or composition is less than 20mM, such as less than about 15mM, For example, less than about 14mM, less than about 13mM, less than about 12mM, less than about 11mM, less than about 10mM, less than about 9mM, less than about 8mM, less than about 7mM, less than about 6mM, or less than about 5mM.
[0064] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), particularly in embodiments of the second aspect, where the final buffer substance is Tris and its protonated form, the final monovalent anion is selected from the group consisting of anions of MES, MOPS and HEPES, and the final monovalent anion is selected from the group consisting of anions of MES, MOPS and HEPES, and The final concentration of monovalent anions in the composition (particularly the total concentration of all final monovalent anions) is at least equal to the concentration of the final buffer substance in the composition. For example, the concentration of final monovalent anions in the composition (particularly the total concentration of all final monovalent anions) may be higher than the concentration of final buffer material in the composition. Thus, in embodiments of the second aspect where the concentration of the final buffer substance in the composition, particularly Tris and its protonated form, is up to about 20 mM, the concentration of final monovalent anions in the composition (especially the total final monovalent the total concentration of anions) is at least equal to about 20 mM, eg, greater than 20 mM. Generally, the concentration of final monovalent anions in the composition (particularly the total concentration of all final monovalent anions) will be greater than about 20 mM, such as greater than about 21 mM, greater than about 22 mM, greater than about 23 mM, greater than about 24 mM, greater than about 25 mM, about It may be greater than 26mM, greater than about 27mM, greater than about 28mM, greater than about 29mM or greater than about 30mM and preferably up to 50mM, such as up to 45mM, up to 40mM or up to 35mM.
[0065] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the pH of the final buffer system (and the pH of the composition) is from about 6.5 to about 8.0. For example, the pH of the composition can be about 6.9 to about 7.9, such as about 7.0 to about 7.9, about 7.1 to about 7.8, about 7.2 to about 7.7, about 7.3 to about 7.6, about 7.4 to about 7.6, or about 7.5. .
[0066] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the first buffer system (and the pH of the RNA solution obtained in step (a)) is less than 6.0, preferably up to about 5.5, such as up to about 5.0, up to about 4.9, up to about 4.8, up to having a pH of about 4.7, up to about 4.6 or up to about 4.5. For example, the pH of the first buffer system (and the pH of the RNA solution obtained in step (a)) can be about 3.5 to about 5.9, such as about 4.0 to about 5.5 or about 4.5 to about 5.0. For this purpose, the RNA solution obtained in step (a) may further contain one or more di- and / or polybasic organic acids (eg citrate anion and / or EDTA anion). In this embodiment, the final aqueous phase is such that the one or more di- and / or polybasic organic acids are removed and the final aqueous phase is substantially free of the one or more di- and / or polybasic organic acids. Preferably, step (d) is carried out under conditions that result in a formulation comprising LNPs dispersed in. For example, such conditions can be used to transfer the intermediate formulation containing LNPs dispersed in the intermediate aqueous phase obtained in step (c) to a final buffer solution containing the final buffer system (i.e., the final buffer substance and the final monovalent anion). may include subjecting the final buffer solution to at least one step of filtration, such as tangential flow filtration or diafiltration, using one or more di- and / or polybasic organic acids. (and preferably ethanol-free). Alternatively, such conditions may include (i) adding an intermediate formulation comprising LNPs (i.e., the first intermediate formulation) dispersed in the intermediate aqueous phase obtained in step (c) to a further aqueous buffer solution comprising an additional buffer system; to prepare a further intermediate formulation comprising LNPs dispersed in a further aqueous phase comprising a further buffer system, wherein , the further buffer system of the further aqueous buffer solution may be the same as or different from the buffer system used in step (a); (ii) optionally repeating step (i) one or more times, wherein: A further intermediate formulation containing LNPs dispersed in a further aqueous phase obtained after step (i) of the cycle is used as the first intermediate formulation in the next cycle, where in each cycle further buffering of a further aqueous buffer solution is carried out. The system may be the same or different from the first buffer system used in step (a); and (iii) the formulation obtained in intermediate step (I) (if step (ii) is not present) or step (ii). The intermediate formulation obtained in (if step (ii) is present) is subjected to at least one step of filtration, such as tangential flow filtration or diafiltration, using a final aqueous buffer solution, wherein: At least one of the intermediate and final aqueous buffer solutions (preferably all intermediate and final aqueous buffer solutions) is free of one or more di- and / or polybasic organic acids (and preferably free of ethanol). include.
[0067] Similarly, step (I) comprises steps (a') to (e') and (h') (and optionally one or more of steps (f'), (g') and (i')). In certain embodiments of the second aspect (in particular in any of the above-mentioned embodiments (1) to (30)) of the first, second, third or fourth subgroup of the second aspect, In certain embodiments), the first aqueous buffer solution (and the pH of the RNA solution obtained under step (c')) is less than 6.0, preferably up to about 5.5, such as up to about 5.0, up to about 4.9, up to having a pH of about 4.8, up to about 4.7, up to about 4.6, or up to about 4.5. For example, the pH of the first aqueous buffer solution (and the pH of the RNA solution obtained under step (c')) can be about 3.5 to about 5.9, such as about 4.0 to about 5.5 or about 4.5 to about 5.0. . For this purpose, the first aqueous buffer solution (and the first aqueous phase) provided under (b') may further contain one or more di- and / or polybasic organic acids (e.g. citrate anion and / or or anion of EDTA). In this embodiment, one or more di- and / or polybasic organic acids are removed from the first intermediate formulation and / or the further intermediate formulation, and the further and / or final aqueous phase contains one or more di- and / or polybasic organic acids. carrying out at least one of steps (f') to (h') under conditions that result in a further intermediate formulation comprising LNPs dispersed in the further or final aqueous phase, which is substantially free of organic acids; It is preferable to carry out . For example, such conditions may include the use of an additional aqueous buffer solution and / or a final buffer solution, wherein at least one of the additional aqueous buffer solutions and the final buffer solution (preferably the additional aqueous buffer solution) liquid solution and final buffer solution) are free of one or more di- and / or polybasic organic acids (and preferably free of ethanol). In certain embodiments, the filtration step may be tangential flow filtration or diafiltration, preferably tangential flow filtration.
[0068] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the first buffer system used in step (a) comprises the final buffer substance used in step (d) and the final monovalent anion, preferably the first buffer system used in step (a) The buffer system and pH of is the same as that of the final aqueous buffer solution used in step (d). For example, in this embodiment of the second aspect, only one aqueous buffer solution is used.
[0069] Similarly, step (I) comprises steps (a') to (e') and (h') (and optionally one or more of steps (f'), (g') and (i')). In certain embodiments of the second aspect (in particular in any of the above-mentioned embodiments (1) to (30)) of the first, second, third or fourth subgroup of the second aspect, In some embodiments), the first buffer system and all further buffer systems used in steps (b'), (f') and (g') each contain the final buffer material used in step (h') and the final buffer system used in step (h'). The buffer system and pH of each of the first aqueous buffer solution containing a monovalent anion and preferably used in steps (b'), (f') and (g') are adjusted to the final The buffer system and pH of the aqueous buffer solution are the same. For example, the aqueous buffer solutions used in step (b'), if present, (f'), if present, (g') and (h') of this embodiment of the second aspect are the same. It is.
[0070] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the formulation and / or composition comprises water as a major component and / or the total amount of solvents other than water included in the composition is less than about 1.0% (v / v). For example, the amount of water included in the formulation and / or composition may be at least 50% (w / w), such as at least 55% (w / w), at least 60% (w / w), at least 65% (w / w). / w), at least 70% (w / w), at least 75% (w / w), at least 80% (w / w), at least 85% (w / w), at least 90% (w / w) or at least It can be 95% (w / w). In particular, if the formulation and / or composition comprises a cryoprotectant, the amount of water included in the formulation and / or composition is at least 50% (w / w), such as at least at least 55% (w / w). , at least 60% (w / w), at least 65% (w / w), at least 70% (w / w), at least 75% (w / w), at least 80% (w / w), at least 85% ( w / w) or at least 90% (w / w). If the formulation and / or composition is substantially free of cryoprotectant, the amount of water included in the formulation and / or composition can be at least 95% (w / w). Additionally or alternatively, the total amount of solvent other than water in the composition is less than about 1.0% (v / v), such as less than about 0.9% (v / v), less than about 0.8% (v / v). / v), less than about 0.7% (v / v), less than about 0.6% (v / v), less than about 0.5% (v / v), less than about 0.4% (v / v), less than about 0.3% (v) / v), less than about 0.2% (v / v), less than about 0.1% (v / v), less than about 0.05% (v / v), or less than about 0.01% (v / v). In this regard, cryoprotectants that are liquid under normal conditions, and not solvents other than water, are considered cryoprotectants. In other words, the above optional limitation that the total amount of solvent other than water in the composition may be less than about 1.0% (v / v) applies to cryoprotectants that are liquid under normal conditions. Not done.
[0071] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the osmolarity of the composition is up to about 400 x 10 -3 osmol / kg, e.g. up to about 390×10 -3 osmol / kg, maximum approximately 380×10 -3 osmol / kg, maximum approximately 370×10 -3 osmol / kg, maximum approximately 360×10 -3 osmol / kg, maximum approximately 350×10 -3 osmol / kg, maximum approximately 340×10 -3 osmol / kg, maximum approximately 330×10 -3 osmol / kg, maximum approximately 320×10 -3 osmol / kg, maximum approximately 310×10 -3 osmol / kg or up to about 300×10 -3 osmol / kg. If the composition does not contain a cryoprotectant, the osmolarity of the composition is 300 x 10 -3 Less than osmol / kg, e.g. up to about 250×10 -3 osmol / kg, maximum approximately 200×10 -3 osmol / kg, maximum approximately 150×10 -3 osmol / kg, maximum approximately 100×10 -3 osmol / kg, maximum approximately 50×10 -3 osmol / kg, maximum approximately 40×10 -3 osmol / kg or up to about 30×10 -3 It can be osmol / kg. If the composition includes a cryoprotectant, it is preferred that a major portion of the osmolality of the composition is provided by the cryoprotectant. For example, the cryoprotectant may contain at least 50%, such as at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% or at least 90% of the osmolality of the composition. can be provided.
[0072] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the concentration of RNA in the composition is from about 5 mg / l to about 150 mg / l. For example, the concentration of RNA in the composition may be about 10 mg / l to about 140 mg / l, such as about 20 mg / l to about 130 mg / l, about 25 mg / l to about 125 mg / l, about 30 mg / l to about 120 mg / l. l, about 35 mg / l to about 115 mg / l, about 40 mg / l to about 110 mg / l, about 45 mg / l to about 105 mg / l or about 50 mg / l to about 100 mg / l.
[0073] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the final buffer substance is Tris and its protonated form, the pH of the composition is from about 6.5 to about 8.0, and the concentration of RNA in the composition is from about 5 mg / l to about 150 mg / l. It is. In this embodiment, the pH of the composition is from about 6.9 to about 7.9, and the concentration of RNA in the composition is from about 25 mg / l to about 125 mg / l, such as from about 30 mg / l to about 120 mg / l. preferable. In particularly preferred embodiments of the second aspect, the buffer substance is Tris and its protonated form; the pH of the composition is from about 6.9 to about 7.9; and the concentration of RNA in the composition is from about 25 mg / l to about 125 mg / l, e.g. about 30 mg / l to about 120 mg / l; the final aqueous phase is substantially free of sulfate anions, substantially free of dibasic organic acids, and substantially free of polybasic organic acids. and the composition includes a cryoprotectant. In another particularly preferred embodiment of the second aspect, the buffer substance is Tris and its protonated form; the pH of the composition is from about 6.9 to about 7.9; and the concentration of RNA in the composition is about 25 mg / l. ~125 mg / l, such as from about 30 mg / l to about 120 mg / l; the final aqueous phase is substantially free of sulfate anions, substantially free of dibasic organic acids, and substantially free of polybasic organic acids. substantially free; and the composition is substantially free of cryoprotectants.
[0074] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the cationically ionizable lipid comprises a head group that includes at least one nitrogen atom that can be protonated under physiological conditions. For example, a cationically ionizable lipid has the formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where L 1 ,L 2 ,G 1 ,G 2 ,G 3 ,R 1 ,R 2 and R 3 is as defined herein. Preferably, the cationically ionizable lipid is selected from: structures I-1 to I-36 (as shown here); and / or structures A to F (as shown here); and / or N ,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), heptatriaconta-6,9,28,31-tetraene-19- yl-4-(dimethylamino)butanoate (DLin-MC3-DMA) and 4-((di((9Z,12Z)-octadec-9,12-dien-1-yl)amino)oxy)-N,N- Dimethyl-4-oxobutan-1-amine (DPL-14). In a particularly preferred embodiment, the cationically ionizable lipid is a lipid having structure I-3.
[0075] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the ethanolic solution prepared in step (b) or (d') further comprises one or more additional lipids, and the LNP further comprises one or more additional lipids. Preferably, the one or more additional lipids are selected from the group consisting of polymer conjugated lipids, neutral lipids, steroids and combinations thereof. In a preferred embodiment of the second aspect (in particular the first, second, third or fourth subgroup of the second aspect as in any of the embodiments (1) to (30) listed above) In certain embodiments), the one or more additional lipids are cationically ionizable lipid polymer conjugate lipids (e.g., pegylated lipids or polysarcosine-lipid conjugates or polysarcosine and lipid polymer-conjugated lipids (e.g., pegylated lipids or polysarcosine-lipid conjugates or polysarcosine and lipid-like substances), neutral lipids (e.g., DSPC), and steroids (e.g., cholesterol); conjugates of substances), neutral lipids (eg, DSPC) and terols, including steroids (eg, cholesterol)).
[0076] In some embodiments of the second embodiment, the one or more additional lipids comprises a polymer-conjugated lipid (particularly in any of the embodiments (1) to (30) listed above). In certain embodiments of the first, second, third or fourth subgroup), the polymer-conjugated lipid is a pegylated lipid. For example, a pegylated lipid has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where R 12 ,R 13 and w are as defined herein.
[0077] In some embodiments of the second embodiment, the one or more additional lipids comprises a polymer-conjugated lipid (particularly in any of the above-listed embodiments (1) to (30)). In certain embodiments of the first, second, third or fourth subgroup), the polymer-conjugated lipid is a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance. For example, polysarcosine-lipid conjugates or polysarcosine and lipid-like substance conjugates include polysarcosine-diacylglycerol conjugates, polysarcosine-dialkyloxypropyl conjugates, polysarcosine-phospholipid conjugates, polysarcosine-ceramide conjugates. and mixtures thereof.
[0078] In some embodiments of the second aspect, the one or more additional lipids comprise neutral lipids (particularly in any of the above-listed embodiments (1) to (30)). In certain embodiments of the first, second, third or fourth subgroup), the neutral lipid is a phospholipid. Such phospholipids are preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin. Specific examples of phospholipids are distearoyl phosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoyl phosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroyl phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialachidoyl phosphatidylcholine (DAPC), dibehenoyl phosphatidylcholine (DBPC), ditricosanoyl phosphatidylcholine (DTPC), dilignocyloyl phosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl- sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine ( C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE). In particularly preferred embodiments, the neutral lipid is DSPC.
[0079] In certain embodiments of the second embodiment, the one or more additional lipids comprises a steroid (in particular the first, second embodiments of the second embodiment as in any of embodiments (1) to (30) above). In certain embodiments of the second, third or fourth subgroup), the steroid is a sterol, such as cholesterol.
[0080] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the ethanolic solution contains between 20% and 60% of cationically ionizable lipids, polymer-conjugated lipids, neutral lipids, and steroids, based on the total molar amount of lipids in the ethanolic solution. Contains molar ratios of cationically ionizable lipids, 0.5% to 15% polymer conjugated lipids, 5% to 25% neutral lipids, and 25% to 55% steroids. For example, the molar ratios are based on the total molar amount of lipids in the ethanolic solution: 40%-55% cationically ionizable lipid, 1.0%-10% polymer-conjugated lipid, 5%-15% Can be neutral lipids and 30%-50% steroids.
[0081] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the first aspect, such as in any of the embodiments (1) to (30) listed above) In some embodiments), the final aqueous phase is free of chelating agent.
[0082] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the LNP comprises at least about 75% of the RNA included in the composition. For example, the LNP comprises at least about 76%, such as at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95%.
[0083] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) is encapsulated or bound to the LNP.
[0084] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) includes a modified nucleoside in place of uridine. For example, the modified nucleoside may be selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).
[0085] In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (e.g., mRNA) has the following: (a) a 5' cap, such as a cap 1 or cap 2 structure; (b) a 5' UTR; (c) a 3' UTR; and (d) A poly-A sequence, such as a poly-A sequence comprising at least 100 nucleotides, preferably one or more poly-A sequences that are interrupted sequences of A nucleotides.
[0086] In certain preferred embodiments of the second aspect (in particular the first, second, third or fourth sub-subjects of the second aspect as in any of the embodiments (1) to (30) listed above) In some embodiments of the group), the RNA (eg, mRNA) encodes one or more polypeptides. For example, one or more polypeptides can include an epitope for inducing an immune response against an antigen in a subject. In a preferred embodiment, the RNA (e.g., mRNA) encodes an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof. Contains an open reading frame (ORF). In certain embodiments of the second aspect (in particular the first, second, third or fourth subgroups of the second aspect, such as in any of the embodiments (1) to (30) listed above) In certain embodiments), the RNA (eg, mRNA) comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1. For example, a SARS-CoV2 S protein variant can have at least 80% identity to SEQ ID NO:7.
[0087] In a third aspect, the invention provides a composition prepared by the method of the second aspect, wherein the composition is heated to a temperature of about -90°C to about -10°C, such as about -90°C to about -40°C or about - A method of storing a composition is provided, comprising storing at a temperature in the range of 40°C to about -25°C or about -25°C to about -10°C or at a temperature of about -20°C. In certain embodiments of the third aspect, storage of the frozen composition is for at least 1 week, such as at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, At least 12 months, at least 24 months or at least 36 months, preferably at least 4 weeks. In certain embodiments of the third aspect, storage of the frozen composition at -20°C is for at least 4 weeks, preferably at least 1 month, more preferably at least 2 months, more preferably at least 3 months, more preferably at least 6 months. It's a month. In certain embodiments of the third aspect, the composition can be stored at -70°C.
[0088] In certain embodiments of the third aspect, the method of storing the composition comprises preparing the composition by the method of the second aspect comprising step (II) (i.e., freezing the formulation to about -10°C or below). the composition is stored at a temperature ranging from about -90°C to about -10°C for a period of time (e.g., at least one week); and the frozen composition is stored for a period of time (e.g., at least one week) at a temperature ranging from about 0°C to about Including storage at temperatures in the range of 20°C.
[0089] Any of the embodiments described herein in the first or second aspect (in particular any of the embodiments (1) to (30) of the first aspect listed above) Any of the first, second, third or fourth subgroups or the embodiments (1) to (30) of the second aspect listed above, It is understood that any of the second, third or fourth subgroups) may also apply to any of the third embodiments.
[0090] In a fourth aspect, the present invention provides for preparing a liquid composition by the method of the second aspect, wherein the liquid composition is from about 0°C to about 20°C, such as from about 1°C to about 15°C, from about 2°C to about A method of storing a composition is provided, comprising storing at a temperature in the range of 10°C or about 2°C to about 8°C, or at a temperature of about 5°C. In certain embodiments of the fourth aspect, storage of the liquid composition is for at least 1 week, such as at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months or at least 6 months, Preferably at least 4 weeks. In certain embodiments of the fourth aspect, storage of the liquid composition at 5°C is for at least 4 weeks, preferably at least 1 month, more preferably at least 2 months, more preferably at least 3 months, more preferably at least 6 months. It is.
[0091] In certain embodiments of the fourth aspect, the method of storing the composition comprises preparing the composition according to the method of the second aspect comprising step (II) (i.e., freezing the formulation to about -10°C or below). and storing the frozen composition at a temperature of about 0°C to about 20°C for a period of time (eg, at least one week).
[0092] Any embodiment described herein in the first, second or third aspect (in particular the first aspect such as any of the embodiments (1) to (30) of the first aspect listed above) or any of the above-mentioned first, second, third or fourth subgroups of the second embodiment, such as any of embodiments (1) to (30) of the second embodiment listed above. It is understood that any of the first, second, third or fourth subgroups) may also be applied to any of the fourth aspects.
[0093] In a fifth aspect, the invention provides a composition preparable by the method of the second, third or fourth aspect. In certain embodiments of the fifth aspect, the composition may be in frozen form, preferably capable of being stored at temperatures of about -90°C or higher, such as from about -90°C to about -10°C. For example, the frozen composition of the fifth embodiment may be frozen at a temperature in the range of about -90°C to about -40°C or about -40°C to about -25°C or about -25°C to about -10°C or about -20°C. can be stored at temperatures of In certain embodiments of the fifth aspect, the composition is administered for at least 1 week, such as at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 12 months. , for at least 24 months or at least 36 months, preferably for at least 4 weeks. For example, frozen compositions may be stored at -20°C for at least 4 weeks, preferably at least 1 month, more preferably at least 2 months, more preferably at least 3 months, and more preferably at least 6 months.
[0094] In certain embodiments of the fifth aspect, where the composition is in frozen form, the RNA integrity of the frozen composition after thawing is at least 50%, e.g. At least 52%, at least 54%, at least 55%, at least 56%, at least 58% or at least 60%.
[0095] Additionally or alternatively, in certain embodiments of the fifth aspect, where the composition is in frozen form, the size of the LNPs (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm. In certain embodiments, the PDI of the LNPs after thawing the frozen composition is less than 0.3, preferably less than 0.2, more preferably less than 0.1. In some embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, and the size of LNP after thawing the frozen composition (Z 平均 ) (and / or size distribution and / or PDI) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, the size of the LNPs after thawing the frozen composition (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, and the PDI of LNPs after thawing the frozen composition is less than 0.3 (preferably less than 0.2, more preferably 0.1 less than).
[0096] In another embodiment of the fifth aspect, the composition is in liquid form.
[0097] In certain embodiments of the fifth aspect, where the composition is in liquid form, the RNA integrity of the liquid composition, when stored for at least one week, e.g. sufficient to induce a response. For example, when stored for at least one week at or above 0°C, the RNA integrity of the liquid composition is at least 50%, such as at least 52%, at least 54%, at least 55%, at least 56%, at least 58%, or It can be at least 60%.
[0098] Additionally or alternatively, in certain embodiments of the fifth aspect, where the composition is in liquid form, the size of the liquid composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)), e.g., when stored above 0°C for at least one week, is sufficient to produce the desired effect, e.g., induce an immune response. be. For example, when stored at 0°C or higher for at least one week, the size of the liquid composition (Z 平均 ) (and / or size distribution and / or polydispersity index (PDI)) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, for example, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm. In certain embodiments, for example, the PDI of the LNPs of the liquid composition after storage for at least one week at or above 0° C. is less than 0.3, preferably less than 0.2, more preferably less than 0.1. In some embodiments, for example, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, for example, the size (Z 平均 ) (and / or size distribution and / or PDI) is the size (Z 平均 )(and / or size distribution and / or PDI). In some embodiments, for example, the size of the LNPs (Z 平均 ) is about 50 nm to about 500 nm, preferably about 40 nm to about 200 nm, more preferably about 40 nm to about 120 nm, for example, the PDI of the LNP of the liquid composition after storage at 0° C. or higher for at least 1 week is less than 0.3. (preferably less than 0.2, more preferably less than 0.1).
[0099] Any of the embodiments described herein in the first, second, third or fourth aspect (in particular any of the embodiments (1) to (30) of the first aspect listed above) A second aspect such as any of the first, second, third or fourth subgroups of the first aspect or any of the embodiments (1) to (30) of the second aspect listed above. It is understood that any of the first, second, third or fourth subgroups above) may also be applied to any of the fifth embodiments.
[0100] In a sixth aspect, the invention comprises the steps of providing a frozen composition prepared by the method of the second or third aspect, and thawing the frozen composition, thereby obtaining a ready-to-use pharmaceutical composition. provides a method of preparing a ready-to-use pharmaceutical composition.
[0101] Any of the embodiments described herein in the first, second, third, fourth or fifth aspect (in particular any of the embodiments (1) to (30) of the first aspect listed above) Any of the first, second, third or fourth subgroups of the first aspect, such as, or any of the embodiments (1) to (30) of the second aspect listed above, It is understood that any of the above first, second, third or fourth subgroups of the second embodiment may also be applied to any of the sixth embodiment.
[0102] In a seventh aspect, the invention provides a ready-to-use pharmaceutical composition comprising the step of providing a liquid composition prepared by the method of the second or fourth aspect, thereby obtaining a ready-to-use pharmaceutical composition. Provided are methods for preparing.
[0103] Any embodiment described herein in the first, second, third, fourth, fifth or sixth aspect (in particular embodiments (1) to (30) of the first aspect listed above) Any of the first, second, third or fourth subgroups of the first aspect, such as any of the above, or any of the embodiments (1) to (30) of the second aspect listed above. It is understood that any of the above first, second, third or fourth subgroups of the second embodiment, such as, may also be applied to any of the seventh embodiment.
[0104] In an eighth aspect, the invention provides a ready-to-use pharmaceutical composition prepareable by the method of the sixth or seventh aspect.
[0105] Any embodiment described herein in the first, second, third, fourth, fifth, sixth or seventh aspect (in particular embodiment (1) of the first aspect listed above) Any of the first, second, third or fourth subgroups of the first aspect, such as any of (30), or embodiments (1) to (30) of the second aspect listed above. It is understood that any of the above first, second, third or fourth subgroups of the second aspect, such as any of the above, may be applied to any of the eighth aspect.
[0106] In a ninth aspect, the invention provides a composition according to any of the first, fifth and eighth aspects for use in therapy.
[0107] Any embodiment described herein in the first, second, third, fourth, fifth, sixth, seventh or eighth aspect may also be applied to any of the ninth aspects. is understood.
[0108] In a tenth aspect, the invention provides a composition according to any of the first, fifth and eighth aspects for use in inducing an immune response.
[0109] Any embodiment described herein under the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth aspect also applies to any of the tenth aspects. It is understood that it can be done.
[0110] Further itemized embodiments are as follows: 1. A composition comprising lipid nanoparticles (LNPs) dispersed in an aqueous phase, wherein the LNPs comprise a cationically ionizable lipid and RNA; the aqueous phase comprises a buffer substance and a monovalent anion. a buffer system, wherein the buffer substance is tris(hydroxymethyl)aminomethane (Tris) and its protonated form, bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (bis-Tris-methane) and its protonated form; forms and triethanolamine (TEA) and its protonated forms and anions of chloride, acetic acid, glycolic acid, lactic acid, morpholinoethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS) and selected from the group consisting of a monovalent anion selected from the group consisting of the anion of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES); and the aqueous phase is substantially free of inorganic phosphate anions, substantially free of citrate anions, and substantially free of ethylenediaminetetraacetic acid (EDTA) anions.
[0111] 2. The composition of paragraph 1, wherein the buffering substance is Tris and its protonated form.
[0112] 3. The composition of paragraph 1 or 2, wherein the concentration of the buffer substance, in particular Tris and its protonated form, in the composition is at most about 20 mM, preferably at most about 15 mM, more preferably at most about 10 mM, such as about 10 mM.
[0113] 4. The aqueous phase is substantially free of inorganic sulphate anions and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions, in particular inorganic sulphate anions, carbonate anions, dibasic organic acid anions. 3. The composition according to any one of Items 1 to 3, which is substantially free of acid anions and polybasic organic acid anions.
[0114] 5. The monovalent anion is selected from the group consisting of chloride, acetate, glycolic acid and lactic acid, and the concentration of the monovalent anion in the composition is at most equal to the concentration of the buffer substance in the composition, preferably the buffer in the composition. The composition of any of items 1 to 4, wherein the concentration of the substance is less than, for example, less than about 9mM.
[0115] 6. The monovalent anion is selected from the group consisting of MES, MOPS and HEPES anions, and the concentration of the monovalent anion in the composition is at least equal to the concentration of the buffer substance in the composition, preferably the concentration of the buffer substance in the composition. The composition of any of items 1 to 4, which is higher.
[0116] 7. The composition according to any one of items 1 to 6, wherein the pH of the composition is about 6.5 to about 8.0, preferably about 6.9 to about 7.9, for example about 7.0 to about 7.8.
[0117] 8. The composition of any of Items 1 to 7, wherein water is the main component of the composition and / or the total amount of solvents other than water contained in the composition is less than about 0.5% (v / v).
[0118] 9. The osmolarity of the composition is up to approximately 400 x 10 -3 The composition according to any of Items 1 to 8, which is osmol / kg.
[0119] 10. Items 1 to 1, wherein the concentration of RNA in the composition is about 5 mg / l to about 150 mg / l, preferably about 10 mg / l to about 130 mg / l, more preferably about 30 mg / l to about 120 mg / l. Any composition of 9.
[0120] 11. The composition comprises a cryoprotectant, preferably at a concentration of at least about 1% w / v, wherein the cryoprotectant preferably comprises one or more compounds selected from the group consisting of carbohydrates and sugar alcohols. , more preferably the cryoprotectant is selected from the group consisting of sucrose, glucose, glycerol, sorbitol and combinations thereof, more preferably the cryoprotectant comprises sucrose and / or glycerol. thing.
[0121] 12. The composition according to any one of Items 1 to 10, wherein the composition is substantially free of a cryoprotectant.
[0122] 13. The composition of any of paragraphs 1 to 12, wherein the cationically ionizable lipid comprises a head group containing at least one nitrogen atom that can be protonated under physiological conditions.
[0123] 14. Cationically ionizable lipids have formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where: L 1 or L 2 -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 is alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 Cycloalkylene, C 3 -C 8 Cycloalkenylene; R a is H or C 1 -C 12 is alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 is alkenyl; R 3 is H, OR 5 ,CN,-C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 And; R 4 is C 1 -C 12 is alkyl; R 5 is H or C1 -C 6 is alkyl; and x is 0, 1 or 2, The composition according to any of Items 1 to 13.
[0124] 15. (α) the cationically ionizable lipid is selected from structures I-1 to I-36 shown herein; or (β) the cationically ionizable lipid is selected from structures A-F shown herein; or (γ) The cationically ionizable lipid is a lipid having structure I-3 shown here, The composition according to any of Items 1 to 13.
[0125] 16. The LNP preferably comprises one or more additional lipids selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids and combinations thereof, more preferably the LNPs comprise cationically ionizable lipids, The composition according to any one of Items 1 to 15, comprising a polymer conjugated lipid, a neutral lipid, and a steroid.
[0126] 17. The polymer conjugate lipid comprises a pegylated lipid, where the pegylated lipid preferably has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where: R 12 and R 13 is independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester bonds; and The composition according to item 16, wherein w has an average value in the range of 30 to 60.
[0127] 18. The polymer-conjugated lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance, wherein the polysarcosine-lipid conjugate or the conjugate of polysarcosine and a lipid-like substance is preferably polysarcosine. - diacylglycerol conjugate, polysarcosine-dialkyloxypropyl conjugate, polysarcosine-phospholipid conjugate, polysarcosine-ceramide conjugate, and mixtures thereof.
[0128] 19. The neutral lipid is preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin, more preferably distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC). ), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialchydoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), Dilignoceleoylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl- 2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanol amine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE). The composition according to any one of Items 16 to 18, which is a lipid.
[0129] 20. The composition according to any of Items 16 to 19, wherein the steroid contains a sterol such as cholesterol.
[0130] 21. The composition according to any one of Items 1 to 20, wherein the aqueous phase does not contain a chelating agent.
[0131] 22. The composition of any of paragraphs 1 to 21, wherein the LNP comprises at least about 75%, preferably at least about 80%, of the RNA contained in the composition.
[0132] 23. The composition according to any one of Items 1 to 22, wherein RNA is encapsulated or bound to LNP.
[0133] 24. The RNA comprises a modified nucleoside in place of uridine, wherein the modified nucleoside is preferably selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U), The composition according to any of Items 1 to 23.
[0134] 25. The composition according to any of paragraphs 1 to 24, wherein the RNA comprises at least one, preferably all, of a 5' cap; 5' UTR; 3' UTR; and poly-A sequence.
[0135] 26. The composition of paragraph 25, wherein the poly-A sequence comprises at least 100 A nucleotides, preferably the poly-A sequence is an interrupted sequence of A nucleotides.
[0136] 27. The composition of paragraph 25 or 26, wherein the 5' cap is of Cap 1 or Cap 2 configuration.
[0137] 28. The composition of any of paragraphs 1 to 27, wherein the RNA encodes one or more polypeptides, wherein the one or more polypeptides preferably include an epitope for inducing an immune response to the antigen in an elephant.
[0138] 29. The RNA comprises an open reading frame (ORF) encoding an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof; Composition of item 28.
[0139] 30. The composition of paragraph 28 or 29, wherein the RNA comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1.
[0140] 31. The composition of paragraph 29 or 30, wherein the SARS-CoV2 S protein variant has at least 80% identity to SEQ ID NO:7.
[0141] 32. The composition according to any of Items 1 to 31, wherein the composition is in frozen form.
[0142] 33. The composition of paragraph 32, wherein the RNA integrity after thawing the frozen composition is at least 50% compared to the RNA integrity before the composition was frozen.
[0143] 34. Size of LNPs after thawing frozen composition (Z 平均 ) and / or size distribution and / or polydispersity index (PDI) of the LNPs before the composition is frozen (Z 平均 ) and / or size distribution and / or PDI.
[0144] 35. The composition according to any one of items 1 to 31, wherein the composition is in liquid form.
[0145] 36. A method of preparing a composition comprising LNPs dispersed in a final aqueous phase, wherein the LNPs comprise a cationically ionizable lipid and RNA; the final aqueous phase comprises a final buffer substance and a final monovalent a final buffer system comprising an anion, wherein the final buffer substance is selected from the group consisting of Tris and its protonated form, bis-Tris-methane and its protonated form, and TEA and its protonated form, and the final monovalent anion is selected from the group consisting of Tris and its protonated form; the final buffer substance concentration in the composition is up to about 25 mM; and the final aqueous phase contains inorganic phosphorus. substantially free of acid anions, substantially free of citrate anions and substantially free of EDTA anions; (I) preparing a formulation comprising LNPs dispersed in a final aqueous phase, wherein the LNPs comprise cationically ionizable lipids and RNA; and (II) If desired, freeze the preparation to approximately -10°C or lower, thereby obtaining a composition; Here, step (I) is: (a) preparing an RNA solution containing water and a first buffer system; (b) preparing an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; (c) Mixing the RNA solution prepared under (a) and the ethanolic solution prepared under (b), thereby creating a first buffer system containing LNPs dispersed in an intermediate aqueous layer containing a first buffer system. prepare an intermediate formulation; and (d) filtering the first intermediate formulation prepared under (c) using the final aqueous buffer solution containing the final buffer system; A method comprising thereby preparing a formulation comprising LNPs dispersed in a final aqueous phase.
[0146] 37. The method of paragraph 36, wherein step (I) further comprises one or more steps selected from dilution and filtration.
[0147] 38. Process (I) (a’) prepare an aqueous RNA solution; (b') preparing a first aqueous buffer solution comprising a first buffer system; (c') Mix the aqueous RNA solution prepared under (a') and the first aqueous buffer solution prepared under (b'), thereby preparing an RNA solution containing water and the first buffer system. death; (d') preparing an ethanolic solution comprising a cationically ionizable lipid and, if present, one or more additional lipids; (e') Mix the RNA solution prepared under (c') and the ethanolic solution prepared under (d'), thereby dispersing the LNPs dispersed in the first aqueous phase containing the first buffer system. preparing a first intermediate formulation comprising; (f') optionally filtering the first intermediate formulation prepared under (e') using a further aqueous buffer solution containing a further buffer system, thereby dispersing it in a further aqueous phase containing a further buffer system; preparing a further intermediate formulation comprising the LNPs, wherein the further aqueous buffer solution may be the same or different from the first aqueous buffer solution; (g') optionally repeating step (f') one or more times, wherein a further step (f') comprising LNPs dispersed in a further aqueous phase comprising a further buffer system obtained after one cycle of step (f'); the intermediate formulation is used as the first intermediate formulation in the next cycle, where in each cycle the further aqueous buffer solution may be the same or different from the first aqueous buffer solution; (h') If there is no filtration step (f'), then the first intermediate preparation obtained in step (e') or step (f') exists, and if step (g') does not exist, then step (f') ) or, if steps (f') and (g') are present, the further intermediate formulation obtained after step (g'), including the final buffer system and having a pH of at least 6.0. filtered using an aqueous buffer solution; and (i') optionally diluting the formulation obtained in step (h') with a diluent solution; 38. The method of paragraph 36 or 37, thereby comprising preparing a formulation comprising LNPs dispersed in the final aqueous phase.
[0148] 39. The method according to any of items 36 to 38, wherein the filtration is tangential flow filtration or diafiltration, preferably tangential flow filtration.
[0149] 40. (II) The method of any of Items 36 to 39, which includes freezing the preparation to about -10°C or lower.
[0150] 41. The method of any of paragraphs 36 to 40, wherein the final buffer substance is Tris and its protonated form.
[0151] 42. Any of paragraphs 36 to 41, wherein the concentration of the final buffer substance, particularly Tris and its protonated form, in the composition is at most about 20 mM, preferably at most about 15 mM, more preferably at most about 10 mM, such as about 10 mM. the method of.
[0152] 43. The final aqueous phase is substantially free of inorganic sulphate anions and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions, in particular inorganic sulphate anions, carbonate anions, dibasic organic acid anions. 43. The method according to any one of Items 36 to 42, wherein the method is substantially free of organic acid anions and polybasic organic acid anions.
[0153] 44. (i) The RNA solution prepared in step (a) further comprises one or more di- and / or polybasic organic acid anions, and step (d) provides that the final aqueous phase contains the RNA prepared in step (a). one or more di- and / or polybasic resulting in a formulation comprising LNPs dispersed in the final aqueous layer that is substantially free of one or more di- and / or polybasic organic acid anions present in solution or (ii) the first aqueous buffer solution and the first aqueous phase comprise one or more di- and / or polybasic organic acid anions; step (f') Any of paragraphs 36 to 43, wherein at least one of ~(h') is carried out under conditions that remove one or more di- and / or polybasic organic acid anions from the first intermediate preparation and / or further intermediate preparation. That method.
[0154] 45. (i) the RNA solution obtained in step (a) has a pH of less than 6.0, preferably at most about 5.0, more preferably at most about 4.5; or (ii) the first aqueous buffer solution is less than 6.0, preferably has a pH of at most about 5.0, more preferably at most about 4.5.
[0155] 46. The method of paragraph 44 or 45, wherein the one or more di- and / or polybasic organic acid anions comprise a citrate anion and / or an anion of EDTA.
[0156] 47. (i) The first buffer system used in step (a) comprises the final buffer substance used in step (d) and the final monovalent anion, preferably the buffer of the first buffer system used in step (a). system and pH are the same as the buffer system and pH of the final aqueous buffer solution used in step (d); or (ii) the first buffer system and steps (b'), (f') and (g'). All further buffer systems used in step (h') each contain the final buffer substance and the final monovalent anion used in step (h'), preferably the first aqueous buffer solution and steps (b'), (f') and ( The method of any of paragraphs 36 to 43, wherein the buffer system and pH of each of all further aqueous buffer solutions used in g') is the same as the buffer system and pH of the final aqueous buffer solution.
[0157] 48. The final monovalent anion is selected from the group consisting of chloride, acetate, glycolic acid and lactic acid, and the concentration of the final monovalent anion in the composition is preferably equal to the concentration of the final buffer substance in the composition. 48. The method of any of paragraphs 36 to 47, wherein the concentration of the final buffer substance in the composition is less than, for example less than about 9 mM.
[0158] 49. The final monovalent anion is selected from the group consisting of MES, MOPS and HEPES anions, and the concentration of the final monovalent anion in the composition is at least equal to the concentration of the final buffer substance in the composition, preferably in the composition. The method according to any of paragraphs 36 to 48, in which the final buffer substance concentration is higher than the final concentration of the buffer substance.
[0159] 50. The method according to any of items 36 to 49, wherein the pH of the composition is about 6.5 to about 8.0, preferably about 6.9 to about 7.9, for example about 7.0 to about 7.8.
[0160] 51. Any of paragraphs 36 to 50, wherein water is the main component of the formulation and / or composition and / or the total amount of solvents other than water contained in the composition is less than about 0.5% (v / v). Method.
[0161] 52. The osmolarity of the composition is up to approximately 400 x 10 -3 The method of any of Items 36 to 51, which is osmol / kg.
[0162] 53. Item 36~, wherein the concentration of RNA in the composition is about 5 mg / l to about 150 mg / l, preferably about 10 mg / l to about 130 mg / l, more preferably about 30 mg / l to about 120 mg / l. Any of 52 methods.
[0163] 54. (i) Step (I) further comprises diluting the formulation prepared under (d) with a diluting solution, or there is a step (i'), wherein the diluting solution contains a cryoprotectant. and / or (ii) the formulations and compositions obtained in step (I) contain a cryoprotectant, preferably at a concentration of at least about 1% w / v, wherein the cryoprotectant preferably contains carbohydrates and one or more selected from sugar alcohols, more preferably the cryoprotectant is selected from the group consisting of sucrose, glucose, glycerol, sorbitol and combinations thereof, more preferably the cryoprotectant comprises sucrose and / or glycerol , any method of items 36 to 53.
[0164] 55. The method according to any one of Items 36 to 53, wherein the preparation and composition obtained in step (I) are substantially free of cryoprotectants.
[0165] 56. The method of any of paragraphs 36 to 55, wherein the cationically ionizable lipid comprises a head group containing at least one nitrogen atom that can be protonated under physiological conditions.
[0166] 57. Cationically ionizable lipids have formula (I): [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer structure thereof, where: L 1 or L 2 -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x-, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -,NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 is alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 Cycloalkylene, C 3 -C 8 Cycloalkenylene; R a is H or C 1 -C 12 is alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 is alkenyl; R 3 is H, OR 5 ,CN,-C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 And; R 4 is C 1 -C 12 is alkyl; R 5 is H or C 1 -C 6 is alkyl; and x is 0, 1 or 2, Any method from items 36 to 56.
[0167] 58. (α) the cationically ionizable lipid is selected from structures I-1 to I-36 shown herein; or (β) the cationically ionizable lipid is selected from structures A-F shown herein; or (γ) The cationically ionizable lipid is a lipid having structure I-3 shown here, Any method from items 36 to 56.
[0168] 59. The ethanolic solution prepared in step (b) or (d') further comprises one or more additional lipids, and the LNP further comprises one or more additional lipids, wherein the one or more additional lipids Paragraphs 36-58, preferably selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids and combinations thereof, more preferably one or more additional lipids comprising polymer-conjugated lipids, neutral lipids and steroids Either method.
[0169] 60. The polymer conjugate lipid comprises a pegylated lipid, where the pegylated lipid preferably has the following structure: [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer structure thereof, where: R 12 and R 13 is independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester bonds; and The method of paragraph 59, wherein w has an average value in the range of 30 to 60.
[0170] 61. The polymer-conjugated lipid comprises a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance, wherein the polysarcosine-lipid conjugate or the conjugate of polysarcosine and a lipid-like substance is preferably polysarcosine. - The method of paragraph 59, wherein the conjugate is a member selected from the group consisting of: - diacylglycerol conjugate, polysarcosine-dialkyloxypropyl conjugate, polysarcosine-phospholipid conjugate, polysarcosine-ceramide conjugate, and mixtures thereof.
[0171] 62. The neutral lipid is preferably selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine and sphingomyelin, more preferably distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC). ), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dialchydoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), Dilignoceleoylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl- 2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanol amine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE). The method according to any of Items 59 to 61, which is a lipid.
[0172] 63. The method according to any of Items 59 to 62, wherein the steroid contains a sterol such as cholesterol.
[0173] 64. Cationically ionizable lipids, polymer conjugated lipids, neutral lipids and steroids in ethanolic solution with 20% to 60% cationically ionizable lipids, 0.5% to 15% polymer conjugated lipids, Molar ratio of 5% to 25% neutral lipids and 25% to 55% steroids, preferably 45% to 55% cationically ionizable lipids, 1.0% to 5% polymer conjugated lipids, 8% The method of any of paragraphs 36 to 63, wherein the molar ratio of ~12% neutral lipid and 35% to 45% steroid is present.
[0174] 65. The method of any of paragraphs 36 to 64, wherein the final aqueous phase does not contain a chelating agent.
[0175] 66. The method of any of paragraphs 36 to 65, wherein the LNP comprises at least about 75%, preferably at least about 80%, of the RNA comprised in the composition.
[0176] 67. The method of any of paragraphs 36 to 66, wherein RNA is encapsulated or bound to LNP.
[0177] 68. The RNA comprises a modified nucleoside in place of uridine, wherein the modified nucleoside is preferably selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U), Any method from items 36 to 67.
[0178] 69. The method of any of paragraphs 36 to 68, wherein the RNA comprises at least one, preferably all, of a 5' cap; 5' UTR; 3' UTR; and poly-A sequence.
[0179] 70. The method of paragraph 69, wherein the poly-A sequence comprises at least 100 A nucleotides, preferably the poly-A sequence is an interrupted sequence of A nucleotides.
[0180] 71. The method of paragraph 69 or 70, wherein the 5' cap is of Cap 1 or Cap 2 construction.
[0181] 72. The method of any of paragraphs 36 to 71, wherein the RNA encodes one or more polypeptides, wherein the one or more polypeptides preferably include an epitope for inducing an immune response to the antigen in an elephant.
[0182] 73. The RNA comprises an open reading frame (ORF) encoding an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof; Method of Section 72.
[0183] 74. The method of paragraph 72 or 73, wherein the RNA comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1.
[0184] 75. The method of paragraph 73 or 74, wherein the SARS-CoV2 S protein variant has at least 80% identity to SEQ ID NO:7.
[0185] 76. The method of any of Items 36 to 39 and 41 to 75, which does not include step (II).
[0186] 77. Prepare a composition by any method of items 36 to 75, and heat the composition to about -90°C to about -10°C, such as about -90°C to about -40°C or about -25°C to about -10°C. A method of storing a composition comprising storing it at a temperature in the range of °C.
[0187] 78. Storage of the composition is for at least 1 week, such as at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 12 months, at least 24 months or at least 36 months. The method of Section 77, which is months.
[0188] 79. Prepare a composition by any of the methods in Items 36 to 78, and heat the composition to about 0°C to about 20°C, such as about 1°C to about 15°C, about 2°C to about 10°C, or about 2°C to A method of storing a composition comprising storing at a temperature in the range of about 8°C or at a temperature of about 5°C.
[0189] 80. The method of paragraph 79, wherein storage of the composition is for at least 1 week, such as at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months or at least 6 months.
[0190] 81. A composition that can be prepared by any method of items 36 to 80.
[0191] 82. The composition of paragraph 81, which is in frozen form.
[0192] 83. The composition of paragraph 82, wherein the RNA integrity after thawing the frozen composition is at least 50% compared to the RNA integrity before the composition was frozen.
[0193] 84. Size of LNPs after thawing frozen composition (Z 平均 ) and / or size distribution and / or polydispersity index (PDI) of the LNPs before the composition is frozen (Z 平均 ) and / or size distribution and / or PDI.
[0194] 85. The composition of paragraph 81, which is in liquid form.
[0195] 86. The composition of paragraph 85, wherein the RNA integrity after storing the composition for at least one week is at least 50% compared to the RNA integrity before storage.
[0196] 87. Size of LNPs (Z 平均 ) and / or size distribution and / or polydispersity index (PDI) equal to that of the LNPs before storage.
[0197] 88. A ready-to-use pharmaceutical composition, comprising the step of preparing a frozen composition by any of the methods of paragraphs 36 to 75, 77, and 78, and thawing the frozen composition, thereby obtaining a ready-to-use pharmaceutical composition. How to prepare.
[0198] 89. Prepare a ready-to-use pharmaceutical composition, comprising the step of preparing a liquid composition by any of the methods of items 36-39, 41-76, 79, and 80, thereby obtaining a ready-to-use pharmaceutical composition. Method.
[0199] 90. A ready-to-use pharmaceutical composition that can be prepared by the method of paragraph 88 or 89.
[0200] 91. The composition according to any of Items 1 to 35, 81 to 87, and 90 for use in treatment.
[0201] 92. The composition according to any one of Items 1 to 35, 81 to 87, and 90 for use in inducing an immune response in a subject.
[0202] Further aspects of the invention are disclosed herein. [Brief explanation of drawings]
[0203]
Figure 1
[0204]
Figure 2
[0205] [Figure 3] The morphology of selected RNA LNP compositions is shown. The vitrified samples were analyzed by cryo-electron microscopy. For the D028 sample, 2.5x higher magnification was used.
[0206] [Figure 4] Figure 2 shows mouse immunogenicity of LNP compositions. 1 μg of RNA LNP compositions D028 (LNP A), D029 (LNP B) and D030 (LNP C) were injected i.m. into mice, and reference composition (ATM) and saline were used as controls. S1 protein expression (left panel) and S1 IgG production (right panel) were followed for 28 days. Total RNA LNP compositions have comparable biological activity relative to each other and the reference composition.
[0207] [Figure 5] Stability of RNA LNP composition D028 (A) and RNA LNP compositions D029 (B) and D030 (C) is shown. Square: room temperature, diamond: 5℃, triangle: -20℃, circle -70℃. Solid line: particle size, RNA integrity or RNA content; dotted line: PDI, LMS (RNA meaning stable folding) or RNA encapsulation.
[0208] [Figure 6] Colloidally stable RNA LNP compositions with buffer strengths of 10mM or 50mM are shown. Square: room temperature, diamond: 5℃, triangle: -20℃. The solid line shows the particle size and the dotted line shows the PDI.
[0209] [Figure 7] The stability of RNA against the strength of Tris buffer is shown. Results indicate the % of RNA modalities present in the sample after a certain time and condition. RNA refers to full-length RNA; LMS refers to the highly stable folded form of RNA; and Frag refers to RNA fragments of the sample.
[0210] Sequence description The following table provides a list of certain sequences mentioned herein. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6]
[0211] Detailed description of the invention Although the invention is described in further detail below, it is to be understood that this disclosure is not limited to the particular methods, protocols and reagents described herein, as they may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the invention, which is limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[0212] Below, elements of the invention are described in further detail. Although these elements are listed in conjunction with particular embodiments, it is to be understood, however, that they may be combined in any way and in any number to produce additional embodiments. The various described examples and preferred embodiments are not to be construed as limiting the invention only to the specifically stated embodiments. This description is to be understood to support and encompass embodiments that combine any number of disclosed and / or preferred elements with the specified embodiments. Furthermore, all permutations and combinations of all elements described in this application should be construed as disclosed by the description of this application, unless the context indicates otherwise. For example, if in a preferred embodiment the composition (or formulation) comprises a cryoprotectant and in another preferred embodiment the cationically ionizable lipid has structure I-3, then in a further preferred embodiment the composition (or formulation) comprises a cryoprotectant and a cationically ionizable lipid having structure I-3.
[0213] Preferably, the terms used herein refer to "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Koelbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland , (1995).
[0214] The practice of the present invention will employ, unless otherwise indicated, conventional chemistry, biochemistry, cell biology, immunology and recombinant DNA techniques, as described in the art literature (e.g., Organikum, Deutscher Verlag der Wissenschaften, Berlin). 1990; Streitwieser / Heathcook, "Organische Chemie", VCH, 1990; Beyer / Walter, "Lehrbuch der Organischen Chemie", S. Hirzel Verlag Stuttgart, 1988; Carey / Sundberg, "Organische Chemie", VCH, 1995; March, " "Advanced Organic Chemistry", John Wiley & Sons, 1985; Roempp Chemie Lexikon, Falbe / Regitz (Hrsg.), Georg Thieme Verlag Stuttgart, New York, 1989; Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
[0215] Throughout this specification and the claims that follow, unless the context requires otherwise, the term "comprises" and variations thereof, such as "including" and "comprising," are used to refer to the members, integers or steps listed. or is understood to imply the inclusion of a member, integer or group of steps, but not the exclusion of other members, integers or steps or groups of members, integers or steps. The term "consisting essentially of" means the exclusion of other members, integers or steps of any essential value. The term "comprising" includes the term "consisting essentially of," which in turn includes the term "consisting of." Thus, in each case in this application, the term "comprising" may be replaced by the term "consisting essentially of" or "consisting of." Similarly, in each case in this application, the term "consisting essentially of" may be replaced by the term "consisting of."
[0216] As used in the description of the invention, particularly in the claims, references to the singular and the singular are to be construed as encompassing both the singular and the plural, unless the context clearly dictates otherwise. The recitation of ranges of values herein is intended merely to serve as a shorthand way of individually referring to each individual value falling within the range. Unless otherwise specified herein, each individual value is included herein as if individually set forth herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contrary to context. Any and all examples or exemplary terms (e.g., "etc.") provided herein are intended merely to better illustrate the invention and are not intended to limit the scope of the invention as otherwise claimed. Not imposed. No language in the invention should be construed as indicating any non-claimed element essential to the practice of the invention.
[0217] As used herein, "and / or" is construed as specific disclosure of each of the two specified properties or components, with or without the other. For example, "X and / or Y" shall be construed to disclose the specific disclosure of (i) X, (ii) Y and (iii) each of X and Y as each individually indicated herein. .
[0218] In the present invention, the term "about" means an interval of precision that is understood by a person skilled in the art to still be able to ascertain the technical implications of the nature of the problem. This term refers to ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ± Deviations of 0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05% and eg ±0.01% are indicated. As will be recognized by those skilled in the art, the specific such deviations in numerical values for a given technical effect will depend on the nature of the technical effect. For example, natural or biotechnological influences may generally result in greater deviations than human or engineered technological influences.
[0219] The recitation of ranges of values herein is intended merely to serve as a shorthand way of individually referring to each individual value falling within the range. Unless otherwise specified herein, each individual value is included herein as if individually set forth herein.
[0220] Several documents are cited throughout this specification. Each of the documents cited herein (including all patents, patent applications, scientific articles, manufacturer's specifications, instructions, etc.), whether supra or infra, is incorporated herein by reference in its entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
[0221] definition In the following, definitions are provided that apply to all aspects of the invention. The following terms have the following meanings unless otherwise specified: Any undefined terms have their recognized meanings.
[0222] As used herein, terms such as "reducing" or "inhibiting" the level of, e.g., about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or above means the ability to cause an overall phenomenon of about 40% or more, about 50% or more, or about 75% or more. The term "inhibition" or similar terms includes complete or essentially complete inhibition, ie, a reduction to zero or essentially zero.
[0223] Terms such as "increase" or "enhance" refer to at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 80% or at least about 100% in certain embodiments. relating to an increase or enhancement of.
[0224] "Physiological pH" as used herein refers to a pH of about 7.5.
[0225] "Physiological conditions" as used herein refers to conditions (especially pH and temperature) in living subjects, especially humans. Preferably, physiological conditions refer to a physiological pH and / or a temperature of about 37°C.
[0226] As used herein, "%(w / v)" or "(%w / v)" refers to the amount of solute in grams (g) expressed as a percent of the total volume of a solution in milliliters (ml). It refers to weight / volume percent, which is the concentration unit for measuring concentration.
[0227] As used herein, "% by weight" or "%(w / w)" or "(%w / w)" means grams (g) expressed as a percent of the total weight of the total composition in grams (g). weight percent, which is a concentration unit for measuring the amount of a substance in g).
[0228] Regarding the presence of inorganic divalent ions, particularly divalent inorganic cations, their concentration or effective concentration (in the presence of free ions) due to the presence of a chelating agent is, in certain embodiments, sufficiently low to prevent RNA degradation. In certain embodiments, the concentration or effective concentration of divalent inorganic ions is below the catalytic level for hydrolysis of phosphodiester bonds between RNA nucleotides. In certain embodiments, the concentration of free divalent inorganic ions is 20 μM or less. In certain embodiments, there are no or essentially no free divalent inorganic ions.
[0229] "Osmolality" refers to the concentration of a particular solute expressed as osmoles of solute / kilograms of solvent.
[0230] The term "freezing" refers to the solidification of a liquid, usually by removing heat.
[0231] The term "aqueous phase" as used herein in relation to compositions / formulations containing particles, particularly LNPs, refers to a mobile or liquid phase containing all the elements dissolved therein except (formally) excluding the particles, i.e. , meaning continuous aqueous phase. Therefore, if particles such as LNPs are dispersed in an aqueous phase and the aqueous phase is substantially free of compound The concentration of Compound X in the composition is less than 1% by weight. However, at the same time it is possible that the particles dispersed in the aqueous phase may contain compound X in an amount of more than 1% by weight.
[0232] The expression "protonated form" as used herein in connection with a base (e.g., an organic primary amine such as Tris) refers to a conjugate of a base in which the conjugate acid contains a proton that can be removed by deprotonation to yield the base. means acid. For example, the protonated form of Tris has the formula [H 3 N(CH 2 CH 2 OH) 3 ] + has. As used herein, a "buffer substance" is a mixture of a base and its protonated form (e.g., Tris and [H 3 N(CH 2 CH 2 OH) 3 ] + a mixture of As a result, the amount of buffer material included in the composition is the total amount of both base and conjugated acid in the composition.
[0233] The term "recombinant" in the present invention means "produced through genetic engineering." In certain embodiments, "recombinant" in the present invention is not naturally occurring.
[0234] The term "naturally occurring" as used herein refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that occurs in organisms (including viruses), that can be isolated from a natural source, and that has not been intentionally modified by humans in a laboratory is naturally occurring. The term "naturally occurring" means "occurring in nature" and includes both known objects as well as objects that have not yet been discovered and / or isolated from nature, but will be discovered and / or isolated from natural sources in the future. Contains objects obtained.
[0235] As used herein, the terms "room temperature" and "ambient temperature" are used interchangeably herein and range from at least about 15°C, preferably from about 15°C to about 35°C, from about 15°C to about 30°C, from about 15°C to It refers to a temperature of about 25°C or about 17°C to about 22°C. Such temperatures include 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C and 22°C.
[0236] The term "alkyl" refers to a saturated straight or branched hydrocarbon monoradical. Preferably the alkyl group is C 1-12 Alkyl abbreviated as 1 to 12 (e.g. 1 to 10) carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. C 1-10 Alkyl (abbreviated as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 1 to 8 carbon atoms, e.g. Contains ~6 or 1-4 carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, iso-propyl (also called 2-propyl or 1-methylethyl), butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, sec- Pentyl, neo-pentyl, 1,2-dimethyl-propyl, iso-amyl, n-hexyl, iso-hexyl, sec-hexyl, n-heptyl, iso-heptyl, n-octyl, 2-ethyl-hexyl, n- Includes nonyl, n-decyl, n-undecyl, n-dodecyl, etc. "Substituted alkyl" refers to one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkyl group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein. Examples of substituted alkyl include chloromethyl, dichloromethyl, fluoromethyl and difluoromethyl.
[0237] The term "alkylene" refers to a saturated straight or branched hydrocarbon diradical. Preferably, alkylene has 1 to 12 (e.g. 1 to 10) carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11 or 12 carbon atoms (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 1 to 12 carbon atoms Contains 8 carbon atoms, such as 1-6 or 1-4 carbon atoms. Examples of alkylene groups are methylene, ethylene (i.e. 1,1-ethylene, 1,2-ethylene), propylene (i.e. 1,1-propylene, 1,2-propylene (-CH(CH 3 )CH 2 -), 2,2-propylene(-C(CH 3 ) 2 -) and 1,3-propylene), butylene isomers (e.g. 1,1-butylene, 1,2-butylene, 2,2-butylene, 1,3-butylene, 2,3-butylene (cis or trans or mixtures thereof), 1,4-butylene, 1,1-iso-butylene, 1,2-iso-butylene and 1,3-iso-butylene), pentylene isomers (e.g. 1,1-pentylene, 1, 2-pentylene, 1,3-pentylene, 1,4-pentylene, 1,5-pentylene, 1,1-iso-pentylene, 1,1-sec-pentyl, 1,1-neo-pentylene), hexylene isomers (e.g. 1,1-hexylene, 1,2-hexylene, 1,3-hexylene, 1,4-hexylene, 1,5-hexylene, 1,6-hexylene and 1,1-isohexylene), heptylene isomers ( For example, 1,1-heptylene, 1,2-heptylene, 1,3-heptylene, 1,4-heptylene, 1,5-heptylene, 1,6-heptylene, 1,7-heptylene and 1,1-isoheptylene) , octylene isomers (e.g. 1,1-octylene, 1,2-octylene, 1,3-octylene, 1,4-octylene, 1,5-octylene, 1,6-octylene, 1,7-octylene, 1 , 8-octylene and 1,1-isooctylene). Straight chain alkylene moieties having at least 3 carbon atoms and a free valence at each end are also considered methylenes (eg, 1,4-butylene can also be referred to as tetramethylene). Generally, instead of using "ylene" at the end of an alkylene moiety as above, "diyl" may be used at the end (e.g., 1,2-butylene can also be referred to as butane-1,2-diyl). ). "Substituted alkylene" refers to one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkylene group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0238] The term "alkenyl" refers to an unsaturated straight or branched hydrocarbon monoradical having at least one carbon-carbon double bond. Generally, the maximum number of carbon-carbon double bonds in an alkenyl group is determined by dividing the carbon atoms in the alkenyl group by 2, and if the alkenyl group has an odd number of carbon atoms, rounding the result of the division to the next lower integer. , equal to an integer. For example, for an alkenyl group with 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenyl group has 1 to 6 (eg 1 to 4) carbon-carbon double bonds, ie 1, 2, 3, 4, 5 or 6 carbon-carbon double bonds. Preferably, the alkenyl group has 2 to 12 (eg 2 to 10) carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 2 to 8 carbon atoms , having, for example, 2 to 6 carbon atoms or 2 to 4 carbon atoms. Thus, in a preferred embodiment, the alkenyl group is C 2-12Alkenyl abbreviated as having 2 to 12, (e.g. 2 to 10) carbon atoms and 1, 2, 3, 4, 5 or 6 (e.g. 1, 2, 3, 4 or 5) carbon-carbon double bonds, more preferably 2 to 8 carbon atoms and 1, 2, 3 or 4 carbon-carbon double bonds, such as 2 to 6 of carbon atoms and 1, 2 or 3 carbon-carbon double bonds or 2 to 4 carbon atoms and 1 or 2 carbon-carbon double bonds. Carbon-carbon double bonds can be in the cis (Z) or trans (E) configuration. Examples of alkenyl groups are vinyl, 1-propenyl, 2-propenyl (i.e. allyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1 -hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl , 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8 -nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl , 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6 -Dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, 11-dodecenyl, etc. If the alkenyl group is attached to a nitrogen atom, the double bond cannot be alpha to the nitrogen atom. "Substituted alkenyl" refers to one or more hydrogen atoms of an alkenyl group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkenyl group, e.g. 1, 2, 3, 4, 5, 6, 7 , 8, 9 or up to 10, such as 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen (1 When more than 1 hydrogen atoms are substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0239] The term "alkenylene" refers to an unsaturated straight or branched hydrocarbon diradical having at least one carbon-carbon double bond. In general, the maximum number of carbon-carbon double bonds in an alkenylene group is determined by dividing the carbon atoms in the alkenylene group by 2 and rounding the result of the division to the next lower integer if the alkenylene group has an odd number of carbon atoms. is equal to an integer. For example, for an alkenylene group with 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenylene group has 1 to 6 (eg 1 to 4) carbon-carbon double bonds, ie 1, 2, 3, 4, 5 or 6 carbon-carbon double bonds. Preferably, the alkenylene group has 2 to 12 (eg 2 to 10) carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms (e.g. 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 2 to 8 carbon atoms , containing, for example, 2 to 6 carbon atoms or 2 to 4 carbon atoms. Thus, in preferred embodiments, alkenylene groups have 2 to 12 (e.g. 2 to 10 carbon) atoms and 1, 2, 3, 4, 5 or 6 (e.g. 1, 2) atoms. , 3, 4 or 5) carbon-carbon double bonds, more preferably 2 to 8 carbon atoms and 1, 2, 3 or 4 carbon-carbon double bonds, For example, it contains 2 to 6 carbon atoms and 1, 2 or 3 carbon-carbon double bonds or 2 to 4 carbon atoms and 1 or 2 carbon-carbon double bonds. Carbon-carbon double bonds can be in the cis (Z) or trans (E) configuration. Examples of alkenylene groups are ethene-1,2-diyl, vinylidene (also called ethenylidene), 1-propene-1,2-diyl, 1-propene-1,3-diyl, 1-propene-2,3 -diyl, arylidene, 1-butene-1,2-diyl, 1-butene-1,3-diyl, 1-butene-1,4-diyl, 1-butene-2,3-diyl, 1-butene-2 ,4-diyl, 1-butene-3,4-diyl, 2-butene-1,2-diyl, 2-butene-1,3-diyl, 2-butene-1,4-diyl, 2-butene-2 ,3-diyl, 2-butene-2,4-diyl, 2-butene-3,4-diyl, etc. If the alkenylene group is attached to a nitrogen atom, the double bond cannot be alpha to the nitrogen atom. "Substituted alkenylene" refers to one or more hydrogen atoms of an alkenylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to an alkenylene group, e.g. 1, 2, 3, 4, 5, 6, 7). , 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen ( When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0240] The term "cycloalkylene" is a cyclic non-aromatic version of "alkylene" and is a geminal, vicinal or lone diradical. In certain embodiments, the cycloalkylene is (i) monocyclic or polycyclic (e.g., bi- or tricyclic) and / or (ii) 3- to 14-membered (i.e., 3-, 4-, 5-, 6-membered). , 7 members, 8 members, 9 members, 10 members, 11 members, 12 members, 13 members or 14 members, for example 3 to 12 members or 3 to 10 members). In certain embodiments, cycloalkylene is a mono-, di- or tricyclic 3- to 14-membered (i.e., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-membered, member, 13 member or 14 member, for example 3 to 12 member or 3 to 10 member) cycloalkylene. Generally, instead of using ``ylene'' at the end of a cycloalkylene moiety as above, you may use ``diyl'' at the end (for example, 1,2-cyclopropylene is also called cyclopropane-1,2-diyl). ). Examples of cycloalkylene groups are cyclohexylene, cycloheptylene, cyclopropylene, cyclobutylene, cyclopentylene, cyclooctylene, bicyclo[3.2.1]octylene, bicyclo[3.2.2]nonylene and adamantanylene (e.g. tricyclo[ 3.3.1.1 3,7 ]decane-2,2-diyl). "Substituted cycloalkylene" means one or more hydrogen atoms of an alkylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to a cycloalkylene group, e.g. 1, 2, 3, 4, 5, 6). , 7, 8, 9 or up to 10, such as 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen. (When more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0241] The term "cycloalkenylene" represents a cyclic non-aromatic version of "alkenylene" and is a geminal, vicinal or isolated diradical. Generally, the maximum number of carbon-carbon double bonds in a cycloalkenylene group is determined by dividing the carbon atoms in the cycloalkenylene group by 2, and if the carbon atoms in the cycloalkenylene group are odd, then dividing the result of the division by an integer below Equal to an integer, rounded to . For example, for a cycloalkenylene group having 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the cycloalkenylene group has 1 to 6 (eg 1 to 4), ie, 1, 2, 3, 4, 5 or 6 elementary-carbon double bonds. In certain embodiments, the cycloalkenylene is (i) monocyclic or polycyclic (e.g., bi- or tricyclic) and / or (ii) 3- to 14-membered (i.e., 3-, 4-, 5-, 6-membered). , 7 members, 8 members, 9 members, 10 members, 11 members, 12 members, 13 members or 14 members, for example 3 to 12 members or 3 to 10 members). In certain embodiments, cycloalkenylene is a mono-, di- or tricyclic 3- to 14-membered (i.e., 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-membered) 13- or 14-membered, such as 3-12 or 3-10) cycloalkenylene. Examples of cycloalkenylene groups include cyclohexenylene, cycloheptenylene, cyclopropenylene, cyclobutenylene, cyclopentenylene and cyclooctenylene. "Substituted cycloalkenylene" refers to one or more hydrogen atoms of a cycloalkenylene group (e.g. 1 to the maximum number of hydrogen atoms bonded to a cycloalkenylene group, e.g. 1, 2, 3, 4, 5, 6 , 7, 8, 9 or up to 10, for example 1 to 5, 1 to 4 or 1 to 3 or 1 or 2) are substituted with substituents other than hydrogen. meaning (when more than one hydrogen atom is substituted, the substituents may be the same or different). Preferably, the substituents other than hydrogen are first level substituents as specified herein.
[0242] The term "aromatic" used in connection with hydrocarbons means that the entire molecule must be aromatic. For example, if a monocyclic aryl is hydrogenated (partially or fully), the resulting hydrogenated cyclic structure is classified as a cycloalkyl for purposes of this invention. Similarly, if a di- or polycyclic aryl (e.g. naphthyl) is hydrogenated, the resulting hydrogenated di- or polycyclic structure (e.g. 1,2-dihydronaphthyl) is a cycloalkyl (even if one of the rings is still aromatic, such as in 1,2-dihydronaphthyl).
[0243] Typical first level substituents are preferably C 1-3 Alkyl, phenyl, halogen, -CF 3 , -OH, -OCH 3 ,-SCH 3 ,-NH 2-z (CH 3 ) z , -C(=O)OH and -C(=O)OCH 3where z is 0, 1 or 2 and C 1-3 Alkyl is methyl, ethyl, propyl or isopropyl. Particularly preferred first level substituents are methyl, ethyl, propyl, isopropyl, halogen (e.g. F, Cl or Br) and -CF 3 , for example halogens (e.g. F, Cl or Br) and -CF 3 selected from the group consisting of.
[0244] As used herein in reference to frozen compositions, the phrase "frozen composition after thawing" means that the frozen compositions are free from characteristics such as RNA integrity and / or size (Z) of the LNPs contained in the composition. 平均 ) and / or size distribution and / or PDI) must be thawed before they can be measured.
[0245] "Monovalent" compounds relate to compounds having only one functional group of interest. For example, a monovalent anion relates to a compound having only one negatively charged group, preferably under physiological conditions.
[0246] "Divalent" or "dibasic" compounds relate to compounds having two functional groups of interest. For example, a dibasic organic acid has two acid groups.
[0247] "Polyvalent" or "polybasic" compounds relate to compounds having three or more functional groups of interest. For example, polybasic organic acids have three or more acid groups.
[0248] The expression "RNA integrity" refers to the percentage of full-length (ie, non-fragmented) RNA relative to the total amount of RNA contained in the sample (ie, non-fragmented + fragmented RNA). RNA integrity is determined by separating the RNA chromatographically (e.g., using capillary electrophoresis) and determining the peak area of the main RNA peak (i.e., the peak area of full-length (i.e., non-fragmented) RNA); It can be determined by determining the peak area of total RNA and dividing the peak area of the main RNA peak by the peak area of total RNA.
[0249] The term "cryoprotectant" relates to a substance that is transferred to a formulation (eg, a formulation or composition) to protect the active ingredients of the formulation during the freezing phase.
[0250] According to the present invention, the term "peptide" includes oligos and polypeptides, including about 2 or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, which are linked to each other via peptide bonds. The above refers to a substance containing about 16 or more, about 20 or more, and up to about 50, about 100, or about 150 consecutive amino acids. Although the term "protein" refers to large peptides, particularly peptides having at least about 151 amino acids, the terms "peptide" and "protein" are generally used synonymously herein.
[0251] A "therapeutic protein" has a positive or beneficial effect on a condition or disease state of a subject when provided to the subject in a therapeutically effective amount. In certain embodiments, therapeutic proteins have curative or palliative properties and can be administered to ameliorate, palliate, alleviate, reverse, delay onset, or reduce the severity of one or more symptoms of a disease or disorder. Therapeutic proteins may have prophylactic properties and may be administered to delay disease onset or reduce the severity of such disease or condition. The term "therapeutic protein" includes the entire protein or peptide and may also refer to therapeutically active fragments thereof. Therapeutically active variants of the protein may also be included. Examples of therapeutically active proteins include, but are not limited to, vaccination antigens and immunostimulants such as cytokines.
[0252] According to the invention, once a nucleic acid, such as an RNA (e.g. mRNA) encoding a peptide or protein, has been taken up or introduced into a cell, ie transfected or transduced, that cell is present in vitro or Preferably, the peptide or protein can be brought about in expression. A cell may express the encoded peptide or protein intracellularly (eg, in the cytoplasm and / or nucleus), secrete the encoded peptide or protein, or express the encoded peptide or protein on its surface.
[0253] According to the invention, terms such as "expressing nucleic acid" and "encoding nucleic acid" or similar terms are used interchangeably herein, and with respect to a particular peptide or polypeptide, the nucleic acid is present in a suitable environment, preferably If present in a cell, it means that it can be expressed to produce the peptide or polypeptide.
[0254] The term "portion" refers to a fraction. With respect to a particular structure, such as an amino acid sequence or a protein, the term "portion" may refer to a continuous or non-contiguous fraction of the structure.
[0255] The terms "portion" and "fragment" are used interchangeably herein and refer to a contiguous element. For example, a part of a structure, such as an amino acid sequence or a protein, refers to the contiguous elements of the structure. When used in the context of a composition, the term "portion" means a portion of the composition. For example, a portion of a composition can be any portion from 0.1% to 99.9% (e.g., 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90% or 99%) of the composition. .
[0256] A "fragment" in reference to an amino acid sequence (peptide or protein) refers to a sequence representing a portion of the amino acid sequence, ie, an amino acid sequence truncated at the N-terminus and / or C-terminus. Fragments truncated at the C-terminus (N-terminal fragments) can be obtained, for example, by translation of a truncated open reading frame lacking the 3' end of the open reading frame. Fragments truncated at the N-terminus (C-terminal fragments) can be obtained, for example, by translation of a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains an initiation codon for initiating translation. It can be done. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, especially at least 8, at least 12, at least 15, at least 20, at least 30, at least 50 or at least 100 contiguous amino acids from the amino acid sequence.
[0257] According to the invention, a part or fragment of a peptide or protein preferably has at least one of the functional properties of the peptide or protein from which it is brought. Such functional properties include pharmacological activity, interaction with other peptides or proteins, enzymatic activity, interaction with antibodies, and selective binding of nucleic acids. For example, a pharmacologically active fragment of a peptide or protein comprises at least one of the pharmacological activities of the peptide or protein from which the fragment was produced. A part or fragment of a peptide or protein preferably comprises a sequence of at least 6, especially at least 8, at least 10, at least 12, at least 15, at least 20, at least 30 or at least 50 consecutive amino acids of the peptide or protein. A part or fragment of a peptide or protein preferably comprises a sequence of at most 8, especially at most 10, at most 12, at most 15, at most 20, at most 30 or at most 55 consecutive amino acids of the peptide or protein.
[0258] "Variant" herein refers to an amino acid sequence that differs from a parent amino acid sequence by at least one amino acid modification. The parent amino acid sequence can be a naturally occurring or wild type (WT) amino acid sequence or a modified version of a wild type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, such as 1 to about 20 amino acid modifications and preferably 1 to about 10 or 1 to about 5 amino acid modifications compared to the parent. have
[0259] "Wild type" or "WT" or "natural" herein means an amino acid sequence found in nature, including allelic variations. A wild-type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.
[0260] For the purposes of the present invention, "variants" of an amino acid sequence (peptide, protein or polypeptide) include amino acid insertion variants, amino acid addition variants, amino acid deletion variants and / or amino acid substitution variants. variants, splice variants, post-translational modifications, conformations, isoforms, allelic variants, species variants and species homologs, especially those that occur in nature. The term "variant" specifically includes fragments of amino acid sequences.
[0261] Amino acid insertion variants include insertions of single or more amino acids into a particular amino acid sequence. In the case of amino acid sequence variants with insertions, one or more amino acid residues are inserted at specific positions in the amino acid sequence, but random insertions with appropriate screening of the resulting products are also possible. Amino acid addition variants include amino and / or carboxy terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, eg, 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. The deletion can be made at any position in the protein. Amino acid deletion variants containing deletions at the N-terminus and / or C-terminus of a protein are also referred to as N-terminal and / or C-terminal truncated variants. Amino acid substitution variants are characterized by at least one residue in the sequence that is removed and another residue inserted in its place. Preference is given to modification of positions in the amino acid sequence that are not conserved in homologous proteins or peptides and / or substitution of amino acids by others with similar properties. Preferably, amino acid changes in peptide and protein variants are conservative amino acid changes, ie, substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes include substitutions of one of a family of amino acids that are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), and nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan). and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan and tyrosine are sometimes classified together as aromatic amino acids. In certain embodiments, conservative amino acid substitutions include substitutions within the following groups: - glycine, alanine; - valine, isoleucine, leucine; - aspartic acid, glutamic acid; - asparagine, glutamine; - serine, threonine; - lysine, arginine; and - Phenylalanine, tyrosine.
[0262] Preferably, the degree of similarity, preferably identity, between an amino acid sequence and an amino acid sequence that is a variant of the certain amino acid sequence is at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Similarity or identity is preferably at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, of the total length of the reference amino acid sequence. Indicated for amino acid regions that are at least about 80%, at least about 90% or about 100%. For example, when the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least About 160, at least about 180 or about 200 amino acids, in certain embodiments, are indicated for contiguous amino acids. In certain embodiments, similarity or identity is indicated for the entire length of the reference amino acid sequence. Alignments for determining sequence similarity, preferably sequence identity, are performed using tools known in the art, preferably using the best sequence alignment, e.g. using Align, with standard settings, preferably EMBOSS:: Can be implemented using needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0263] "Sequence similarity" indicates the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences indicates the percentage of amino acids that are identical between these sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between these sequences.
[0264] The terms "% identical" and "% identity" or similar terms are specifically intended to refer to the percentage of nucleotides or amino acids that are identical in optimal alignment between the sequences being compared. The percentage is purely statistical, and the differences between the two sequences may, but are not necessarily, randomly distributed over the entire length of the sequences being compared. Comparison of two sequences is usually performed by comparing segments or "comparison regions" of the sequences to identify local regions of corresponding sequences after optimal alignment. Optimal alignments for comparison were performed manually or with the help of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443 with the help of the local homology algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444 or with the aid of a computer program that uses said algorithm. (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In certain embodiments, the percent identity of two sequences is determined on the United States National Center for Biotechnology Information (NCBI) website (e.g., blast.ncbi.nlm.nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC=align2seq). Determine using available BLASTN or BLASTP algorithms. In one embodiment, the algorithm parameters used in the BLASTN algorithm on the NCBI website are: (i) threshold set to 10; (ii) term size set to 28; (iii) query range set to 0. maximum match; (iv) match / mismatch score set to 1, -2; (v) gap cost set to linear; and (vi) low complexity region filter used. In one embodiment, the algorithm parameters used in the NCBI website's BLASTP algorithm are: (i) threshold set to 10; (ii) term size set to 3; (iii) query range set to 0. (iv) matrix set to BLOSUM62; (v) gap cost set to Existence: 11 Extension: 1; and (vi) conditional composition score matrix adjustment.
[0265] Percentage identity involves determining the number of identical positions to which the compared sequences correspond, dividing this number by the number of compared positions (eg, the number of positions in the reference sequence), and multiplying the result by 100.
[0266] In certain embodiments, similarity or identity is expressed over a region that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the total length of the reference sequence. It will be done. For example, if the reference nucleic acid sequence consists of 200 nucleotides, the degree of identity will be at least about 100, at least about 120, at least about 140, at least about 160, at least about 180 or about 200 nucleotides, in some embodiments contiguous nucleotides. is shown about. In certain embodiments, similarity or identity is expressed over the entire length of the reference sequence.
[0267] A homologous amino acid sequence according to the invention comprises at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98 or at least 99% of the amino acid residues. Show identity.
[0268] Amino acid sequence variants described herein can be readily prepared by those skilled in the art, eg, by recombinant DNA engineering. Manipulation of DNA sequences to prepare peptides or proteins with substitutions, additions, insertions or deletions is detailed, for example, in Sambrook et al. (1989). Moreover, the peptide and amino acid variants described herein can be readily prepared with the aid of known peptide synthesis techniques, such as, for example, solid phase synthesis and similar methods.
[0269] In certain embodiments, the fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant." The term "functional fragment" or "functional variant" of an amino acid sequence refers to any fragment or variant that exhibits one or more functional properties that are identical or similar to the amino acid sequence from which it is derived, i.e., is functionally equivalent. be. With respect to antigens or antigenic sequences, one particular function is one or more immunogenic activities exhibited by the amino acid sequence from which the fragment or variant is derived. As used herein, the term "functional fragment" or "functional variant" specifically means that one or more amino acids have been changed as compared to the amino acid sequence of the parent molecule or sequence, and that one or more of the functions of the parent molecule or sequence are For example, refers to a variant molecule or sequence capable of eliciting an immune response. In certain embodiments, modifications to the amino acid sequence of a parent molecule or sequence do not significantly affect or alter the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced, but still significantly present, e.g., the immunogenicity of the functional variant is at least 50%, at least 60% that of the parent molecule or sequence. %, at least 70%, at least 80% or at least 90%. However, in other embodiments, the immunogenicity of a functional fragment or variant may be enhanced compared to the parent molecule or sequence.
[0270] A designated amino acid sequence (peptide, protein or polypeptide) "derived from" an amino acid sequence (peptide, protein or polypeptide) refers to the origin of the original amino acid sequence. Preferably, an amino acid sequence derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to the particular sequence or a fragment thereof. An amino acid sequence derived from a particular amino acid sequence can be a variant of the particular sequence or a fragment thereof. For example, those skilled in the art will appreciate that antigens suitable for use herein can be modified to differ in sequence from the naturally occurring or native sequence from which they are derived, but retain the desired activity of the native sequence.
[0271] "Isolated" means altered or removed from its natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely isolated from concomitant materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially pure form or can exist in a non-natural environment, eg, in a host cell. In a preferred embodiment, the (eg, mRNA) used in the invention is in substantially pure form. In certain embodiments, the solution (preferably an aqueous solution) of substantially pure form of RNA (eg, mRNA) comprises a first buffer system.
[0272] The term "genetic modification" or simply "modification" includes transfecting a cell with a nucleic acid. The term "transfection" relates to the introduction of nucleic acids, especially RNA, into cells. For purposes of the present invention, the term "transfection" also includes the introduction of a nucleic acid into or uptake of a nucleic acid by such a cell, where the cell may be present in a subject, eg, a patient. Thus, according to the invention, cells for transfection with the nucleic acids described herein can be present in vitro or in vivo, eg, the cells can form part of an organ, tissue and / or organism of a patient. According to the invention, transfection can be transient or stable. For some applications of transfection, it may be sufficient that the transfected genetic material is expressed only transiently. RNA can be transfected into cells to transiently express the encoded protein. Because nucleic acids introduced during the transfection process are not normally integrated into the nuclear genome, foreign nucleic acids are diluted or degraded through mitosis. Cells capable of episomal amplification of nucleic acids exhibit greatly reduced dilution rates. If it is desired that the transfected nucleic acid actually persist in the genome of the cell and its daughter cells, stable transfection must be performed. Such stable transfection can be achieved using virus-based or transposon-based systems for transfection. Generally, a nucleic acid encoding an antigen is transiently transfected into cells. RNA can be transfected into cells to transiently express the encoded protein.
[0273] According to the invention, an analogue of a peptide or protein is a modified version of the peptide or protein from which it is derived and which has at least one of the functional properties of said peptide or protein. For example, a pharmacologically active analog of a peptide or protein has at least one of the pharmacological activities of the peptide or protein from which the analog is derived. Such modifications include any chemical modification, including single or multiple substitutions, deletions and / or additions of carbohydrates, lipids and / or any molecules associated with the protein or peptide, such as the protein or peptide. In certain embodiments, the protein or peptide "analogue" is glycosylated, acetylated, phosphorylated, amidated, palmitoylated, myristoylated, isoprenylated, lipidated, alkylated, derivatized, introduced with protecting / blocking groups. , modified forms derived from proteolytic cleavage or conjugation to antibodies or other cellular ligands. The term "analog" extends to all functional chemical equivalents of the proteins and peptides.
[0274] "Activation" or "stimulation" as used herein refers to the state of immune effector cells, such as T cells, that are sufficiently stimulated to induce detectable cell proliferation. Activation may also be associated with initiation of signal transduction pathways, induction of cytokine production and detectable effector functions. The term "activated immune effector cell" refers, among other things, to an immune effector cell undergoing cell division.
[0275] The term "priming" refers to the process by which an immune effector cell, such as a T cell, first comes into contact with a specific antigen, causing differentiation into an effector cell, such as an effector T cell.
[0276] The term "clonal expansion" or "expansion" refers to the process by which a particular thing increases. In the present invention, the term is preferably used in the context of an immunological response, in which immune effector cells are stimulated by an antigen to proliferate and specific immune effector cells recognized by the antigen are amplified. Preferably, clonal expansion leads to differentiation of immune effector cells.
[0277] An "antigen" according to the present invention refers to any substance that causes an immune response and / or to which an immune response or immune system is directed, such as a cellular response. This also includes situations in which an antigen is processed into antigenic peptides, particularly when presented in the context of MHC molecules, and an immune response or immune mechanism is directed towards one or more antigenic peptides. In particular, "antigen" relates to any substance, preferably a peptide or protein, that reacts specifically with antibodies or T lymphocytes (T cells). According to the present invention, the term "antigen" includes any molecule that contains at least one epitope, such as a T cell epitope. Preferably, the antigen in the present invention is a molecule that, optionally after treatment, induces an immune response that is preferably antigen (including antigen-expressing cells) specific. In certain embodiments, the antigen is a disease-associated antigen, such as a tumor, viral or bacterial antigen, or an epitope derived from such an antigen.
[0278] According to the invention, any suitable antigen that is a candidate for an immune response may be used, where the immune response can be both a humoral and a cellular immune response. In certain embodiments of the invention, the antigen is presented by cells, preferably antigen presenting cells, preferably in the context of MHC molecules, which results in an immune response against the antigen. Antigens are preferably products directed against or derived from naturally occurring antigens. Such naturally occurring antigens may include or be derived from allergens, viruses, bacteria, fungi, parasites and other infectious agents and pathogens or the antigen may be a tumor antigen. According to the invention, an antigen may correspond to a naturally occurring product, for example a viral protein or a part thereof.
[0279] The term "disease associated antigen" is used in its broadest sense to refer to any antigen associated with a disease. Disease-associated antigens are molecules that contain epitopes that stimulate the host's immune system to mount a cellular antigen-specific and / or humoral antibody response against the disease. Disease-associated antigens include pathogen-associated antigens, ie, antigens associated with infection by microorganisms, typically associated with cancer, typically tumors, such as microbial antigens (eg, bacterial or viral antigens) or tumor antigens.
[0280] In a preferred embodiment, the antigen is a tumor antigen, ie one that appears intracellularly or as a surface antigen on the part of the tumor cell, especially primarily on the tumor cell. In other embodiments, the antigen is a pathogen-associated antigen, ie, an antigen from a pathogen, eg, a virus, a bacterium, a unicellular organism, or a parasite, eg, a viral antigen, such as a viral ribonucleoprotein or coat protein. In particular, the antigen is targeted to cells of the immune system, preferably CD4, in particular through modulation of T cell receptor activity. + and CD8 + It should be presented by MHC molecules that regulate lymphocyte activation.
[0281] The term "tumor antigen" refers to a component of a cancer cell that may be derived from the cytoplasm, cell surface, or cell nucleus. In particular, it refers to antigens produced intracellularly or as surface antigens of tumor cells. For example, tumor antigens include carcinoembryonic antigen, α1-fetoprotein, isoferritin and fetal sulfoglycoprotein, α2-H-ferroprotein and γ-fetoprotein, and various viral tumor antigens. According to the invention, tumor antigens preferably include any antigen that is characteristic of a tumor or cancer and of tumor or cancer cells in terms of type and / or level of expression.
[0282] The term "viral antigen" refers to any viral element that has antigenic properties, ie, is capable of inducing an immune response in an individual. Viral antigens can be viral ribonucleoproteins or envelope proteins.
[0283] The term "bacterial antigen" refers to any bacterial element that has antigenic properties, ie, is capable of inducing an immune response in an individual. Bacterial antigens may be derived from bacterial cell walls or cytoplasmic membranes.
[0284] The term "epitope" refers to an antigenic determinant of a molecule in an antigen, i.e., a molecule recognized by the immune system, e.g., recognized by an antibody T or B cell, especially when presented in the context of an MHC molecule. A part or fragment. Epitopes of a protein preferably include continuous or discontinuous portions of the protein, preferably about 5 to about 100, preferably about 5 to about 50, more preferably about 8 to about 0, most preferably about 10 ~25 amino acids in length, for example, the epitope is preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids in length. could be. It is particularly preferred in the present invention that the epitope is a T cell epitope.
[0285] Terms such as "epitope", "fragment of an antigen", "immunogenic peptide" and "antigenic peptide" are used interchangeably herein, preferably an antigen or a cell expressing or containing and preferably presenting the antigen. Preferably, it relates to incomplete expression of an antigen capable of eliciting an immune response against. Preferably, the term relates to an immunogenic portion of an antigen. Preferably, it is that portion of an antigen that is recognized (ie, specifically bound) by a T cell receptor, especially if presented in the context of an MHC molecule. Certain preferred immunogenic moieties bind to MHC class I or class II molecules. The term "epitope" refers to a portion or fragment of a molecule, such as an antigen, that is recognized by the immune system. For example, epitopes can be recognized by T cells, B cells or antibodies. Epitopes of an antigen may include contiguous or non-contiguous portions of the antigen and are about 5 to about 100, such as about 5 to about 50, more preferably about 8 to about 30, most preferably about 8 to about 25 amino acids in length. For example, the epitope may preferably be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids long. . In certain embodiments, the epitope is about 10 to about 25 amino acids long. The term "epitope" includes T cell epitopes.
[0286] The term "T cell epitope" refers to a portion or fragment of a protein that is recognized by a T cell when presented in the context of an MHC molecule. The term "major histocompatibility complex" and the abbreviation "MHC" refer to a gene complex that includes MHC class I and MHC class II molecules and is present in all vertebrates. MHC proteins or molecules are important for signal transduction between lymphocytes and antigen-presenting or diseased cells in immune responses, where MHC proteins or molecules bind to peptide epitopes and are recognized by T cell receptors on T cells. Present the epitope as shown. Proteins encoded by MHC are expressed on the cell surface and present self-antigens (peptide fragments from the cell itself) and non-self-antigens (eg, fragments of invading microorganisms) to T cells. For class I MHC / peptide complexes, the binding peptide is typically about 8 to about 10 amino acids long, although longer or shorter peptides may be effective. For class II MHC / peptide complexes, the binding peptide is typically about 10 to about 25 amino acids in length, particularly about 13 to about 18 amino acids in length, although longer or shorter peptides may be effective.
[0287] Peptide and protein antigens can be from 2 to 100 amino acids, including, for example, 5 amino acids, 10 amino acids, 15 amino acids, 20 amino acids, 25 amino acids, 30 amino acids, 35 amino acids, 40 amino acids, 45 amino acids or 50 amino acids in length. In certain embodiments, a peptide can be more than 50 amino acids. In certain embodiments, a peptide can be more than 100 amino acids.
[0288] A peptide or protein antigen can be any peptide or protein that can induce or increase the ability of the immune system to produce antibodies against the peptide or protein and a T cell response.
[0289] In certain embodiments, the vaccine antigen, ie, the antigen whose inoculation into a subject induces an immune response, is recognized by immune effector cells. Preferably, the vaccine antigen, if recognized by the immune effector cells, can induce stimulation, priming and / or expansion of immune effector cells carrying antigen receptors that recognize the vaccine antigen under appropriate co-stimulatory signals. . In an embodiment of the invention, the vaccine antigen is preferably presented on or present on the surface of a cell, preferably an antigen presenting cell. In certain embodiments, the antigen is presented by a diseased cell (eg, a tumor cell or an infected cell). In certain embodiments, the antigen receptor is a TCR that binds to an epitope of an antigen presented in the context of MHC. In certain embodiments, binding of a TCR results in the stimulation, priming and / or expansion of a T cell when expressed and / or presented by a T cell to an antigen presented by a cell, such as an antigen presenting cell. bring about. In certain embodiments, binding of the TCR results in cytolysis and / or apoptosis of the diseased cell when expressed by and / or presented by the T cell to an antigen presented to the diseased cell, wherein: The T cells preferably release cytotoxic factors such as perforin and granzymes.
[0290] In certain embodiments, the antigen receptor is an antibody or a B cell receptor that binds to an epitope of the antigen. In certain embodiments, the antibody or B cell receptor binds to a natural epitope of the antigen.
[0291] The term "cell surface expressed" or "cell surface bound" means that a molecule, such as an antigen, is associated with and located at the plasma membrane of a cell, where at least a portion of the molecule is located outside the cell's extracellular region. It faces the space and is accessible from outside the cell, for example by an antibody located outside the cell. In this context, the portion is preferably at least 4, preferably at least 8, preferably at least 12, more preferably at least 20 amino acids. Coupling may be direct or indirect. For example, the binding may be through one or more transmembrane domains, one or more lipid anchors, or through interaction with some other protein, lipid, saccharide, or other structure that may be found in the outer leaflet of the plasma membrane of the cell. obtain. For example, a molecule that binds to the cell surface may be a transmembrane protein that has an extracellular portion or may be a protein that binds to the cell surface by interaction with another protein that is a transmembrane protein.
[0292] "Cell surface" or "surface of a cell" is used according to its ordinary meaning in the art, and thus includes the outside of the cell that is accessible for binding by proteins and other molecules. An antigen is expressed on the cell surface if it is located on the surface of the cell and is accessible for binding by, for example, an antigen-specific antibody added to the cell.
[0293] In the present invention, the term "extracellular portion" or "exodomain" refers to the extracellular space of a cell and is preferably accessible from outside the cell by a binding molecule such as an antibody located outside the cell. A part of a certain molecule, such as a protein. Preferably, the term refers to one or more extracellular loops or domains or fragments thereof.
[0294] The terms "T cell" and "T lymphocyte" are used interchangeably herein and refer to T helper cells (CD4 + Cytotoxic T cells (CTL, CD8 + T cells). The term "antigen-specific T cell" or similar terms refers to an antigen that, when presented on the surface of an antigen-presenting cell or a diseased cell, such as a cancer cell, recognizes and preferably targets an antigen, particularly in the context of an MHC molecule. Concerning T cells that exert T cell effector functions. A T cell is considered specific for an antigen if the cell kills target cells that express the antigen. T cell specificity can be assessed using any of a variety of standard techniques, for example within a chromium release assay or a proliferation assay. Alternatively, the synthesis of lymphokines (eg, interferon-γ) can be measured. In certain embodiments of the invention, the RNA (particularly the mRNA) encodes at least one epitope.
[0295] The term "target" means an agent, such as a cell or tissue, that is a target for an immune response, such as a cellular immune response. Targets include cells that present antigens or antigenic epitopes, ie, peptide fragments derived from the antigen. In certain embodiments, the target cell is a cell that expresses the antigen, preferably presenting the antigen in conjunction with class I MHC.
[0296] "Antigen processing" is the fragmentation of the antigen (e.g., the breakdown of a protein into peptides) and the fragmentation of one or more of these fragments (e.g., the breakdown of a protein into peptides) for presentation by a cell, preferably an antigen-presenting cell, for specific T cells. (e.g., by binding) to MHC molecules (e.g., by binding).
[0297] "Antigen-responsive CTL" refers to CD8 cells that are responsive to antigens or peptides derived from the antigen and are presented together with class I MHC on the surface of antigen-presenting cells. + means T cell.
[0298] According to the present invention, CTL responsiveness is associated with sustained calcium flux, cell division, cytokine production such as IFN-γ and TNF-α, upregulation of activation markers such as CD44 and CD69, and tumor antigen expression in specific cells of target cells. May include lytic killing. CTL responsiveness may also be determined using artificial reporters that accurately indicate CTL responsiveness.
[0299] The terms "immune response" and "immune response" are used interchangeably herein in their conventional sense and refer to an integrated bodily response to an antigen, preferably a cellular immune response, a humoral immune response, or both. . According to the present invention, the term "immune response" or "immune response against" an agent such as an antigen, cell or tissue relates to an immune response such as a cellular response directed against the agent. The immune response includes the production of antibodies against one or more antigens and antigen-specific T lymphocytes, preferably CD4, which can be detected in vitro with various proliferation or cytokine production tests. + and CD8 + T lymphocytes, more preferably CD8 + The response may include one or more reactions selected from the group consisting of expansion of T lymphocytes.
[0300] The terms "inducing an immune response" and "evoking an immune response" and similar terms in the present invention refer to the induction of an immune response, preferably a cellular immune response, a humoral immune response, or both. The immune response may be preventive / inhibitory / prophylactic and / or therapeutic. The immune response may be against some immunogen or antigen or antigenic peptide, preferably against a tumor-associated antigen or a pathogen-associated antigen, such as an antigen of a virus (e.g. influenza virus (A, B or C), CMV or RSV). ). "Induction" in this context can mean that prior to induction there was no immune response to the particular antigen or pathogen, and that prior to induction there was a level of immune response to the particular antigen or pathogen; It can also mean enhanced after said immune response. Therefore, "induction of an immune response" in this context also includes "enhancement of an immune response." Preferably, after the induction of an immune response in an individual, the individual is protected from the development of a disease, such as an infectious disease or a cancerous disease, or has a disease condition reduced due to the induction of the immune response.
[0301] The term "cellular immune response", "cellular response", "cell-mediated immunity" or similar terms refers to a cell to a cell characterized by expressing an antigen and / or presenting an antigen with class I or class II MHC. Means to include a response. The cellular response involves cells called T cells or T lymphocytes that act as "helpers" or "killers." Helper T cells (CD4 + Killer cells (also known as T cells) play a more central role in regulating immune responses, and killer cells (cytotoxic T cells, cytolytic T cells, CD8 + T cells or CTLs) kill cells such as diseased cells.
[0302] The term "humoral immune response" refers to the process in a living organism in which antibodies are produced in response to factors and organisms that are ultimately neutralized and / or eliminated. The specificity of the antibody response is mediated by T and / or B cells through membrane-associated receptors that bind monospecific antigens. After binding to the appropriate antigen and receiving various other activation signals, B lymphocytes divide and produce memory B cells and antibody-secreting plasma cell clones, each identical to that recognized by its antigen receptor. produce antibodies that recognize antigenic epitopes of Memory B lymphocytes remain dormant until they are subsequently activated by a specific antigen. These lymphocytes provide the cellular basis of memory and the consequent increase in antibody responses when re-exposed to specific antigens.
[0303] The term "antibody" as used herein refers to an immunoglobulin molecule that can specifically bind to an epitope on an antigen. In particular, the term "antibody" refers to a glycoprotein that includes at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies and any combinations of the foregoing. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). Variable and constant regions are also referred to herein as variable and constant domains, respectively. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), separated by more conserved regions, termed framework regions (FR). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino-terminus to the carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs of VH are referred to as HCDR1, HCDR2 and HCDR3, and the CDRs of VL are referred to as LCDR1, LCDR2 and LCDR3. The variable regions of heavy and light chains contain binding domains that interact with antigen. The constant regions of antibodies include the heavy chain constant region (CH) and the light chain constant region (CL), where the CH can be further subdivided into the constant domain CH1, the hinge region and the constant domains CH2 and CH3 (from the amino terminus Arranged in the following order in the carboxy-terminal direction: CH1, CH2, CH3). The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component of the classical complement system (C1q). The antibody may be an intact immunoglobulin of natural or recombinant origin and may be an immunoactive portion of an intact immunoglobulin. Antibodies are typically tetramers of immunoglobulin molecules. Antibodies include, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab) 2 and can exist in a variety of forms, including single chain antibodies and humanized antibodies.
[0304] The term "immunoglobulin" relates to proteins of the immunoglobulin superfamily, preferably antibodies or antigen receptors such as the B cell receptor (BCR). Immunoglobulins are characterized by structural domains that have a characteristic immunoglobulin (Ig) fold, ie, immunoglobulin domains. The term includes membrane-bound immunoglobulins and soluble immunoglobulins. Membrane-bound immunoglobulin also generally refers to surface or membrane immunoglobulins that are part of the BCR. Soluble immunoglobulin generally refers to antibodies. Immunoglobulins generally contain several chains, typically two identical heavy chains and two identical light chains, linked by disulfide bonds. These chains are mainly V L (variable light chain) domain, C L (constant light chain) domain, V H (variable heavy chain) domain and C H (constant heavy chain) domain C H 1.C H 2,C H 3 and C H Consists of 4 immunoglobulin domains. There are five types of mammalian immunoglobulin heavy chains, namely α, δ, ε, γ and μ, which are responsible for different classes of antibodies, namely IgA, IgD, IgE, IgG and IgM. Contrary to the heavy chains of soluble immunoglobulins, the heavy chains of membrane or surface immunoglobulins contain a transmembrane domain and a short cytoplasmic domain at the carboxy terminus. In mammals, there are two types of light chains: lambda and kappa. Immunoglobulin chains include variable regions and constant regions. The constant region is essentially conserved in the various isotypes of immunoglobulins, where the variable portion is highly variable and is responsible for antigen recognition.
[0305] The terms "vaccination" and "immunization" are the process of treating an individual for therapeutic or prophylactic reasons with one or more immunogens or antigens or derivatives thereof, as described herein, specifically encoding the same. It relates to administering to an individual in the form of RNA (particularly mRNA) to stimulate an immune response against said one or more immunogens or antigens or cells characterized by the presentation of said one or more immunogens or antigens.
[0306] "Cells characterized by the presentation of antigens" or "antigen-presenting cells" or "MHC molecules that present antigens on the surface of antigen-presenting cells" or similar expressions refer to MHC molecules, preferably MHC class I and / or MHC It refers to diseased cells, especially cells such as tumor cells or infected cells or antigen-presenting cells, which present antigens or antigenic peptides, either directly or upon subsequent processing, in the context of class II molecules, most preferably MHC class I molecules.
[0307] In the present invention, the term "transcription" relates to the process by which the genetic code of a DNA sequence is transcribed into RNA (particularly mRNA). Subsequently, RNA (particularly mRNA) can be translated into peptides or proteins.
[0308] In the context of RNA, the terms "expression" or "translation" refer to the process by which the mRNA strand directs the assembly of amino acid sequences to form a peptide or protein.
[0309] As used herein, the term "any" or "optionally" means that the subsequently described event, situation, or condition may or may not occur; Including cases where this occurs and cases where it does not occur.
[0310] Prodrugs of certain compounds described herein are compounds that, when administered to an individual, undergo a chemical transformation under physiological conditions to provide the specified compound. Additionally, prodrugs can be converted to specific compounds by chemical or biochemical methods in an ex vivo environment. For example, a prodrug may slowly convert to a specific compound, eg, when placed in a transdermal patch reservoir with the appropriate enzyme or chemical reagent. Examples of prodrugs are in vivo hydrolysable esters (using alcohol or carboxy groups contained in certain compounds) or amides (using amino or carboxy groups contained in certain compounds). Specifically, any amino group contained in a particular compound that carries at least one hydrogen atom can be converted into a prodrug form. Typical N-prodrug forms include carbamates, Mannich bases, enamines and enaminones.
[0311] "Isomers" are compounds that have the same molecular formula but differ in structure ("structural isomers") or in the geometric (spatial) position of functional groups and / or atoms ("stereoisomers"). "Enantiomers" are pairs of stereoisomers that are non-superimposable mirror images of each other. A "racemic mixture" or "racemate" contains a pair of enantiomers in equal amounts and is indicated by the prefix (±). "Diastereomers" are pairs of stereoisomers that are not superimposable or mirror images of each other. "Tautomers" are structural isomers of the same chemical that, even when pure, spontaneously and reversibly interconvert with each other by movement of individual atoms or groups of atoms; i.e., tautomers The sexual forms are in dynamic chemical equilibrium with each other. An example of a tautomer is the keto-enol-tautomer. "Conformers" are stereoisomers that can formally be interconverted only by rotation around a single bond, such as - in particular - the chair, half-chair, wing and twisted-bone forms of cyclohexane. This results in various three-dimensional forms of (hetero)cyclic rings.
[0312] The term "average diameter" is measured by dynamic light scattering (DLS) and refers to the length dimension, the so-called Z 平均 and the mean hydrodynamic diameter of the particles whose data were analyzed using the so-called cumulant algorithm, which results in a polydispersity index (PDI) that is dimensionless (Koppel, D., J. Chem. Phys. 57, 1972 , pp 4814-4820, ISO 13321). Here, "average diameter", "diameter" or "size" for particles is Z 平均 used synonymously with this value.
[0313] The "polydispersity index" is preferably calculated on the basis of dynamic light scattering measurements by so-called cumulant analysis, as described in the definition of "average diameter". Under certain essential conditions, it can be interpreted as a measurement of the size distribution of an ensemble of nanoparticles.
[0314] The “radius of rotation” of the particle with respect to the axis of rotation (here R g ) is the radial distance from the point of the axis of rotation at which the moment of inertia about an axis is the same as the actual distribution of mass if the entire mass of the particle is assumed to be concentrated. Mathematically, R g is the root mean square distance of a component of a particle from its center of mass or some axis. For example, a fixed distance s from the center of mass i A mass m consisting of n mass elements located at i For macromolecules (i=1, 2, 3,..., n), R g is s for all mass elements i 2 is the square root of the mass average of and can be calculated as:
number
[0315] The radius of gyration can be determined or calculated experimentally, for example using light scattering methods. In particular, small scattering vectors
number
number
[0316] The "D10 value" is the diameter at which 10% of the particles have a diameter smaller than this value, especially with respect to the quantitative size distribution of the particles. The D10 value is intended to describe the proportion of the smallest particles within a particle population (eg within a particle peak obtained with a flow field separation method).
[0317] A "D50 value" is the diameter at which 50% of the particles have a diameter smaller than this value, particularly with respect to the quantitative size distribution of the particles. The D50 value is intended to describe the average particle size within a particle population (eg within a particle peak obtained by flow field separation method).
[0318] A "D90 value" is the diameter at which 90% of the particles have a diameter smaller than this value, especially with respect to the quantitative size distribution of the particles. "D95", "D99" and "D100" values have corresponding meanings. The D90, D95, D99 and D100 values are intended to describe the proportion of large particles within a particle population (eg within a particle peak obtained with a flow field separation method).
[0319] The "hydrodynamic radius" (sometimes referred to as the "Stokes radius" or "Stokes-Einstein radius") of a particle is the radius of an imaginary hard sphere that diffuses at the same velocity as the particle. Hydrodynamic radius is related to particle mobility, taking into account not only size but also solvent effects. For example, particles that are less electrically charged and more hydrated may have a larger hydrodynamic radius than particles that are more electrically charged and less hydrated. This is because small particles attract a large number of water molecules as they move through the solution. Although the actual dimensions of particles in a solvent cannot be measured directly, the hydrodynamic radius can be defined by the Stokes-Einstein equation:
number
[0320] As used herein, the term "agglomeration" refers to agglomerates of particles, where the particles are identical or very similar and interact with each other in a non-covalent manner (e.g., ionic interactions, H-bridge interactions, dipole interactions). bond through interactions and / or van der Waals interactions).
[0321] As used herein, the expression "light scattering" refers to a physical process in which light is forced to deviate from a straight trajectory in one or more paths due to local inhomogeneities in the medium through which it passes.
[0322] The term "UV" means ultraviolet, and refers to a band of the electromagnetic spectrum with wavelengths from 10 nm to 400 nm, ie, shorter than visible light but longer than X-rays.
[0323] As used herein, the expression "multi-angle light scattering" or "MALS" relates to a technique that measures the scattering of light by a sample into multiple angles. "Multi-angle" in this respect means that the scattered light is measured by different, distinct, e.g. This means that it can be detected at an angle of . In one preferred embodiment, the light source used in MALS is a laser source (MALLS: Multi-Angle Laser Light Scattering). Based on the MALS signal of a composition containing particles and using an appropriate formulation (e.g. ZimM plot, Berry plot or Debye plot), the radius of gyration (R g ), hence the size can be determined. Preferably, the ZimM plot is a graphical representation using the following formula:
number
number
number
[0324] As used herein, the expression "dynamic light scattering" or "DLS" refers to a technique that determines the size and size distribution profile of particles, particularly with respect to the hydrodynamic radius of the particles. A monochromatic light source, usually a laser, is directed through a polarizer and onto the sample. The scattered light then passes through a second polarizer, where it is detected and the resulting image is projected onto a screen. Particles in solution are struck by light and diffract light in all directions. The diffracted light from the particles is interfered either constructively (light region) or destructively (dark region). This process is repeated at short intervals, and the resulting set of speckle patterns is analyzed using an autocorrelator that compares the light intensity of each spot over time.
[0325] As used herein, the expression "static light scattering" or "SLS" refers to a technique for determining the size and size distribution profile of particles, particularly with respect to the radius of gyration of the particles and / or the molar mass of the particles. High-intensity monochromatic light, usually a laser, is fired into a solution containing particles. Measure the scattered intensity at one or many angles using one or many detectors. Angular dependence is necessary for accurate measurement of both molar mass and size of the radius of the entire macromolecule. Therefore, simultaneous measurements at several angles relative to the direction of the incident light, known as multi-angle light scattering (MALS) or multi-angle laser light scattering (MALLS), are generally considered as the standard practice for static light scattering. .
[0326] The term "nucleic acid" includes deoxyribonucleic acid (DNA), ribonucleic acid (RNA), combinations thereof and modified forms thereof. The term includes genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. Nucleic acids can exist as single-stranded or double-stranded and linear or covalently closed molecules. Nucleic acids can be isolated. The term "isolated nucleic acid" means, according to the invention, that the nucleic acid (i) has been amplified in vitro, e.g. by polymerase chain reaction (PCR) for DNA or by in vitro transcription (e.g. using RNA polymerase) for RNA. (ii) recombinantly produced by cloning, (iii) purified, eg, by cleavage and separation by gel electrophoresis, or (iv) synthesized, eg, by chemical synthesis.
[0327] The term "nucleoside" (abbreviated herein as "N") relates to compounds that can be considered nucleotides lacking a phosphate group. A nucleoside is a nucleobase attached to a sugar (eg, ribose or deoxyribose), whereas a nucleotide consists of a nucleoside and one or more phosphate groups. Examples of nucleosides include cytidine, uridine, pseudouridine, adenosine and guanosine.
[0328] The five standard nucleosides that normally make up naturally occurring nucleic acids are uridine, adenosine, thymidine, cytidine, and guanosine. The five nucleosides are commonly abbreviated to their one-letter codes U, A, T, C and G, respectively. However, thymidine is more commonly written as "dT" (the "d" stands for "deoxy") because it contains a 2'-deoxyribofuranose moiety rather than the ribofuranose ring found in uridine. . This is because thymidine is found in deoxyribonucleic acid (DNA) and not in ribonucleic acid (RNA). Conversely, uridine is found in RNA and not DNA. The remaining three nucleosides can be found in both RNA and DNA. In RNA they are represented as A, C and G, while in DNA they are represented as dA, dC and dG.
[0329] The modified purine (A or G) or pyrimidine (C, T or U) base moiety preferably contains one or more alkyl groups, more preferably one or more C 1-4 Modified with an alkyl group, even more preferably one or more methyl groups. A specific example of a modified purine or pyrimidine base moiety is N 7 -alkyl-guanine, N 6 -alkyl-adenine, 5-alkyl-cytosine, 5-alkyl-uracil and N(1)-alkyl-uracil, e.g. N 7 -C 1-4 Alkyl-guanine, N 6 -C 1-4 Alkyl-adenine, 5-C 1-4 Alkyl-cytosine, 5-C 1-4 Alkyl-uracil and N(1)-C 1-4 Alkyl-uracil, preferably N 7 -Methyl-guanine, N 6 -Methyl-adenine, 5-methyl-cytosine, 5-methyl-uracil and N(1)-methyl-uracil.
[0330] As used herein, the term "DNA" refers to nucleic acid molecules containing deoxyribonucleotide residues. In a preferred embodiment, the DNA contains all or mostly deoxyribonucleotide residues. As used herein, "deoxyribonucleotide" refers to a nucleotide lacking a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. DNA may include double-stranded DNA, single-stranded DNA, isolated DNA, such as partially purified DNA, essentially pure DNA, synthetic DNA, recombinantly produced DNA as well as naturally occurring DNA. It includes, but is not limited to, modified DNA that differs by addition, deletion, substitution, and / or change of the above nucleotides. Such changes may refer to the addition of internal DNA nucleotides or non-nucleotide material to the ends of the DNA. It is also contemplated herein that the nucleotides in the DNA may be non-standard nucleotides such as chemically synthesized nucleotides or ribonucleotides. For the purposes of this invention, these modified DNAs are considered analogs of naturally occurring DNA. A molecule has a deoxyribonucleotide residue content of more than 50% (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%) based on the total number of nucleotide residues in the molecule. , at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) then it is "predominantly deoxyribonucleotide residues". The total number of nucleotide residues in a molecule is the sum of all nucleotide residues, whether the nucleotide residues are standard (ie, naturally occurring) nucleotide residues or analogs thereof.
[0331] The DNA may be recombinant DNA and may be obtained by cloning nucleic acids, especially cDNA. cDNA can be obtained by reverse transcription of RNA.
[0332] RNA According to the present invention, the term "RNA" means a nucleic acid molecule containing ribonucleotide residues. In a preferred embodiment, the RNA comprises all or mostly ribonucleotide residues. As used herein, "ribonucleotide" refers to a nucleotide having a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. RNA includes double-stranded RNA, single-stranded RNA, isolated RNA, such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA as well as naturally occurring RNA. It includes, but is not limited to, modified RNA that differs by addition, deletion, substitution, and / or change of the above nucleotides. Such changes can refer to the addition of internal RNA nucleotides or non-nucleotide material to the RNA terminus. It is also contemplated herein that the nucleotides in the RNA can be chemically synthesized nucleotides or non-standard nucleotides such as deoxynucleotides. For the purposes of the present invention, these altered / modified nucleotides may be referred to as analogs of naturally occurring nucleotides, and the corresponding RNA containing such altered / modified nucleotides (i.e. altered / modified RNA) may be referred to as analogs of naturally occurring nucleotides. It may be called an analog of RNA. The molecule has more than 50% ribonucleotide residues (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, based on the total number of nucleotide residues in the molecule). "predominantly ribonucleotide residues" if (at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%). The total number of nucleotide residues in a molecule is the sum of all nucleotide residues, whether the nucleotide residues are standard (ie, naturally occurring) nucleotide residues or analogs thereof.
[0333] "RNA" refers to mRNA, tRNA, ribosomal RNA (rRNA), small nuclear RNA (snRNA), self-amplifying RNA (saRNA), single-stranded RNA (ssRNA), dsRNA, inhibitory RNA (e.g. antisense ssRNA, small molecule interfering RNA (siRNA) or microRNA (miRNA)), activating RNA (eg, small activating RNA) and immunostimulatory RNA (isRNA).
[0334] In a preferred embodiment, the RNA includes an open reading frame (ORF) that encodes a peptide or protein.
[0335] The term "in vitro transcription" or "IVT" as used herein means that transcription (ie, production of RNA) is performed in a cell-free manner. That is, IVT does not use live / cultured cells, but rather uses the transcriptional machinery extracted from the cells, such as cell lysates or isolated components thereof containing RNA polymerase (preferably T7, T3 or SP6 polymerase).
[0336] According to the present invention, the term "mRNA" means "messenger RNA" and relates to a "transcript" that can be produced using a DNA template and that can code for a peptide or protein. Typically, mRNA includes a 5'-UTR, a peptide / protein coding region and a 3'-UTR. In the present invention, mRNA is preferably produced by in vitro transcription (IVT) from a DNA template. As mentioned above, in vitro transcription methods are known to those skilled in the art, and a variety of in vitro transcription kits are commercially available.
[0337] Although mRNA is single-stranded, it may contain self-complementary sequences, and portions of the mRNA can fold and pair with themselves to form a double helix.
[0338] According to the invention, "dsRNA" means double-stranded RNA, which is RNA with two partially or completely complementary strands.
[0339] In a preferred embodiment of the invention, mRNA refers to an RNA transcript encoding a peptide or protein.
[0340] In certain embodiments, the RNA encoding the peptide or protein preferably contains at least 45 nucleotides (e.g., at least 60, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1,000, at least 1,500, at least 2,000, at least 2,500, at least 3,000, at least 3,500, at least 4,000, at least 4,500, at least 5,000, at least 6,000, at least 7,000, at least 8,000, at least 9,000 nucleotides), preferably up to 15,000, e.g. having a length of up to 14,000, up to 13,000, up to 12,000 nucleotides, up to 11,000 nucleotides or up to 10,000 nucleotides.
[0341] In certain embodiments, the RNA (eg, mRNA) includes a 5' untranslated region (5'-UTR), a peptide coding region, and a 3' untranslated region (3'-UTR). In certain embodiments, RNA (eg, mRNA) is produced by in vitro transcription or chemical synthesis. In certain embodiments, RNA (eg, mRNA) is produced by in vitro transcription using a DNA template. In vitro transcription methods are known to those skilled in the art; for example, Molecular Cloning: A Laboratory Manual, 2 nd See Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989. Additionally, versatile in vitro transcription kits are available, for example from Thermo Fisher Scientific (e.g. TranscriptAid TM T7 kit, MEGAscript® T7 kit, MAXIscript®), New England BioLabs Inc. (e.g. HiScribe TM T7 kit, HiScribe TM T7 ARCA mRNA kit), Promega (e.g. RiboMAX TM , HeLaScribe®, Riboprobe® systems), Jena Bioscience (e.g. SP6 or T7 transcription kits) and Epicentre (e.g. AmpliScribe TM ) is commercially available from. Synthesizing (preferably in vitro transcription) correspondingly modified nucleotides such as modified naturally occurring nucleotides, non-naturally occurring nucleotides and / or modified non-naturally occurring nucleotides to provide modified mRNA Modifications can be carried out and / or added to the mRNA after transcription.
[0342] In certain embodiments, the RNA (eg, mRNA) is in vitro transcribed mRNA (IVT-RNA), which can be obtained by in vitro transcription of a suitable DNA template. The promoter for controlling transcription can be any promoter of any RNA polymerase. Particular examples of RNA polymerases are T7, T3 and SP6 RNA polymerases. Preferably, in vitro transcription is controlled by the T7 or SP6 promoter. A DNA template for in vitro transcription can be obtained by cloning a nucleic acid, in particular a cDNA, and introducing it into a suitable vector for in vitro transcription. cDNA can be obtained by reverse transcription of RNA.
[0343] In certain embodiments of the invention, RNA (e.g., mRNA) is "replicon RNA" (e.g., "replicon mRNA") or simply "replicon", in particular "self-replicating RNA" (e.g., "self-replicating mRNA") or " ``Self-amplifying RNA'' (or ``self-amplifying mRNA''). In certain particularly preferred embodiments, the replicon or self-replicating RNA (eg, self-replicating mRNA) is derived from or contains elements derived from a positive-strand ssRNA virus, such as an ssRN virus, particularly an alphavirus. Alphaviruses are typical representatives of positive-strand RNA viruses. Alphaviruses replicate in the cytoplasm of infected cells (for a review of the alphavirus life cycle, see Jose et al., Future Microbiol., 2009, vol. 4, pp. 837-856). The total genome length of many alphaviruses typically ranges from 11,000 to 12,000 nucleotides, and the genomic RNA typically has a 5' cap and a 3' poly(A) tail. The alphavirus genome encodes non-structural proteins (involved in transcription, modification and replication of viral RNA and protein modification) and structural proteins (viral particle formation). There are typically two open reading frames (ORFs) in a genome. The four nonstructural proteins (nsP1-nsP4) are encoded by the first ORF, which typically together start near the 5' end of the genome, whereas the alphavirus structural proteins are encoded together by the first ORF. It is encoded by a second ORF found downstream of the first ORF and extending near the 3' end of the genome. Typically, the first ORF is larger than the second ORF, with a ratio of approximately 2:1. In cells infected by alphaviruses, only nucleic acid sequences encoding non-structural proteins are translated from genomic RNA, whereas genetic information encoding structural proteins is transferred to RNA molecules that mimic eukaryotic messenger RNA (mRNA). (Gould et al., 2010, Antiviral Res., vol. 87 pp. 111-124). After infection, ie, during the early stages of the viral life cycle, (+) strand genomic RNA acts directly like messenger RNA for the translation of the open reading frame encoding the nonstructural poly-protein (nsP1234). Alphavirus-derived vectors have been proposed for the delivery of foreign genetic information to target cells or organisms. In a simple approach, open reading frames encoding alphavirus structural proteins are replaced with open reading frames encoding proteins of interest. The alphavirus-based trans replication system relies on alphavirus nucleotide sequence elements on two separate nucleic acid molecules, one encoding the viral replicase and the other nucleic acid molecule capable of being replicated in trans by the replicase ( Hence the name trans-replication system). Trans-replication requires the presence of both of these nucleic acid molecules in a given host cell. A nucleic acid molecule that can be replicated in trans by a replicase must contain certain alphavirus sequence elements to enable recognition by the alphavirus replicase and RNA synthesis.
[0344] In certain embodiments of the invention, the RNA (e.g., mRNA) comprises one or more modifications, e.g., to increase stability and / or increase translation efficiency and / or reduce immunogenicity and / or reduce cytotoxicity. . For example, for increased RNA (eg, mRNA) expression, modifications may be made within the coding region, ie, the sequence encoding the expressed peptide or protein, preferably without altering the sequence of the expressed peptide or protein. Such modifications are described, for example, in WO2007 / 036366 and PCT / EP2019 / 056502 and include: 5' cap structures; elongation or shortening of the naturally occurring poly(A) tail; Modifications to the 5'- and / or 3'-untranslated regions (UTRs), such as the introduction of UTRs that are unrelated to the coding region; substitution of one or more naturally occurring nucleotides with synthetic nucleotides; and codon optimization (e.g. (altering, preferably increasing) the GC content of the RNA). The term "modification" in the context of modified mRNA according to the invention preferably relates to any modification of the mRNA that does not occur naturally in said RNA (eg mRNA).
[0345] In certain embodiments, the RNA (eg, mRNA) includes a 5' cap structure. In certain embodiments, the mRNA does not have an uncapped 5'-triphosphate. In certain embodiments, the mRNA may include a conventional 5' cap and / or a 5' cap analog. The term "conventional 5' cap" refers to the cap structure found at the 5' end of an mRNA molecule, generally consisting of guanosine 5'-triphosphate (Gppp), which binds the mRNA via its triphosphate moiety. (ie, the guanosine is attached to the rest of the mRNA via a 5'→5' triphosphate bond). Guanosine is N 7 can be methylated at position (cap structure m 7 Gppp). The term “5’ cap analog” is based on the conventional 5’ cap, but to avoid incorporation of the 5’ cap analog in the reverse orientation, m 7 Refers to a 5' cap that is modified at the 2' or 3' position of a guanosine structure (such 5' cap analogs are also referred to as anti-reverse cap analogs (ARCA)). Particularly preferred 5' cap analogs are phosphorothioate-modified 5' cap analogs with β-phosphate (e.g. m 2 7,2’O G(5')ppSp(5')G (referred to as beta-S-ARCA or β-S-ARCA) with one or more substitutions on the bridging and non-bridging oxygens in the phosphate bridge. As described herein, the provision of a 5' cap structure to RNA (e.g., mRNA) can be applied to a DNA template in the presence of a corresponding 5' cap compound, and the 5' cap structure is applied to the produced RNA (e.g., This can be achieved by in vitro transcription, or the RNA (e.g., mRNA) is co-transcriptionally incorporated into the strand (mRNA), or the RNA (e.g., mRNA) is produced by, e.g. can be used to bind to mRNA post-transcriptionally.
[0346] In certain embodiments, the RNA (e.g., mRNA) is m 2 7,2’O G(5’)ppSp(5’)G (especially its D1 diastereomer), m 2 7,3’O G(5’)ppp(5’)G and m 2 7,3’-O Gppp(m 1 2’-O )ApG.
[0347] In certain embodiments, the RNA (eg, mRNA) comprises Cap0, Cap1 or Cap2, preferably Cap1 or Cap2. According to the invention, the term "cap 0" is replaced by the structure "m 7 GpppN', where N is any nucleoside with an OH moiety in the 2' position. According to the invention, the term "cap 1" is replaced by the structure "m 7 GpppNm”, where Nm is OCH at the 2’ position 3 Any nucleoside that has a moiety. According to the invention, the term "cap 2" is replaced by the structure "m 7 GpppNmNm”, where each Nm is independently OCH at the 2’ position 3 Any nucleoside that has a moiety.
[0348] The D1 diastereomer of beta-S-ARCA (β-S-ARCA) has the following structure: [ka]
[0349] "D1 diastereomer of Beta-S-ARCA" or "Beta-S-ARCA(D1)" is compared with D2 diastereomer of Beta-S-ARCA (Beta-S-ARCA(D2)) on HPLC column It is the diastereomer of beta-S-ARCA that is eluted first and therefore has a short retention time. HPLC is preferably analytical HPLC. In one embodiment, a Supelcosil LC-18-T RP column, preferably in the format 5 μm, 4.6×250 mm, is used for the separation, whereby a flow rate of 1.3 ml / min can be applied. In certain embodiments, a methanol in ammonium acetate gradient within 15 minutes is used, such as a 0-25% linear gradient of methanol in 0.05M ammonium acetate, pH=5.9. UV detection (VWD) can be performed at 260 nm and fluorescence detection (FLD) can be performed with excitation at 280 nm and detection at 337 nm.
[0350] 5’ cap analog m which is a component of cap 1 2 7,3’-O Gppp(m 1 2’-O )ApG(m 2 7,3’O G(5’)ppp(5’)m 2’-O ApG) has the following structure: [ka]
[0351] An example of cap0 mRNA containing β-S-ARCA and mRNA has the following structure: [ka]
[0352] m 2 7,3’O An example of a cap 0 mRNA containing G(5')ppp(5')G and mRNA has the following structure: [ka]
[0353] m 2 7,3’-O Gppp(m 1 2’-O ) An example of a cap1 mRNA containing ApG and mRNA has the following structure: [ka]
[0354] As used herein, the term "poly A tail" or "poly A sequence" typically refers to an RNA (eg, mRNA) molecule. Poly-A tails or poly-A sequences are known to those skilled in the art and can follow the 3'-UTR of the RNAs described herein. The uninterrupted poly-A tail is characterized by consecutive adenylate residues. A naturally uninterrupted poly-A tail is typical. The RNA (e.g., mRNA) disclosed herein is encoded by a polyA tail or DNA attached to the free 3' end of the mRNA by a post-transcriptional template-independent RNA polymerase and transcribed by a template-dependent RNA polymerase. May have a poly A tail.
[0355] A polyA tail of approximately 120 A nucleotides has been shown to have a beneficial effect on the level of mRNA in transfected eukaryotic cells and on the level of protein translated from the open reading frame present upstream (5') of the polyA tail. (Holtkamp et al., 2006, Blood, vol. 108, pp. 4009-4017).
[0356] PolyA tails can be of any length. In certain embodiments, the polyA tail comprises at least 20, at least 30, at least 40, at least 80 or at least 100 and at most 500, at most 400, at most 300, at most 200 or at most 150 A nucleotides, in particular about 120 A nucleotides. consisting essentially of or consisting of. In this context, "consisting essentially of" means the majority of the nucleotides in the polyA tail, typically at least 75%, at least 80%, at least 85%, at least 90%, depending on the number of nucleotides in the polyA tail, At least 95%, at least 96%, at least 97%, at least 98% or at least 99% are A nucleotides, but the remaining nucleotides are other than A nucleotides, such as U nucleotides (uridylic acid), G nucleotides (guanylic acid) or C nucleotide (cytidylic acid). In this context, "consisting of" means that all nucleotides of the polyA tail, ie, 100%, by the number of nucleotides in the polyA tail, are A nucleotides. The term "A nucleotide" or "A" refers to adenylic acid.
[0357] In certain embodiments, the poly-A tail is attached during RNA transcription, e.g., during the preparation of in vitro transcribed RNA, based on a DNA template containing repeating dT nucleotides (deoxythymidylic acid) in a strand complementary to the coding strand. . The DNA sequence encoding the poly-A tail (coding strand) is called the poly(A) cassette.
[0358] In certain embodiments, the poly(A) cassette present in the coding strand of DNA consists essentially of dA nucleotides, but is interrupted by random sequences of 4 nucleotides (dA, dC, dG and dT). Such random sequences can be 5-50, 10-30 or 10-20 nucleotides long. Such a cassette is disclosed in WO2016 / 005324A1, which is incorporated herein by reference. Any poly(A) cassette disclosed in WO2016 / 005324A1 can be used in the present invention. At the DNA level, a poly(A) cassette consisting essentially of dA nucleotides but interrupted by random sequences with equally distributed four nucleotides (dA, dC, dG, dT) and having a length of e.g. It exhibits constant propagation of plasmid DNA in E. coli and is associated with beneficial properties at the RNA level, including support for RNA stability and translation efficiency. As a result, in certain embodiments, the poly-A tail included in the mRNA molecules described herein consists essentially of A nucleotides, but is interrupted by a random sequence of 4 nucleotides (A, C, G, U). . Such random sequences can be 5-50, 10-30 or 10-20 nucleotides long.
[0359] In certain embodiments, no nucleotides other than A nucleotides flank the poly A tail at the 3' end, ie, the poly A tail is not masked or continued at the 3' end with nucleotides other than A.
[0360] In certain embodiments, the poly-A sequence comprises at least 100 nucleotides. In certain embodiments, the poly-A sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 14. In certain embodiments, the poly-A sequence has a nucleotide sequence that has at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO: 14. .
[0361] In certain embodiments, the RNA (eg, mRNA) used in the invention includes a 5'-UTR and / or a 3'-UTR. The term "untranslated region" or "UTR" refers to a region in a DNA molecule that is transcribed but not translated into an amino acid sequence or a corresponding region in an RNA molecule, such as an mRNA molecule. An untranslated region (UTR) may be present 5' (upstream) of an open reading frame (5'-UTR) and / or 3' (downstream) of an open reading frame (3'-UTR). The 5'-UTR, if present, is located at the 5' end, upstream of the start codon of the protein coding region. The 5'-UTR is downstream of, eg, directly adjacent to, the 5' cap (if present). The 3'-UTR, if present, is located at the 3' end downstream of the stop codon of the protein coding region, but the term "3'-UTR" preferably does not include polyA sequences. Thus, the 3'-UTR is upstream of the polyA sequence (if present), eg, directly adjacent to the polyA sequence. Incorporation of the 3'-UTR into the 3'-untranslated region of an RNA (preferably mRNA) molecule can enhance translation efficiency. A synergistic effect may be achieved by the incorporation of two or more such 3'-UTRs (these are preferably arranged in a head-to-tail orientation; see, for example, Holtkamp et al., Blood 108, 4009-4017 (2006 )reference). The 3'-UTR can be autologous or heterologous to the introduced RNA (preferably mRNA). In certain embodiments, the 3'-UTR is linked to a globin gene or mRNA, such as the gene or mRNA of alpha2-globin, alpha1-globin or beta-globin, preferably beta-globin, more preferably human beta-globin. Originates from For example, the RNA (preferably mRNA) may contain one or more, preferably two copies of a globin gene, such as alpha2-globin, alpha1-globin, beta-globin, preferably beta-globin, more preferably human beta-globin. It can be modified by replacing or inserting an existing 3'-UTR with a 3'-UTR.
[0362] In certain embodiments, the RNA (e.g., mRNA) used in the invention is at least 99%, 98%, 97%, 96%, 95%, 90% the nucleotide sequence of SEQ ID NO: 12 or the nucleotide sequence of SEQ ID NO: 12. , a 5' UTR containing a nucleotide sequence with 85% or 80% identity.
[0363] In certain embodiments, the RNA (e.g., mRNA) used in the invention is at least 99%, 98%, 97%, 96%, 95%, 90% the nucleotide sequence of SEQ ID NO: 13 or the nucleotide sequence of SEQ ID NO: 13. , a 3' UTR containing a nucleotide sequence with 85% or 80% identity.
[0364] RNA (eg, mRNA) may have modified ribonucleotides for increased stability and / or decreased immunogenicity and / or decreased cytotoxicity. For example, in certain embodiments, uridine in the RNA (eg, mRNA) described herein is replaced (partially or completely, preferably completely) with a modified nucleoside. In certain embodiments, the modified nucleoside is a modified uridine.
[0365] In certain embodiments, the modified uridine that replaces uridine is selected from the group consisting of pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), 5-methyl-uridine (m5U), and combinations thereof.
[0366] In certain embodiments, modified nucleosides that replace (partially or completely, preferably completely) uridine in RNA (e.g. mRNA) include 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), 5-Aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio -pseudouridine, 5-hydroxy-uridine (ho5U), 5-aminoallyl-uridine, 5-halo-uridine (e.g. 5-iodo-uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U) ), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm5s2U), 5-aminomethyl-2-thio-uridine (nm5s2U), 5-methylaminomethyl-uridine ( mnm5U), 1-ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno-uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm5U), 1-Taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (τm5s2U), 1-taurinomethyl-4-thio-pseudouridine), 5-methyl-2-thio-uridine (m5s2U), 1-methyl-4 -thio-pseudouridine (m1s4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudo Uridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio-dihydrouridine , 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3ψ), 5-(isopentenylaminomethyl)uridine (inm5U) ), 5-(isopentenylaminomethyl)-2-thio-uridine (inm5s2U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m5Um) ), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm5Um), 5 -Carbamoylmethyl-2'-O-methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm5Um), 3,2'-O-dimethyl-uridine (m3Um), 5 -(isopentenylaminomethyl)-2'-O-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH- It can be any one or more of ara-uridine, 5-(2-carbomethoxyvinyl)uridine, 5-[3-(1-E-propenylamino)uridine or any other modified uridine known in the art.
[0367] RNA (preferably mRNA) that has been modified by pseudouridine (partially or completely, preferably completely replacing uridine) is referred to herein as "Ψ-modified", whereas the term "m1Ψ-modified" refers to It means that the RNA (preferably the mRNA) contains N(1)-methylpseudouridine (partially or completely, preferably completely replacing uridine). Furthermore, the term "m5U-modified" means that the RNA (preferably the mRNA) comprises 5-methyluridine (partially or completely, preferably completely replacing uridine). Such Ψ- or m1Ψ- or m5U-modified RNAs are generally less immunogenic compared to unmodified forms and are therefore preferred in applications where induction of an immune response is to be avoided or minimized.
[0368] The codons of the RNA (preferably mRNA) used in the present invention can be modified, for example, by increasing the GC content of the RNA and / or by adding rare codons to the cell (or subject) in which the peptide or protein of interest is to be expressed. ) can be further optimized to replace codons that are synonymous high-frequency codons in ). In certain embodiments, the amino acid sequence encoded by the RNA used in the invention may be encoded by a coding sequence that has codon optimization and / or increased G / C content compared to the wild-type coding sequence. This also includes embodiments in which one or more sequence regions of the coding sequence have been codon-optimized and / or have increased G / C content compared to the corresponding sequence region of the wild-type coding sequence. In certain embodiments, codon optimization and / or G / C content increase preferably does not change the sequence of the encoded amino acid sequence.
[0369] The term "codon optimization" refers to altering the codons of a coding region of a nucleic acid molecule to reflect the typical codon usage of the host organism, preferably without altering the amino acid sequence encoded by the nucleic acid molecule. In the present invention, the coding region is preferably codon-optimized for optimal expression in the subject to be treated using the RNA (preferably mRNA) described herein. Codon optimization is based on the knowledge that translation efficiency is also determined by differences in the frequency of tRNA presence in cells. Therefore, the sequence of the RNA (preferably mRNA) can be modified such that codons that occur frequently in tRNAs are inserted in place of "rare codons."
[0370] In certain embodiments, the guanosine / cytosine (G / C) content of the coding region of the RNA (preferably mRNA) described herein is increased compared to the G / C content of the corresponding coding sequence of the wild-type RNA; Here, the amino acid sequence encoded by the RNA (preferably mRNA) is preferably unmodified compared to the amino acid sequence encoded by wild-type RNA. This RNA sequence modification is based on the fact that the sequence of any RNA region to be translated is important for efficient translation of that mRNA. Sequences with increased G (guanosine) / C (cytosine) content are more stable than sequences with increased A (adenosine) / U (uracil) content. For several codons coding for one and the same amino acid (so-called degeneracy of the genetic code), the most favorable codon for stability can be determined (so-called alternative codon usage). Depending on the amino acid encoded by the RNA (preferably mRNA), there are various possibilities for modification of the RNA sequence compared to the wild-type sequence. In particular, replacing codons containing A and / or U nucleotides by other codons that code for the same amino acids but do not contain A and / or U or have a low content of A and / or U nucleotides. It can be modified by
[0371] In various embodiments, the G / C content of the coding region of the mRNA described herein is at least 10%, at least 20%, at least 30%, at least It can be increased by 40%, at least 50%, at least 55% or more.
[0372] the above modifications, i.e. incorporation of a 5' cap structure, incorporation of a polyA sequence, unmasking of a polyA sequence, modification of the 5'- and / or 3'-UTR (e.g. incorporation of one or more 3'-UTRs); Replacement of one or more naturally occurring nucleotides with synthetic nucleotides (e.g. 5-methylcytidine for cytidine and / or pseudouridine (Ψ) or N(1)-methylpseudouridine (m1Ψ) for uridine or The combination of 5-methyluridine (m5U)) and codon optimization has a synergistic effect on increasing RNA (preferably mRNA) stability and translation efficiency. Therefore, in a preferred embodiment, the RNA (preferably mRNA) used in the present invention, in particular the RNA (preferably mRNA) encoding an antigen or epitope for inducing an immune response as disclosed herein, is modified as described above, i.e. (i) incorporation of a 5' cap structure, (ii) incorporation of polyA sequences, unmasking of polyA sequences; (iii) modification of 5'- and / or 3'-UTRs (e.g. one or more 3'-UTRs); (iv) replacement of one or more naturally occurring nucleotides with synthetic nucleotides (e.g., 5-methylcytidine for cytidine and / or pseudouridine (Ψ) for uridine or N(1)- methylpseudouridine (m1Ψ) or 5-methyluridine (m5U)) and (v) a combination of at least 2, at least 3, at least 4 or all 5 of codon optimizations. In certain embodiments, the RNA comprises a cap 1 or cap 2, preferably a cap 1 structure. In certain embodiments, the poly-A sequence comprises at least 100 nucleotides. In certain embodiments, the poly-A sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 14. In certain embodiments, the 5' UTR is at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identical to the nucleotide sequence of SEQ ID NO: 12 or the nucleotide sequence of SEQ ID NO: 12. nucleotide sequence having the following. In certain embodiments, the 3' UTR is at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identical to the nucleotide sequence of SEQ ID NO: 13 or the nucleotide sequence of SEQ ID NO: 13. nucleotide sequence having the following.
[0373] Certain embodiments of the invention relate to targeted delivery of RNA (preferably mRNA) disclosed herein to certain cells or tissues. In certain embodiments, the invention involves targeting the lymphatic system, particularly secondary lymphoid organs, more specifically the spleen. Targeting of the lymphatic system, particularly secondary lymphoid organs, more specifically the spleen, is achieved by providing that the RNA (preferably mRNA) to be administered encodes an antigen or epitope for induction of an immune response (preferably mRNA). It is particularly preferable when In certain embodiments, the target cells are spleen cells. In certain embodiments, the target cells are antigen presenting cells, such as professional antigen presenting cells in the spleen. In certain embodiments, the target cells are splenic dendritic cells. The "lymphatic system" is part of the circulatory system, including the network of lymph vessels that transport lymph, and is an important part of the immune system. The lymphatic system consists of lymphoid organs, a ductal network of lymph vessels, and circulating lymph. Primary or central lymphoid organs produce lymphocytes from immature progenitor cells. The thymus and bone marrow constitute the primary lymphoid organs. Secondary or peripheral lymphoid organs, including the lymph nodes and spleen, maintain mature naive lymphocytes and mount adaptive immune responses.
[0374] Lipid-based RNA (eg, mRNA) delivery systems have inherent preference for the liver. Hepatic accumulation is caused by discontinuities in the hepatic vasculature or lipid metabolism (liposomes and lipid or cholesterol conjugates). In certain embodiments, the target organ is the liver and the target tissue is liver tissue. Delivery to such a target tissue may be particularly advantageous if the presence of the mRNA or encoded peptide or protein in this organ or tissue is desired and / or the expression of large quantities of the encoded peptide or protein is desired and / or particularly significant. Preferred if systemic presence of the encoded peptide or protein in amounts is desired or necessary.
[0375] In certain embodiments, at least a portion of the RNA is delivered to the target cell or organ after administration of the RNA LNP compositions described herein. In certain embodiments, at least a portion of the RNA is delivered to the cytosol of the target cell. In certain embodiments, the RNA is RNA (preferably mRNA) that encodes a peptide or protein, and the RNA is translated by the target cell to produce the peptide or protein. In certain embodiments, the target cells are cells in the liver. In certain embodiments, the target cell is a muscle cell. In certain embodiments, the target cells are endothelial cells. In certain embodiments, the target cells are tumor cells or cells of the tumor microenvironment. In certain embodiments, the target cells are blood cells. In certain embodiments, the target cells are lymph node cells. In certain embodiments, the target cells are lung cells. In certain embodiments, the target cells are blood cells. In certain embodiments, the target cells are skin cells. In certain embodiments, the target cells are spleen cells. In certain embodiments, the target cells are antigen presenting cells, such as professional antigen presenting cells in the spleen. In certain embodiments, the target cells are splenic dendritic cells. In certain embodiments, the target cell is a T cell. In certain embodiments, the target cell is a B cell. In certain embodiments, the target cells are NK cells. In certain embodiments, the target cells are monocytes. Thus, the RNA LNP compositions described herein can be used to deliver RNA (preferably mRNA) to such target cells. Accordingly, the invention also relates to a method of delivering RNA (preferably mRNA) to target cells in a subject, comprising administering to the subject an RNA LNP composition as described herein. In certain embodiments, the RNA is RNA (preferably mRNA) that encodes a peptide or protein, and the RNA is translated by the target cell to produce the peptide or protein.
[0376] "Encodes" refers to genes that have defined nucleotide sequences (i.e., rRNA, tRNA, and mRNA) or defined amino acid sequences that serve as templates for the synthesis of other polymers and macromolecules in biological processes; Refers to the inherent properties of a specific sequence of nucleotides in a polynucleotide such as cDNA or RNA (preferably mRNA) and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of the RNA (preferably mRNA) corresponding to the gene produces the protein in a cell or other biological system. The nucleotide sequence is identical to the RNA sequence, and both the coding strand, usually provided in a sequence listing, and the non-coding strand, used as a template for transcription of the gene or cDNA, are proteins or other products of that gene or cDNA. can be said to be coded.
[0377] In certain embodiments, the RNA (preferably mRNA) used in the invention encodes a nucleic acid sequence (e.g., an ORF) encoding one or more polypeptides, e.g., peptides or proteins, preferably pharmaceutically active peptides or proteins. include.
[0378] In a preferred embodiment, the RNA (preferably mRNA) used in the invention comprises a nucleic acid sequence (e.g. an ORF) encoding a peptide or protein, preferably a pharmaceutically active peptide or protein, and When introduced, the peptide or protein can be expressed. Therefore, the RNA (preferably mRNA) used in the present invention preferably comprises a coding region (ORF) that encodes a peptide or protein, preferably a pharmaceutically active peptide or protein. In this regard, an "open reading frame" or "ORF" is a continuous stretch of codons that begins with a start codon and ends with a stop codon. RNA (preferably mRNA) encoding such a pharmaceutically active peptide or protein is referred to herein as "pharmaceutically active RNA" (or "pharmaceutically active mRNA").
[0379] According to the present invention, the term "pharmaceutically active peptide or protein" refers to a peptide or protein that can be used for the treatment of an individual for whom expression of the peptide or protein is beneficial, for example beneficial in alleviating the symptoms of a disease or disorder. means. Preferably, the pharmaceutically active peptide or protein has curative or palliative properties and can be administered to ameliorate, palliate, alleviate, reverse, delay the onset of, or reduce the severity of or more symptoms of a disease or disorder. . Preferably, the pharmaceutically active peptide or protein has a positive or beneficial effect on a condition or disease state when administered to an individual in a therapeutically effective amount. Pharmaceutically active peptides or proteins may have prophylactic properties and may be used for delaying the onset of a disease or disorder or reducing the severity of such a disease or disorder. The term "pharmaceutically active peptide or protein" includes the entire protein or polypeptide and may also refer to pharmaceutically active fragments thereof. Pharmaceutically active analogs of peptides or proteins may also be included.
[0380] Examples of pharmaceutically active peptides and proteins include cytokines, hormones, adhesion molecules, immunoglobulins, immunologically active compounds, growth factors, protease inhibitors, enzymes, receptors, apoptosis regulators, transcription factors, Including, but not limited to, tumor suppressor proteins, structural proteins, reprogramming factors, genome engineering proteins and blood proteins.
[0381] The term "cytokine" refers to a protein that has a molecular weight of about 5-20 kDa and participates in cell signaling (eg, paracrine, endocrine and / or autocrine signaling). In particular, when released, cytokines exert effects on the behavior of cells surrounding the site of release. Examples of cytokines include lymphokines, interleukins, chemokines, interferons and tumor necrosis factor (TNF). According to the invention, cytokines do not include hormones or growth factors. Cytokines differ from hormones in that (i) their effective concentrations are usually much more variable than hormones, and (ii) they are generally produced by a wide range of cells (nearly all nucleated cells can produce cytokines). Interferons are usually characterized by antiviral, antiproliferative and immunomodulatory activities. Interferons are proteins that modify and control gene transcription within cells by binding to interferon receptors on the surface of regulated cells, thus inhibiting viral replication within cells. Interferons can be classified into two types. IFN-gamma is the only type II interferon; all others are type I interferons. Specific examples of cytokines are erythropoietin (EPO), colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), Bone morphogenetic protein (BMP), interferon alpha (IFNα), interferon beta (IFNβ), interferon gamma (INFγ), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) ), interleukin 11 (IL-11), interleukin 12 (IL-12) and interleukin 21 (IL-21).
[0382] In certain embodiments, the pharmaceutically active peptide or protein comprises a recruitment protein. In this embodiment, the invention provides a method of treating a subject with a disorder requiring protein supplementation (e.g., a protein deficiency disorder), comprising administering to the subject an RNA described herein that encodes a supplemental protein. Provides a method including: The term "protein supplementation" refers to the introduction of proteins (including functional variants thereof) into a subject deficient in such proteins. The term also refers to the introduction of proteins into subjects who otherwise need or would benefit from the provision of proteins, eg, suffering from protein deficiency. The term "disorder characterized by protein deficiency" refers to any disorder in which the pathology is characterized by the absence or insufficient amount of the protein. The term encompasses protein folding disorders, ie, conformational hindrances, that result in biologically inactive protein products. Protein deficiency may be associated with infection, immunosuppression, organ failure, glandular problems, radiation sickness, nutritional deficiencies, poisoning or other environmental or external insults.
[0383] The term "hormone" refers to a class of signaling molecules produced by glands, where signaling typically involves the following steps: (i) synthesis of hormones in specific tissues; (ii) storage and secretion (iii) transport of the hormone to its target; (iv) binding of the hormone by receptors; (v) relay and amplification of the signal; and (vi) degradation of the hormone. Hormones differ from cytokines in that (1) hormones usually have less variable working concentrations and (2) are generally produced by specific types of cells. In certain embodiments, "hormone" includes insulin, vasopressin, prolactin, adrenocorticotropic hormone (ACTH), thyroid hormone, growth hormone (e.g., human growth hormone or bovine somatotropin), oxytocin, atrial natriuretic peptide (ANP), Peptide or protein hormones such as glucagon, somatostatin, cholecystokinin, gastrin and leptin.
[0384] The term "adhesion molecule" relates to proteins located on the surface of cells and involved in the association of cells with other cells or with the extracellular matrix (ECM). Adhesion molecules are typically transmembrane receptors and can be classified as calcium-independent (eg, integrins, immunoglobulin superfamily, lymphocyte homing receptors) and calcium-dependent (cadherins and selectins). Examples of adhesion molecules are integrins, lymphocyte homing receptors, selectins (eg, P-selectin) and addressins.
[0385] Integrins are also involved in signal transduction. In particular, upon ligand binding, integrins modulate cell signaling pathways, such as those of transmembrane protein kinases, such as receptor tyrosine kinases (RTKs). Such regulation may lead to cell proliferation, division, survival or differentiation or apoptosis. A specific example of an integrin is α 1 β 1 ,α 2 β 1 ,α 3 β 1 ,α 4 β 1 ,α 5 β 1 ,α 6 β 1 ,α 7 β 1 ,α L β 2 ,α M β 2 ,α IIb β 3 ,α V β 1 ,α V β 3 ,α V β 5 ,α V β 6 ,α V β 8 and α 6 β 4 including.
[0386] The term "immunoglobulin" or "immunoglobulin superfamily" refers to molecules involved in cell recognition, binding and / or adhesion processes. Molecules belonging to this superfamily share properties in that they contain regions known as immunoglobulin domains or folds. Members of the immunoglobulin superfamily include antibodies (e.g., IgG), T-cell receptors (TCR), major histocompatibility complex (MHC) molecules, co-receptors (e.g., CD4, CD8, CD19), and antigen receptors. Includes accessory molecules (eg, CD-3γ, CD3-δ, CD-3ε, CD79a, CD79b), costimulatory or inhibitory molecules (eg, CD28, CD80, CD86), and others.
[0387] The term "immunologically active compound" preferably refers to a compound that modifies the immune response by inducing and / or suppressing the maturation of immune cells, inducing and / or suppressing cytokine biosynthesis, and / or by stimulating antibody production by B cells. Relates to any compound that modifies humoral immunity. Immunologically active compounds have potent immunostimulatory activity, including but not limited to antiviral and antitumor activity, and can also downregulate other aspects of the immune response, such as in a wide range of TH2-mediated diseases. The immune response that is useful in the treatment of TH2 can be shifted away from the TH2 immune response. Immunologically active compounds can be useful as vaccine adjuvants. Examples of immunologically active compounds are interleukins, colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin, tumor necrosis. including factors (TNF), interferons, integrins, addressins, selectins, homing receptors and antigens, especially tumor-associated antigens, pathogen-associated antigens (eg bacterial, parasitic or viral antigens), allergens and self-antigens. Preferred immunologically active compounds are vaccine antigens, ie, antigens whose inoculation into a subject induces an immune response.
[0388] The term "autoantigen" or "self-antigen" refers to a substance that originates within a subject's body (i.e., an autoantigen may also be referred to as a "self-antigen") and produces an abnormally active immune response against normal parts of this body. refers to an antigen that causes Such vigorous immune responses to self-antigens can be the cause of "autoimmune diseases."
[0389] The term "allergen" refers to an abnormality that originates outside a subject's body (i.e., an allergen may also be referred to as a "foreign antigen") and causes the subject's immune system to fight off a perceived threat that is not otherwise harmful to the subject. An antigen that produces an active immune response to a specific antigen. "Allergy" is a disease caused by such an active immune response to allergens. Allergens are antigens that can stimulate a type-I hypersensitivity response in atopic individuals, usually through an immunoglobulin E (IgE) response. Specific examples of allergens include allergens derived from peanut proteins (eg, Ara h 2.02), ovalbumin, grass pollen proteins (eg, Phl p 5), and dust mite proteins (eg, Der p 2).
[0390] The term "growth factor" refers to molecules that can stimulate cell growth, proliferation, healing and / or cell differentiation. Typically, growth factors act as signaling molecules between cells. The term "growth factor" includes specific cytokines and hormones that bind to specific receptors on the surface of target cells. Examples of growth factors are bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), e.g. VEGFA, epidermal growth factors (EGFs), insulin-like growth factors, ephrins, macrophages. colony stimulating factor, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, neuregulin, neurotrophic factors (e.g. brain derived neurotrophic factor (BDNF), nerve growth factor (NGF)), placental growth factor (PGF), Platelet-derived growth factor (PDGF), renalase (RNLS) (anti-apoptotic survival factor), T cell growth factor (TCGF), thrombopoietin (TPO), transforming growth factor (transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β)) and tumor necrosis factor-alpha (TNF-α). In certain embodiments, a "growth factor" is a peptide or protein growth factor.
[0391] The term "protease inhibitor" refers to molecules, especially peptides or proteins, that inhibit the function of proteases. Protease inhibitors can be classified by the protease inhibited (eg, asparagine protease inhibitors) or by the mechanism of action (eg, suicide inhibitors such as serpins). Examples of protease inhibitors include serpins such as alpha 1 antitrypsin, aprotinin and bestatin.
[0392] The term "enzyme" refers to a macromolecular biological catalyst that accelerates chemical reactions. Like all catalysts, enzymes are not consumed in the reactions they catalyze and do not alter the equilibrium of the reactions. Unlike many other catalysts, enzymes are much more specific. In certain embodiments, the enzyme is essential to the subject's homeostasis, eg, any dysfunction of the enzyme (particularly reduced activity, which may be due to either mutation, deletion, or decreased production) results in disease. Examples of enzymes include herpes simplex virus type 1 thymidine kinase (HSV1-TK), hexosaminidase, phenylalanine hydroxylase, pseudocholinesterase and lactase.
[0393] The term "receptor" refers to a protein molecule that accepts signals from outside the cell, especially chemical signals called ligands. Binding of a signal (eg, a ligand) to a receptor causes some type of response in the cell, such as intracellular activation of a kinase. Receptors include transmembrane receptors (e.g. ionotropic receptors, G protein-coupled (metabotropic) receptors and enzyme-coupled receptors) and intracellular receptors (e.g. cytoplasmic and nuclear receptors). )including. Examples of receptors include steroid hormone receptors, growth factor receptors, and peptide receptors (ie, receptors where the ligand is a peptide), such as P-selectin glycoprotein ligand-1 (PSGL-1). The term "growth factor receptor" refers to a receptor that binds growth factors.
[0394] The term "apoptosis regulator" refers to a molecule, especially a peptide or protein, that modulates, ie activates or inhibits, apoptosis. Apoptosis regulators can be divided into two broad classes: those that control mitochondrial function and those that regulate caspases. The first class includes proteins that preserve mitochondrial integrity (e.g., BCL-2, BCL-xL) by preventing loss of mitochondrial membrane potential and / or release of pro-apoptotic proteins such as cytochrome C into the cytosol. . This first class also contains a pro-apoptotic protein that promotes the release of cytochrome C. (for example, BAX, BAK, BIM). The second class includes proteins such as inhibitors of apoptosis proteins (eg, XIAP) or FLIP that block activation of caspases.
[0395] The term "transcription factor" specifically relates to proteins that control the rate of transcription of genetic information from DNA to messenger RNA by binding to specific DNA sequences. Transcription factors may control cell division, cell proliferation, and cell death throughout life; cell migration and organization during embryonic development; and / or responses to signals from outside the cell, such as hormones. Transcription factors usually contain at least one DNA binding domain that binds to specific DNA sequences that flank the genes controlled by the transcription factor. Specific examples of transcription factors include MECP2, FOXP2, FOXP3, the STAT protein family and the HOX protein family.
[0396] The term "tumor suppressor protein" refers to a molecule, particularly a peptide or protein, that protects cells from a process that leads to cancer. Tumor suppressor proteins (usually encoded by the corresponding tumor suppressor genes) exert attenuating or oppressive effects on cell cycle control and / or promote apoptosis. Their function may be one or more of the following: suppression of inheritance essential for continuation of the cell cycle; coupling of the cell cycle to DNA damage (as long as damaged DNA is present in the cell, cell division will not occur); If damaged DNA cannot be repaired, initiation of apoptosis; suppression of metastasis (eg, preventing tumor cells from dispersing, blocking loss of contact inhibition, inhibiting metastasis); and DNA repair. Specific examples of tumor suppressor proteins are p53, phosphatase and tensin homolog (PTEN), SWI / SNF (SWItch / nonfermentable sucrose), von Hippel-Lindau tumor suppressor (pVHL), and adenomatoid polypoid polypoid (APC). , CD95, tumorigenicity suppressor 5 (ST5), tumorigenicity suppressor 5 (ST5), tumorigenicity suppressor 14 (ST14) and Yippee-like 3 (YPEL3).
[0397] The term "structural protein" refers to proteins that contribute to the stiffness and rigidity of otherwise liquid biological components. Structural proteins are mostly fibrous (eg collagen and elastin) but can also be globular (eg actin and tubulin). Typically, globular proteins are soluble as monomers, but polymerize to form long, fibers that can form, for example, the cytoskeleton. Other structural proteins are motor proteins (such as myosin, kinesin and dynein) and surfactant proteins that can produce mechanical forces. Examples of structural proteins include collagen, surfactant protein A, surfactant protein B, surfactant protein C, surfactant protein D, elastin, tubulin, actin and myosin.
[0398] The term "reprogramming factor" or "reprogramming transcription factor" when expressed in a somatic cell, optionally together with further factors such as further reprogramming factors, renders the somatic cell endowed with stem cell characteristics, especially It relates to molecules, especially peptides or proteins, that reprogram or dedifferentiate cells into pluripotent cells. Specific examples of reprogramming factors include OCT4, SOX2, c-MYC, KLF4, LIN28 and nano-G.
[0399] The term "genome engineering protein" relates to a protein that can be inserted, deleted or replaced with DNA in the genome of a subject. Specific examples of genome-engineered proteins include meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly arranged short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9). )including.
[0400] The term "blood protein" relates to peptides or proteins present in the plasma of a subject, especially the plasma of healthy subjects. Blood proteins are involved in transport (e.g. albumin, transferrin), enzymatic activity (e.g. thrombin or ceruloplasmin), coagulation (e.g. fibrinogen), defense against pathogens (e.g. complement components and immunoglobulins), protease inhibitors (e.g. , alpha 1 antitrypsin). Examples of blood proteins are thrombin, serum albumin, factor VII, factor VIII, insulin, factor IX, factor X, tissue plasminogen activator, protein C, von Willebrand factor, antithrombin III. , glucocerebrosidase, erythropoietin, granulocyte colony stimulating factor (G-CSF), modified factor VIII and anticoagulants.
[0401] Thus, in certain embodiments, the pharmaceutically active peptide or protein is preferably selected from the group consisting of (i) erythropoietin (EPO), interleukin 4 (IL-2) and interleukin 10 (IL-11). (ii) adhesion molecules, especially integrins; (iii) immunoglobulins, especially antibodies; (iv) immunologically active compounds, especially antigens; (v) hormones, especially vasopressin, insulin. or growth hormone; (vi) growth factors, especially VEGFA; (vii) protease inhibitors, especially alpha 1 antitrypsin; (viii) preferably herpes simplex virus type 1 thymidine kinase (HSV1-TK), hexosaminidase, phenylalanine an enzyme selected from the group consisting of hydroxylases, pseudocholinesterases, pancreatic enzymes and lactases; (ix) receptors, especially growth factor receptors; (x) apoptosis regulators, especially BAX; (xi) transcription factors, especially FOXP3 (xii) tumor suppressor proteins, especially p53; (xiii) structural proteins, especially surfactant protein B; (xiv) e.g. (xv) genome-engineered proteins, especially clustered regularly arranged short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9); and (xvi) blood proteins, especially fibrinogen. be.
[0402] In certain embodiments, the pharmaceutically active peptide or protein comprises one or more antigens or one or more epitopes, i.e., administration of the peptide or protein to a subject is therapeutic or partially or fully protective. inducing an immune response against the one or more antigens or one or more epitopes in a possible subject.
[0403] In certain embodiments, the RNA (preferably mRNA) encodes at least one epitope.
[0404] In certain embodiments, the epitope is derived from a tumor antigen. A tumor antigen can be a "standard" antigen commonly known to be expressed in a variety of cancers. Tumor antigens are "neo-antigens" that are specific to an individual's tumor and have not been previously recognized by the immune system. Neo-antigens or neo-epitopes can result from one or more cancer-specific mutations in the cancer cell's genome that lead to amino acid changes. Examples of tumor antigens are p53, ART-4, BAGE, beta-catenin / m, Bcr-abL CAMEL, CAP-1, CASP-8, CDC27 / m, CDK4 / m, CEA, cell surface proteins of the claudin family. , such as CLAUD ΓΝ-6, claudin-18.2 and claudin-12, c-MYC, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gap 100, HAGE, HER- 2 / neu, HPV-E7, HPV-E6, HAST-2, hTERT (or hTRT), LAGE, LDLR / FUT, MAGE-A, preferably MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11 or MAGE-A12, MAGE-B, MAGE-C, MART-1 / Melan-A, MC1R, myosin / m, MUC1, MUM-1, MUM-2, MUM-3, NA88-A, NF1, NY-ESO-1, NY-BR-1, pl90 minor BCR-abL, Pml / RARa, PRAME, proteinase 3 , PSA, PSM, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, SCGB3A2, SCP1, SCP2, SCP3, SSX, Survivin, TEL / AML1, TPI / m, TRP-1, TRP-2, TRP Including, but not limited to -2 / INT2, TPTE, WT and WT-1.
[0405] Cancer mutations vary from individual to individual. Cancer mutations that encode novel epitopes (neo-epitopes) therefore represent attractive targets for vaccine composition and immunotherapy development. The effectiveness of tumor immunotherapy depends on the selection of cancer-specific antigens and epitopes that can induce a strong immune response within the host. RNA can be used to deliver patient-specific tumor epitopes to patients. Dendritic cells (DCs) present in the spleen represent antigen-presenting cells of particular interest for RNA expression of immunogenic epitopes or antigens, such as tumor epitopes. The use of multiple epitopes has been shown to enhance the therapeutic efficacy of tumor vaccine compositions. Rapid sequencing of the tumor mutanome provides multiple epitopes for personalized vaccines, for example, which can be encoded by the mRNA described herein as a single polypeptide, with the epitopes optionally separated by a linker. It is possible. In certain embodiments of the invention, the mRNA has at least one epitope, at least two epitopes, at least three epitopes, at least four epitopes, at least five epitopes, at least six epitopes, at least seven at least 8 epitopes, at least 9 epitopes or at least 10 epitopes. Exemplary embodiments include mRNAs encoding at least 5 epitopes (referred to as "pentatopes") and mRNAs encoding at least 10 epitopes (referred to as "decatopes").
[0406] In certain embodiments, the epitope is derived from a pathogen-associated antigen, particularly a viral antigen. In certain embodiments, the epitope is derived from the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof. Thus, in certain embodiments, the RNA (preferably mRNA) used in the invention is a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof. encodes an amino acid sequence containing. In certain embodiments, the RNA comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1. In certain embodiments, the SARS-CoV2 S protein variant has at least 80% identity (e.g., at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity or at least 99% identity).
[0407] In certain embodiments, the immunogenic fragment of the SARS-CoV-2S protein comprises the S1 subunit of the SARS-CoV-2S protein or the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2S protein. In certain embodiments, the RNA (e.g., mRNA) used in the invention comprises an open reading frame encoding a polypeptide that includes a receptor-binding portion of the SARS-CoV-2S protein, and the RNA Suitable for expression. In certain embodiments, such encoded polypeptides do not include the entire S protein. In certain embodiments, the encoded polypeptide comprises a receptor binding domain (RBD), eg, as shown in SEQ ID NO:5. In certain embodiments, the encoded polypeptide comprises the peptide of SEQ ID NO: 29 or 31.
[0408] In certain embodiments, the amino acid sequence comprising the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is present in a multimeric complex, particularly a trimeric Can form complexes. For this purpose, an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof is defined as a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment thereof. Multimeric complexes of amino acid sequences comprising sexual variants or immunogenic fragments of the SARS-CoV-2S protein or immunogenic variants thereof, particularly domains that allow trimeric complex formation. In certain embodiments, the domain capable of multimeric complex formation comprises a trimerization domain, eg, a trimerization domain described herein.
[0409] In certain embodiments, a trimerization domain as defined herein includes, but is not limited to, a sequence comprising the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10, or a functional variant thereof. In certain embodiments, a trimerization domain as defined herein includes, but is not limited to, a sequence comprising the amino acid sequence of SEQ ID NO: 10 or a functional variant thereof.
[0410] In certain embodiments, the trimerization domain is at least 99%, 98%, 97%, 96% of the amino acid sequence comprising the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10, and the amino acid sequence of SEQ ID NO: 10. , 95%, 90%, 85% or 80% identical to, or at least 99% to, the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10 or an amino acid sequence comprising the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10. , 98%, 97%, 96%, 95%, 90%, 85% or 80% identity. In certain embodiments, the trimerization domain comprises the amino acid sequence of amino acids 3-29 of SEQ ID NO:10.
[0411] In certain embodiments, the RNA encoding the trimerization domain is (i) at least 99%, 98%, 97% the nucleotide sequence of nucleotides 7-87 of SEQ ID NO: 11; , 96%, 95%, 90%, 85% or 80% identical to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11 or at least 99% to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11; comprises a fragment of a nucleotide sequence having 98%, 97%, 96%, 95%, 90%, 85% or 80% identity; and / or (ii) comprises the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10. an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity with an amino acid sequence comprising the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10; or At least 99%, 98%, 97%, 96%, 95%, 90%, 85% or Encodes functional fragments of amino acid sequences with 80% identity. In certain embodiments, the RNA encoding the trimerization domain (i) comprises the nucleotide sequence of nucleotides 7-87 of SEQ ID NO: 11; and / or (ii) comprises the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10. Codes for an amino acid sequence.
[0412] In certain embodiments, an RBD antigen expressed by an RNA encoding a SARS-CoV-2S protein, an immunogenic variant thereof or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof (e.g., (as described) can be modified, for example, by the addition of a T4-fibritin-derived "Foldon" trimerization domain to increase immunogenicity.
[0413] In certain embodiments, an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof has a codon sequence as compared to a wild-type coding sequence. Encoded by a coding sequence that has been optimized and / or has increased G / C content, the codon optimization and / or increased G / C content preferably does not alter the sequence of the encoding amino acid sequence.
[0414] In some embodiments, (i) RNA encoding the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9; a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9. or the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9 or the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9 and at least 99%, 98%, 97%, 96%, 95%, 90 %, 85% or 80% identical; and / or (ii) the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1; an amino acid sequence that has at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity with an amino acid sequence comprising the amino acid sequence from amino acids 327 to 528 or amino acids 327 to SEQ ID NO: 1; Amino acids having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to an amino acid sequence comprising the amino acid sequence of 528 or amino acids 327 to 528 of SEQ ID NO: 1 Contains immunogenic fragments of the sequence.
[0415] In some embodiments, (i) RNA encoding the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9; a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity with the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9. or the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9 or the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9 and at least 99%, 98%, 97%, 96%, 95%, 90 %, 85% or 80% identical; and / or (ii) the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1; an amino acid sequence that has at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to an amino acid sequence comprising the amino acid sequence from amino acids 17 to 685 or amino acids 17 to SEQ ID NO: 1; Amino acids having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to an amino acid sequence comprising the amino acid sequence 685 or amino acids 17 to 685 of SEQ ID NO: 1 Contains immunogenic fragments of sequences.
[0416] In some embodiments, (i) RNA encoding the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9; at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identical to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, comprising the nucleotide sequence of The nucleotide sequence or the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9 or the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9 and at least 99%, 98%, 97%, 96%, 95% , comprising fragments of nucleotide sequences with 90%, 85% or 80% identity; and / or (ii) the SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2S protein or an immunogenic variant thereof is the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, SEQ ID NO: Amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity with the amino acid sequence of amino acids 17 to 1273 of 1 or 7 or the amino acids of SEQ ID NO: 1 or 7 or having at least 99...
Claims
1. 1. A composition comprising lipid nanoparticles (LNPs) dispersed in an aqueous phase, wherein the LNPs comprise cationically ionizable lipids and RNA; the aqueous phase comprises a buffer system comprising a buffer substance and a monovalent anion, wherein the buffer substance is selected from the group consisting of tris(hydroxymethyl)aminomethane (Tris) and its protonated forms, bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (bis-Tris-methane) and its protonated forms, and triethanolamine (TEA) and its protonated forms, and a monovalent anion selected from the group consisting of chloride, acetate, glycolate, and lactate; the concentration of the buffer substance in the composition is up to about 25 mM; and the aqueous phase is substantially free of inorganic phosphate anions, substantially free of citrate anions, and substantially free of anions of ethylenediaminetetraacetic acid (EDTA), and the concentration of the monovalent anion in the composition is up to equal to the concentration of the buffer substance in the composition. (i) the buffer substance is Tris and its protonated form; (ii) the concentration of the buffer in the composition is at most about 20 mM, at most about 15 mM, at most about 10 mM, or at most about 10 mM; (iii) the aqueous phase is substantially free of inorganic sulfate anions and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions or the aqueous phase is substantially free of inorganic sulfate anions, carbonate anions, dibasic organic acid anions and polybasic organic acid anions; (iv) the concentration of the monovalent anion in the composition is less than the concentration of the buffer substance in the composition, or less than about 9 mM; (iii) the aqueous phase is substantially free of inorganic sulfate anions and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions or the aqueous phase is substantially free of inorganic sulfate anions, carbonate anions, dibasic organic acid anions and polybasic organic acid anions; (v) the pH of the composition is from about 6.5 to about 8.0, from about 6.9 to about 7.9, or from about 7.0 to about 7.8; (vi) water is the major component of the composition and / or the total amount of solvents other than water contained in the composition is less than about 0.5% (v / v); (vii) the composition has an osmolality of up to about 400×10 osmol / kg; (viii) the concentration of RNA in the composition is from about 5 mg / L to about 150 mg / L, from about 10 mg / L to about 130 mg / L, or from about 30 mg / L to about 120 mg / L; (ix) the composition a. a cryoprotectant at a concentration of at least about 1% w / v; b. a cryoprotectant comprising one or more compounds selected from the group consisting of carbohydrates and sugar alcohols or selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof; c. a cryoprotectant which is sucrose and / or glycerol; d. a cryoprotectant comprising one or more compounds selected from the group consisting of carbohydrates and sugar alcohols at a concentration of at least about 1% w / v or selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof; e. A cryoprotectant that is sucrose and / or glycerol at a concentration of at least about 1% w / v. Contains; or the composition is substantially free of cryoprotectants; and / or (x) the aqueous phase does not contain a chelating agent; The composition of claim 1.
3. The cationically ionizable lipid is (i) comprising a head group containing at least one nitrogen atom capable of being protonated under physiological conditions; (ii) comprising a compound of formula (I): [Formula 1] or a pharma- ceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein: one of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O-; and the other of L 1 and L 2 is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -S-S-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a - or -NR a C(=O)O- or a direct bond; G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 2 -C 12 alkenylene; G 3 is C 1 -C 24 alkylene, C 2 -C 24 alkenylene, C 3 -C 8 cycloalkylene, C 3 -C 8 cycloalkenylene; R a is H or C 1 -C 12 alkyl; R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 alkenyl; R 3 is H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 ; R 4 is C 1 -C 12 alkyl; R 5 is H or C 1 -C 6 alkyl; and x is 0, 1 or 2; (iii) selected from the following structures A to F: [Table 1] or (iv) Structure [Table 2] having The composition of claim 1 or 2. (i) the LNP comprises one or more additional lipids; or (ii) the LNPs comprise one or more additional lipids selected from the group consisting of polymer-conjugated lipids, neutral lipids, steroids, and combinations thereof; (iii) the LNPs comprise a cationically ionizable lipid, a polymer-conjugated lipid, a neutral lipid, and a steroid; The composition of any one of claims 1 to 3.
5. Polymer-conjugated lipids (i) a PEGylated lipid; (ii) a structure: [chemical 2] or a pharma- ceutically acceptable salt, tautomer, or stereoisomer thereof, wherein: R 12 and R 13 is independently a linear or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, where the alkyl chain is optionally interrupted by one or more ester bonds; and w has an average value in the range of 30 to 60. (iii) Polysarcosine-lipid conjugates or conjugates of polysarcosine and lipid-like substances (iv) a polysarcosine-lipid conjugate or a conjugate of polysarcosine and a lipid-like substance, which is a member selected from the group consisting of polysarcosine-diacylglycerol conjugate, polysarcosine-dialkyloxypropyl conjugate, polysarcosine-phospholipid conjugate, polysarcosine-ceramide conjugate, and mixtures thereof; The composition of claim 4 comprising:
6. Neutral lipids are (i) phospholipids; (ii) a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin; (iii) distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoseleoylphosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE) and diphytanoyl-phosphatidylethanolamine (DPyPE). The composition of claim 4 or 5,
7. The composition of any one of claims 4 to 6, wherein the steroid comprises a sterol such as cholesterol. (i) the LNPs comprise at least about 75% or at least about 80% of the RNA contained in the composition; (ii) the RNA is encapsulated or associated with the LNP; (iii) the RNA contains a modified nucleoside in place of uridine or the RNA contains a modified nucleoside in place of uridine selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U); (iv) the RNA comprises at least one or all of a 5' cap; a 5' UTR; a 3' UTR; and a poly-A sequence; (v) the RNA comprises at least one or all of a 5' cap; a 5' UTR; a 3' UTR; and a poly-A sequence; a. the poly-A sequence comprises at least 100 A nucleotides; b. the poly-A sequence comprises at least 100 A nucleotides, and the poly-A sequence is an interrupted sequence of A nucleotides; and / or c. the 5' cap is a cap1 or cap2 structure; and / or (vi) RNA a. encodes one or more polypeptides; b. encoding one or more polypeptides that contain an epitope for inducing an immune response to the antigen in a subject c. comprises an open reading frame (ORF) encoding an amino acid sequence comprising a SARS-CoV-2S protein, an immunogenic variant thereof, or an immunogenic fragment of a SARS-CoV-2S protein or an immunogenic variant thereof; d. comprises an ORF encoding a full-length SARS-CoV2 S protein variant having proline residue substitutions at positions 986 and 987 of SEQ ID NO:1; e. encoding a SARS-CoV2 S protein variant having at least 80% identity to SEQ ID NO:7; The composition of any one of claims 1 to 7. (i) The composition is in frozen form; (ii) the RNA integrity after thawing the frozen composition is at least 50% compared to the RNA integrity before the composition was frozen; and / or (iii) the composition is in frozen form, and the size (Zaverage) and / or size distribution and / or polydispersity index (PDI) of the LNPs after thawing the frozen composition is equal to the size (Zaverage) and / or size distribution and / or PDI of the LNPs before the composition was frozen; The composition of any one of claims 1 to 8.
10. The composition of any one of claims 1 to 8, wherein the composition is in liquid form.
11. A method of preparing a composition comprising LNPs dispersed in a final aqueous phase, wherein the LNPs comprise cationically ionizable lipids and RNA; the final aqueous phase comprises a final buffer system comprising a final buffer substance and a final monovalent anion, wherein the final buffer substance is selected from the group consisting of Tris and its protonated forms, Bis-Tris-methane and its protonated forms and TEA and its protonated forms, and the final monovalent anion is selected from the group consisting of chloride, acetate, glycolate and lactate; the concentration of the final buffer substance in the composition is up to about 25 mM; and the final aqueous phase is substantially free of inorganic phosphate anions, substantially free of citrate anions and substantially free of anions of EDTA; (I) preparing a formulation comprising LNPs dispersed in a final aqueous phase, the LNPs comprising cationically ionizable lipids and RNA; and (II) optionally freezing the formulation to below about −10° C.; thereby obtaining a composition, wherein step (I) comprises: (a) preparing an RNA solution comprising water and a first buffer system; (b) preparing an ethanolic solution containing a cationically ionizable lipid and, if present, one or more additional lipids; (c) mixing the RNA solution prepared under (a) with the ethanolic solution prepared under (b), thereby preparing a first intermediate formulation comprising LNPs dispersed in an intermediate aqueous phase comprising a first buffer system; and (d) filtering the first intermediate formulation prepared under (c) using a final aqueous buffer solution comprising a final buffer system; Thereby preparing a formulation comprising LNPs dispersed in a final aqueous phase, wherein the concentration of the monovalent anion in the composition is at most equal to the concentration of the buffer substance in the composition.
12. (i) Step (I) further comprises one or more steps selected from dilution and filtration; (ii) Step (I) (a') preparing an aqueous RNA solution; (b') preparing a first aqueous buffer solution comprising a first buffer system; (c') mixing the aqueous RNA solution prepared under (a') with the first aqueous buffer solution prepared under (b'), thereby preparing an RNA solution comprising water and a first buffer system; (d') preparing an ethanolic solution containing a cationically ionizable lipid and, if present, one or more additional lipids; (e') mixing the RNA solution prepared under (c') with the ethanolic solution prepared under (d'), thereby preparing a first intermediate formulation comprising LNPs dispersed in a first aqueous phase comprising a first buffer system; (f') optionally filtering the first intermediate formulation prepared under (e') using an additional aqueous buffer solution comprising an additional buffer system, thereby preparing a further intermediate formulation comprising LNPs dispersed in an additional aqueous phase comprising an additional buffer system, where the additional aqueous buffer solution can be the same as or different from the first aqueous buffer solution; (g') optionally repeating step (f') one or more times, wherein a further intermediate formulation comprising LNPs dispersed in a further aqueous phase comprising a further buffer system obtained after one cycle of step (f') is used as a first intermediate formulation in a next cycle, wherein in each cycle, the further aqueous buffer solution can be the same as or different from the first aqueous buffer solution; (h') filtering the first intermediate formulation obtained in step (e') if step (f') is absent or the further intermediate formulation obtained in step (f') if step (f') is present and step (g') is not present or the further intermediate formulation obtained after step (g') if steps (f') and (g') are present, using a final aqueous buffer solution comprising a final buffer system and having a pH of at least 6.0; and (i') optionally diluting the formulation obtained in step (h') with a diluent; thereby preparing a formulation comprising LNPs dispersed in a final aqueous phase; (iii) the filtration is tangential flow filtration or diafiltration; and / or (iv) (II) freezing the formulation to below about −10° C.
12. The method of claim 11. (i) the final buffer substance is Tris and its protonated form; (ii) the final buffer concentration in the composition is at most about 20 mM, at most about 15 mM, at most about 10 mM, or at most about 10 mM; and / or (iii) the final aqueous phase is substantially free of inorganic sulfate anions and / or carbonate anions and / or dibasic organic acid anions and / or polybasic organic acid anions or is substantially free of inorganic sulfate anions, carbonate anions, dibasic organic acid anions and polybasic organic acid anions; 13. The method of claim 11 or 12.
14. (i) the RNA solution prepared in step (a) further comprises one or more di- and / or polybasic organic acid anions, and step (d) is carried out under conditions to remove the one or more di- and / or polybasic organic acid anions resulting in a formulation comprising LNPs dispersed in a final aqueous phase, wherein the final aqueous phase is substantially free of the one or more di- and / or polybasic organic acid anions present in the RNA solution prepared in step (a); or (ii) the first aqueous buffer solution and the first aqueous phase comprise one or more di- and / or polybasic organic acid anions, and at least one of steps (f')-(h') is carried out under conditions to remove the one or more di- and / or polybasic organic acid anions from the first intermediate formulation and / or the further intermediate formulation; and / or (i) the RNA solution obtained in step (a) or (ii) the first aqueous buffer solution has a pH of less than 6.0 or up to about 5.0 or up to about 4.5; The method according to any one of claims 11 to 13.
15. 15. The method of claim 14, wherein the one or more di- and / or polybasic organic acid anions include citrate anion and / or anion of EDTA.
16. (i) the first buffer system used in step (a) comprises the final buffer substance and the final monovalent anion used in step (d); or (ii) the first buffer system used in step (a) comprises the final buffer substance and the final monovalent anion used in step (d), and the buffer system and pH of the first buffer system used in step (a) are the same as the buffer system and pH of the final aqueous buffer solution used in step (d); or (iii) the first buffer system and each of all further buffer systems used in steps (b'), (f') and (g') each contain a final buffer substance and a final monovalent anion used in step (h'); or (iv) the first buffer system and each of all further buffer systems used in steps (b'), (f') and (g') comprise the final buffer substance and final monovalent anion used in step (h'), and the buffer system and pH of the first aqueous buffer solution and each of all further aqueous buffer solutions used in steps (b'), (f') and (g') are the same as the buffer system and pH of the final aqueous buffer solution; The method according to any one of claims 11 to 13.
17. (i) The final monovalent anion concentration in the composition is less than or equal to about 9 mM, or less than the final buffer concentration in the composition; (ii) the pH of the composition is from about 6.5 to about 8.0, from about 6.9 to about 7.9, or from about 7.0 to about 7.8; (iii) water is the major component of the formulation and / or composition and / or the composition contains less than about 0.5% total non-water solvents (v / v); (iv) the composition has an osmolality of up to about 400×10 -3 is osmol / kg; (v) the concentration of RNA in the composition is from about 5 mg / L to about 150 mg / L, from about 10 mg / L to about 130 mg / L, or from about 30 mg / L to about 120 mg / L; (vi) (i) step (I) further comprises diluting the formulation prepared under (d) with a diluent solution or step (i') is present, wherein the diluent solution comprises a cryoprotectant; and / or (ii) the formulations and compositions obtained in step (I) a. a cryoprotectant at a concentration of at least about 1% w / v b. a cryoprotectant comprising one or more selected from carbohydrates and sugar alcohols or selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof; c. a cryoprotectant comprising sucrose and / or glycerol; d. a cryoprotectant comprising one or more selected from carbohydrates and sugar alcohols at a concentration of at least about 1% w / v or selected from the group consisting of sucrose, glucose, glycerol, sorbitol, and combinations thereof; e. A cryoprotectant comprising sucrose and / or glycerol at a concentration of at least about 1% w / v. Contains; or The preparations and compositions obtained in step (I) are substantially free of cryoprotectants; The method of any one of claims 11 to 16.
18. 18. The method of any of claims 11 to 17, wherein the cationically ionizable lipid is as defined in claim 3.
19. (i) The ethanolic solution prepared in step (b) or (d') further comprises one or more additional lipids, and the LNP further comprises one or more additional lipids; or (ii) the ethanolic solution prepared in step (b) or (d') further comprises one or more additional lipids, and the LNP further comprises one or more additional lipids, wherein the one or more additional lipids are as defined in any one of claims 4 to 7; The method of any one of claims 11 to 18. (i) the cationically ionizable lipid, polymer-conjugated lipid, neutral lipid and steroid are present in an ethanolic solution in a molar ratio of 20% to 60% cationically ionizable lipid, 0.5% to 15% polymer-conjugated lipid, 5% to 25% neutral lipid and 25% to 55% steroid or in a molar ratio of 45% to 55% cationically ionizable lipid, 1.0% to 5% polymer-conjugated lipid, 8% to 12% neutral lipid and 35% to 45% steroid; (ii) the final aqueous phase does not contain a chelating agent; (iii) the LNPs comprise at least about 75% or at least about 80% of the RNA contained in the composition; (iv) the RNA is encapsulated or associated with the LNP; and / or (v) the RNA is as defined in claim 8; 20. The method of any one of claims 11 to 19.
21. The method according to any one of claims 11 to 20, which does not include step (II).
22. The method according to any one of claims 11 to 20, in frozen or liquid form. (i) providing a frozen composition produced by the method of any one of claims 11 to 20, thereby providing a ready-to-use pharmaceutical composition; or (ii) Providing a liquid formulation prepared by the method of any one of claims 11, 12(i) to (iii) and 13 to 21, thereby providing a ready-to-use pharmaceutical composition. A ready-to-use pharmaceutical composition which can be prepared by a method comprising the steps of:
24. 24. The composition of any of claims 1 to 10, 22 and 23 for use in therapy or for use in inducing an immune response in a subject.
